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ABSTRACT 
   
The nasal route is highly promising for the delivery of drugs exerting local effects in the nose or 
for therapeutic molecules having systemic or CNS effect. This is attributed to the fact that the 
nasal epithelium is highly vascularized and permeable, which ensures rapid absorption of the 
drug. The limitation of short residence time of the formulations in the nose and poor 
bioavailability of hydrophilic drugs could be overcome by the inclusion of bioadhesive agents 
into formulation. 
The main objective of this study was to develop novel bioadhesive microspheres and liposomes 
entrapping the anti-Parkinson drugs ropinirole hydrochloride (RH). The microspheres were 
prepared via spray drying in combination with chitosan or sodium alginate and the liposomes 
were prepared using the ethanol-based proliposome method. This study has investigated the 
potential of powdered mucoadhesive microparticles and liquid liposomes for nasal delivery via 
Miat
®
 nasal insufflator and nasal spray devices respectively.  
Optimum mucoadhesive chitosan microparticles were prepared by co-spray drying of chitosan 
glutamate and ropinirole hydrochloride (90:10 w/w). Characterization studies have revealed that 
the drug following spray drying was amorphous and the microparticles were spherical and 
offered drug entrapment efficiency values in the range of 93 - 99%. The optimum formulation 
provided maximum swelling capacity and slowest drug release. Ex vivo toxicity study using 
isolated sheep nasal mucosa proved the safety of the optimized formulations for intranasal 
delivery. Investigation of powder delivery demonstrated that the Miat
®
 nasal insufflator could 
deliver 90% of the dose with the first puff regardless of the loading weight used to fill the 
capsule fitted into the nasal device. The spray cloud had elongated shape and was homogenous; 
this is expected to enhance the impaction of the formulation in the nose following delivery from 
the nasal device. 
The properties of sodium alginate microparticles prepared via spray drying were highly 
dependent on inlet temperature of the spray drier, affecting particle morphology and product 
yield percent. The best performing particles were obtained when the inlet temperature was 
140
o
C. Alginate to RH ratio had marked effect on particle size (2.60 - 4.37µm), entrapment 
efficiency (101 – 109%), physical state of the encapsulated RH, and morphology and surface 
smoothness of the particles as shown by scanning electron microscopy (SEM). In vitro drug 
release profile showed the amount of sodium alginate in formulations has controlled the rate of 
drug release. Results revealed that RH-alginate microparticles in 90:10 w/w polymer to drug 
ratio was the best performing spray dried formulation. Toxicity study proved safety of RH 
loaded sodium alginate for intranasal delivery. In contrast to RH-chitosan microparticles, 
particle trajectories was found from the cloud generated from emitted powder and laser 
diffraction demonstrated that powder was less likely to deposit in the lower respiratory tract 
owing to particle agglomeration.  
Ethanol-based proliposome technology produced oligolamellar liposomes from lipid ethanolic 
solutions as revealed by transmission electron microscopy (TEM). The resultant liposomes 
entrapped approximately 23.30% of the drug. Using five different bioadhesive agents, inclusion 
of any of these agents (0.2% w/v) caused a decrease in drug entrapment except for 
carboxymethyl chitosan which had no effect on the drug entrapment (25.97%). Investigation of 
aerosolized liposome dispersion using a range of nasal spray devices demonstrated integrity of 
liposomes were not changed (i.e particle size, Span, and drug entrapment efficiency were 
unaffected) and RH-loaded liposomes were efficiently delivered from the devices. 
In conclusion, the finding of this study explored mucoadhesive microspheres entrapped the anti-
Parkinson drug, RH, and can potentially be applicable for nasal delivery to enhance nose to 
brain transport using nasal insufflator for improvement of the symptoms of Parkinson disease 
and Restless legs syndrome. Similar findings using nasal sprays were found for liposomes. In 
vivo studies are required in the future to determine the amount of the drug that may reach the 
blood circulation and brain. 
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1.1 Nasal drug delivery  
1.1.1 Historical background 
Since last century intranasal delivery has been used for various purposes such as for 
relieving nasal decongestion, rhinitis and migraine. Crushed leaves of Ranunculus acris 
have been used via nasal inhalation by the Red Indian of North America to relieve 
headache. In China, extracts of aloe wood and sandalwood were used for treating 
emesis by inhalation through the nasal route. The nasal route has also been used to 
administer tobacco by nasal snuffing (Quraishi et al., 1997). American Indians used it as 
early as the 1400s (Christen et al., 1982). Indian tribes in Brazil used V-shape 
instrument known as ʻTipiʼ to blow powdered tobacco to one another for enjoyment and 
relaxation, and refresh their memory (www.snuffhouse.org) (Figure 1.1). The American 
Indian used an instrument known as ʻtobacaʼ or ʻtobagoʼ, which is a hollow Y-shape 
pipe to inhale powdered tobacco. For snuffing, they placed two ends of the Y-shape 
pipe into each nostril and the lower end near the powdered tobacco (Christen et al., 
1982). The nose is still the favoured route for drug abuse, for instance when using 
opium drugs (Davis, 1999).  
     
  
 
Figure 1. 1: Consuming snuff with large V-shaped straws called ʻTipiʼ, by a 
partner (www.snuffhouse.org). 
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1.1.2 Why the nasal route?  
The oral route is the most convenient and popular route for drug delivery. Despite the 
popularity of oral route alternative routes such as transmucosal delivery have been 
extensively investigated for drugs lacking effective systemic absorption via the 
gastrointestinal tract (GIT), therapeutic agents having chemical instability in the GIT 
fluids, drugs that undergo first-pass hepatic deactivation and therapeutic molecules 
which cause GIT adverse effects. Alternative routes have been investigated such as 
intra-nasal and parenteral in order to achieve faster and higher drug absorption and 
hence offering improved drug bioavailability, enhanced therapeutic effect and promoted 
patient compliance (Mathias and Hussain, 2010). Significant enhancement in the drug 
absorption following nasal administration compared to oral delivery has been 
demonstrated (Dhakar et al., 2011). However, for improvement of intranasal drug 
absorption with molecules larger than 1000 Daltons, permeation enhancers are needed 
in the formulation (Ozsoy et al., 2009). 
 
Nasal delivery is appropriate for administration of drugs to treat local nasal diseases 
such as sinusitis and allergic rhinitis since low doses are sufficient to provide 
therapeutic effects with low systemic side effects. In addition, nasal delivery might be 
suitable for drugs which are effective in low doses and have low oral bioavailability 
(Dhakar et al., 2011). The rate of absorption, and the pharmacokinetic properties of 
small drug molecules used for systemic therapeutic effects, administration via the nose 
are comparable to the parenteral route due to the nature of the nasal pathway which 
provide a large surface area, rich vascularity and drug high permeability (Illum, 2003; 
Dhakar et al., 2011) (Figure 1.2). Nasal delivery is also applicable in emergency cases 
(Bitter et al., 2011).  
 
Despite the nose has lower surface area compared to the lung, it provides an efficient 
site for systemic absorption particularly for drugs with low water solubility (Davis, 
1999). Many drugs do not reach the brain following oral or parenteral administration 
due to the blood-brain barrier (BBB). The olfactory region of the nose is not covered by 
the blood brain barrier, hence evasion the BBB following nasal administration might be 
possible. This approach is effective for drug targeting to the brain (Wen, 2011). 
Furthermore, the nose is attractive for vaccine delivery since provoking mucosal 
secretory antibodies at the site of entry of pyrogens may provide additional 
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immunoprotection for immunization (Burt et al., 2011). Nasal drug delivery offers 
many advantages, but has some limitations (Table 1.1). 
 
  
 
Figure 1. 2: Serum level of propranolol after administration using nasal, i.v and 
oral routes (Adapted from Washington et al., 2001). 
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Table 1. 1: Advantage and limitations of nasal route (Behl et al., 1998; Singh et al., 2012).   
 
Advantages Limitations 
Suitable for drugs that are acid labile in the stomach Volume that can be delivered into nasal cavity is restricted to 25–200 μl 
Applicable for drugs that undergo extensive hepatic first-pass effect  High molecular weight compounds cannot be delivered through this 
route (mass cut off ≈1 kDa) 
Rapid drug absorption and onset of action Adversely affected by pathological conditions of the nose 
Offers higher drug bioavailability, thus lower doses of drug are needed Large interspecies and patient to patient variabilities are observed when 
using this route 
Offers large surface area for drug absorption (approximately about 150 
cm
2
) 
Normal defense mechanisms like mucociliary clearance can affect the 
absorption of drug 
No particular skills or expertise are required for nasal  drug 
administration 
Local enzymes in the nasal cavity might degrade some drugs  
Direct transportation of drug to the systemic circulation or CNS is 
possible 
Local side effects like irritation might be happen 
Offers lower risk of overdosing Small surface area compared to the GIT 
Needle-free and patient friendly  Nasal congestion from colds and flues may interfere with efficient drug 
delivery via this route 
Offers induction of immune response when used for vaccine delivery Frequent delivery of drugs may cause mucosal damage, hence patient 
becomes liable to microbial invasion through the nasal epithelium 
CHAPTER 1 
6 
 
1.1.3 Anatomy of the nose 
The nasal passage is 12-14 cm deep and runs from the nasal vestibule to the 
nasopharnyx. It has three main regions; vestibular, respiratory and olfactory regions. 
The nose has a volume of 16-19 cm
3
 and a surface area of approximately 180 cm
2
 with 
two cavities (i.e. nostrils) separated by the nasal septum (Figure 1.3). 
 
 
Figure 1. 3: Anatomy of the human nasal cavity (Adapted from www.lasinus.com). 
 
The vestibular region is located at the front opening of the nasal passages which filters 
out particles from the inhaled air. However, drug delivery and absorption in this region 
is least important. This area is covered with hairs which filter the air to prevent air-
borne particles entering the respiratory system. The respiratory area is large with a high 
degree of vascularity and a surface area of about 130 cm
2
. In this region the majority of 
drug absorption occurs. It is lined with pseudostratified columnar epithelium and 
covered with a dense layer of mucus which moves towards the posterior apertures of the 
nasal cavity because of the ciliary rhythmatic movements (Chien et al., 1989). The 
olfactory region is important for transporting the drug to brain and cerebro-spinal fluid 
and has a surface area of about 15 cm
2
. It is made of thick connective tissue and lamina 
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propria, into which the olfactory epithelium rests. The thickness of nasal mucosa ranges 
between 2 and 4 mm. The epithelium cells line the nasal passage and are covered by a 
mucus layer 5µm in thickness which traps unwanted particles. The mucous secretion 
consists of water (95%), mucin (2%), salts (1%), proteins (1%) such as albumin, 
immunoglobulin, lysozyme, and lactoferrin, and lipids (1%). IgA, IgE and IgG are also 
present in the mucous secretion (Ozsoy et al., 2009). The pH of the nasal secretion is 
ranged from 5 to 6.5 (Ugwoke et al., 2005). Ciliary action is responsible for clearing the 
mucus layer from the nasal cavity and mucus is renewed 4 - 6 times per hour. The 
mucus moves through the nose at a rate of 5-6 mm/min (Graf, 1986). The characteristics 
of human nasal epithelium are summarised in Table 1.2. 
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Table 1. 2: Human nasal epithelium characteristics (Adapted from Pires et al. 2009).  
 
Nasal regions Histology of nasal 
epithelium 
Functions Surface area Blood supply  
(i.e. vascularity) 
Permeability 
Vestibule Stratified squamous and 
keratinized epithelial cells 
with nasal vibrissae   
Support and protection ≈ 0.6 cm2 Low Poor 
Atrium Stratified squamous cells 
and  pseudostratified cells   
Support  --- Low Reduced 
Respiratory 
region 
Columnar non-ciliated 
cells,  
Columnar ciliated cells 
 
Globet cells  
Basal cells   
Support to nasal function  
 
Clearance of particles 
 
Secretes mucus  
Progenitors of other cell types 
≈ 130 c m2 Very high Good 
Olfactory 
region 
Sustentacular cells,   
 
 
Receptor cells  
  
Basal cells  
Support and bears synthetic 
olfactory  
 
Olfaction sensation  
 
Progenitors of other cell type 
≈ 15 cm2 High Direct path 
to CNS 
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1.1.4 Applications of nasal delivery 
 i) Local effects  
The nose is exploited to treat regional disorders at relatively low effective doses with 
less systemic effects. Low molecular weight water-soluble or hydrophobic drugs are 
used to treat local pathological conditions in the nose. For example, Azelastine (Horak, 
2008) is a rapid acting antihistamine, mainly acts as an antagonist on H1- receptors, and 
as a mast cell stabilizer available as a nasal spray. Beclometasone (Ghimire et al., 2007) 
is an anti-inflammatory corticosteroid used to reduce inflammation and local allergy. It 
is a well-established drug for the treatment of allergic rhinitis. Nasal decongestants such 
as oxymetazoline are also administered via the nose for treating common colds (Pires et 
al., 2009; Sharma et al., 2006).  
ii)   Systemic effects  
Nasal delivery is convenient for acid labile drugs, proteins and peptides when rapid 
action is required such as in migraine relief (Swamya and Abbasb, 2012). Nasal 
delivery offers a rapid action and efficient drug absorption compared to oral and 
intravenous delivery (Furubayashi et al., 2007). Most protein and peptide drugs have 
low bioavailability (1–2%) due to their high molecular weight and polarity, causing 
poor absorption through the nasal mucosal membranes. In contrast, the bioavailability 
of progesterone and propranolol via nasal epithelium is comparable to parenteral 
administration (O’Hagan and Illum, 1990). Lower bioavailability can be improved by 
using absorption enhancers in the formulations, thus prolonging the contact time of the 
drug with the mucous membranes using bioadhesive agents. A significant change in the 
relative bioavailability of isosorbide dinitrate was observed using 0.1% N-succinyl 
chitosan as absorption enhancer (69.85%) compared to the 0.5% chitosan (55.36%) and 
control groups (43.32%) in rats (Na et al., 2013). Steyn and co-workers have reported 
that the bioavailability of recombinant human growth hormone was increased 
significantly after nasal delivery in combination with N-trimethyl chitosan chloride as 
an absorption enhancer used in pheroid technology (Steyn et al., 2010). Examples of 
marketed intranasal drug delivery products of proteins, peptides and small molecules are 
summarized in Table 1.3. 
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Table 1. 3: Nasal Proteins, Peptides and non-peptide formulations for systemic effect available in the market (Adapted from Singh et al., 
2012). 
 
Name of the product  Indication (s) Manufacturer 
Miacalcin
®
 (Calcitonin nasal spray) Postmenopausal osteoporosis Novartis Pharma 
Lazanda
®
 (fentanyl nasal spray) 
 
Management breakthrough 
cancer pain  
Archimedes Pharma 
Suprecur
®
 (Buserelin acetate)  Prostate cancer, endometriosis, 
infertility 
Sanofi-Aventis 
Oxytocin
TM 
factor Stress relief ABC Nutriceuticals 
 Zolmist
®
 (Zolmitriptan) Migraine Cipla 
Migranal
®
 (Dihyfroergotamin) Migraine Novartis Pharma 
Aerodiol
®
 (Estradiol) Postmenopausal hormone 
replacement 
Servier 
MSH2-Pro
TM
  (Melanocyte-stimulating hormone) Reduce appetite and 
increases libido 
International Antiaging Systems  
 
DDAVP
® 
 (Desmopressin acetate) Antidiuretic hormone Sanofi-Aventis 
Nascobal
®
 (Cyanocobalamin) Vitamin B12 deficiency Strativa Pharmaceuticals 
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iii) Vaccines delivery 
Vaccines and their applications via nose to treat respiratory infections have been 
investigated. The localization of immune system components in the mucosal membrane 
means that the respiratory epithelium is the first defence line in the body against 
infections (Bitter et al., 2011). Nasal mucosa is further enriched by lymphoid tissue. It 
enhances the systemic levels of specific immunoglobulin G and nasal secretary 
immunoglobulin A and the local immune responses which provide additional protection 
against invading microbes (Mestecky et al., 1997). Nasal mucosa is advantageous for 
immunization due to its permeability, low enzymatic activity and accommodation of the 
nose-associated lymphoid tissue (NALT) (Bitter et al., 2011). The delivery of vaccine 
via the nose represents a convenient needle-free procedure for vaccination. Furthermore, 
the nose-associated lymphoid tissue (NALT) is an effective immune system 
(Brandtzaeg, 2011). Nasal vaccines that have been investigated include influenza A and 
B (Huang et al. 2004), proteasome‐influenza (Langley et al., 2006), adenovirus‐vectored 
influenza (Van Kampen et al., 2005), attenuated respiratory syncytial virus and 
parainfluenza 3 virus (Belshe et al., 2004). Commercially available nasal vaccines 
include nasal spray of Human influenza vaccine (FluMist
®
) and nasal drop of Equine 
influenza vaccine (Flu Avert
®
) manufactured by Medlmmune Inc. and Heska 
respectively. 
 
 iv) CNS delivery 
The intranasal route is promising for the delivery of drugs to the brain via the 
exploitation of the olfactory neuroepithelium in the nose (Figure 1.4a), possible 
pathways to transfer drugs from nose to the brain have been explained by Illum, (2000) 
(Figure 1.4b). This strategy has been considered for the treatment of Alzheimer’s 
disease, brain tumours, epilepsy, pain and sleep disorders (Pires et al., 2009). Delivery 
of nerve growth factor to the brain in rodents has been reported (Frey et al., 1997; Chen 
et al., 1998) and in humans studies insulin (Hinchcliffe and Illum, 1999) and proteins 
(Pietrowsky et al., 1996) have been directly transferred through olfactory path to the 
CNS via nasal cavity. Successfully transnasal delivery 0.5mg/kg of siRNA to the CNS 
with highly brain concentration compared to the other tissue has been reported by 
Malhotra co-workers to treat neurological disorders using peptide-tagged PEGylated 
chitosan nanoparticles formulations to deliver siRNA via nose (Malhotra et al., 2013). 
Recent publications that investigated brain targeting via the nose are summarized in 
Table 1.4. 
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Table 1. 4: Recent studies curried out to deliver drug molecules to the brain via 
nasal route. 
 
Drug molecule Purpose Reference 
siRNA Treatment of  neurological disorder (Malhotra et al., 2013) 
Levodopa Treatment of Parkinson's disease (Sharma et al., 2013) 
Clonazepam Prevent and control seizures (Abdel-Bar et al., 2013) 
Folic Acid Treatment or prevention of 
Alzheimer’s disease 
(Nagaraju et al., 2013) 
 
duloxetine Treatment of depression (Alam et al., 2013) 
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Figure 1. 4: (a) Nose to brain pathway (Adapted from Olson, 2008), (b) a schematic 
illustration of the possible drug molecule transfer delivered nasally. (---) indicates 
limited substrate delivery via this route, and (?) indicates the exact pathway is 
unclear (Adapted from Illum, 2000). 
 (a) 
 (b) 
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1.2 Mechanisms of drug transport following intranasal administration  
The drug must pass through the mucus layer of the nasal cavity for absorption to take 
place. Uncharged molecules pass through the mucus much more readily than charged 
molecules. Two main mechanisms of drug absorption through nasal mucosa have been 
proposed: paracellular absorption and transcellular absorption (Figure 1.5). 
 
Firstly, the paracellular route is energy independent and occurs by drug passing through 
the aqueous spaces between the cells via a slow passive diffusion. In general, as the 
molecular size of the drug increases the intranasal absorption via this route decreases. 
For example, a drug with a molecular weight greater than 1 kDa has poor systemic 
bioavailability following nasal administration (McMartin et al., 1987), and  
bioavailability of these molecules can be enhanced using absorption enhancers (Ozsoy 
et al., 2009). Zhang et al. (2005) demonstrated that the systemic absorption of large 
molecular weight of recombinant hirudin-2 (rHV2) (6900 Daltons) improved 
intranasally by including absorption enhancer (e.g. chitosan 0.5%, hydroxypropyl-β-
cyclodextrin 5%, or ammonium glycyrrhizinate 1%) into the formulation. 
 
Secondly, transcellular absorption mechanism is applicable to lipophilic drugs, which 
are readily absorbed by diffusion through the epithelial cellular membranes of the nose. 
Transcellular transport of drugs might be carrier mediated or may involve opening of 
tight junctions for drug absorption. Excipients used in nasal formulations such as 
chitosan opens the tight junctions between cells and thus the drug transportation from 
nasal cavity to the systemic circulation is facilitated (Dodane et al., 1999; Mathiowitz et 
al., 1999).  
 
Thirdly, substances in the nasal mucosa particularly in the olfactory mucosa include: P-
glycoprotein, organic cation transporter, dopamine transporter, and amino acid 
transporters. These transporters transfer amino acids, amines and cations (Agu et al., 
2003; Kandimalla and Donovan, 2005a, 2005b). This mechanism is known as carrier 
mediated processes (Kimura et al., 1989). 
 
Fourthly, the mechanism for drug transportortation is endocytosis. In this mechanism 
materials are engulfed into the cell. The uptake of particles by nasal epithelial cells is 
mediated by the M cells. Endocytosis is the predominant mechanism for transporting 
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compounds that have molecular weights higher than 1000 Da such as proteins, peptides 
(Costantino et al., 2007), polypeptides and polypeptide-coated nanospheres in the range 
of 500 nm (Porta et al., 2000). It has been reported that the absorption of polar 
molecules (Illum, 2000) and larger peptides (Hinchcliffe and Illum, 1999) are greatly 
improved by the incorporation of absorbing enhancers into the formulation such as 
surfactants (e.g. sodium laurylsulfate), enzyme inhibitors (e.g. bestatin), bile salts (e.g. 
sodium deoxycholate), chitosan, and cyclodextrins (Davis and Illum, 2003; Jadhav et 
al., 2007). 
   
 
Figure 1. 5: Mechanisms of drug transport across epithelial cells: [A1] 
Intercellular spaces, [A2] Tight junctions, [B1] Passive diffusion, [B2] Active 
transport, and [C] Transcytosis (Adapted from Kushwaha et al., 2011). 
 
Permeation enhancers accelerate the rate of transportation of hydrophilic and larger 
protein and peptide molecules through mucosal membranes. A number of parameters 
control the safety and efficacy of nasal permeation enhancer, such as enzymatic 
activities of Cytochrome P450 isoenzymes in the nose, mucociliary clearance, duration 
of contact between formulation and nasal mucosa (Merkus et al., 1998). Absorption 
enhancers reversibly change the nasal mucosa, effectively increasing the drug 
absorption and do not cause local or systemic irritation or toxicity and their action is 
reversible (Aurora, 2008).  
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1.3 Factors affecting nasal drugs delivery  
For applications in brain targeting, local delivery and systemic delivery of drugs several 
factors should be considered prior to designing intranasal formulations. These are the 
physicochemical properties of drug, excipients to be included in formulation and the 
physiological condition of the nasal cavity (Figure 1.6) ( Behl et al., 1998; Dhakar et al., 
2011) . 
 
 
Figure 1. 6: Barriers interfering with drug delivery via the nasal route (Adapted 
Behl et al., 1998; Dhakar et al., 2011). 
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1.4 Barrier interfering nasal drug delivery 
1.4.1  Low drug bioavailability 
 Low bioavailability of some drugs might be ascribed to the high polarity or large 
molecular size (e.g. peptides and proteins). It has been reported that bioavailability of 
low molecular weight of hydrophilic drugs is around 10%, whereas less than 1% of 
lager molecules such as proteins (calcitonin) and peptides (insulin) are bioavailable 
(Illum, 2002). Nasal route is efficient, rapid and suitable for delivery of drug molecules 
having molecular weight less than 1000 Da. For particulate materials, particle size has 
an effect on absorption through the nasal epithelium. It has been reported that particles 
smaller than 1 μm may rapidly be absorbed following intranasal delivery (Donovan & 
Huang 1998). 
 
Proteins and peptides are transported across nasal epithelium in low proportions via 
endocytotsis (Jadhav et al., 2007). The low bioavailability of polar drugs, peptides and 
small proteins could be improved by using permeation enhancers (Dhakar et al., 2011; 
Illum, 2000). Chitosan is a natural mucoadhesive permeation enhancer for water soluble 
drugs (e.g. Atenolol) by opening the tight junctions between cells (Schipper et al., 
1999). Tengamnuay et al. (2000) have shown that chitosan can enhance the nasal 
absorption of peptides. The absorption of relatively impermeable small drug molecules 
also improved since it was prepared as an amino acid prodrug. For example, the 
absorption of acyclovir increased to 8% within 90 min when acyclovir was formulated 
as amino acid prodrug with L-Aspartate beta-ester, suggesting that prodrug might be 
transferred across mucosal membrane by active transportation rather than passing 
through pores (Yang et al., 2001). 
 
 
1.4.2 Mucociliary clearance  
Mucociliary clearance (MCC) is an essential defense mechanism for the elimination of 
foreign materials, pathogens and particles from the nose.  Materials are trapped in the 
mucus layer and are subsequently transported by ciliary beating to the nasopharynx and 
eventually to the gastrointestinal tract (Merkus et al., 1998) (Figure 1.7). This process 
reduces the nasal absorption of drugs (Jadhav et al., 2007). Overcoming the MCC and 
increasing the residence time of drug in the nasal cavity are obtained by incorporation of 
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mucoadhesive agents into formulation, which may enhance nasal absorption. Soane et 
al. (1999) have shown that the clearance half-life of radiolabeled material in liquid was 
15 minutes from the nasal cavity using conscious sheep. By contrast, using bioadhesive 
chitosan solutions the half-life was 43 min and when employing bioadhesive chitosan 
microspheres the half-life exceeded 110 min. Chitosan may decrease MCC, hence 
increasing contact time of the delivery system with nasal mucosa, which enhances the 
drug bioavailability (Soane et al., 1999).  
 
 
Figure 1. 7: Nasal mucociliary clearance (Adapted from Aurora, 2008). 
 
MCC can also be influenced by targeting the region of drug deposition in the nose. 
Posterior part of the nose is more ciliated than its anterior part, therefore the clearance 
of the drug deposited posteriorly might be faster than the drug deposited in the anterior 
part of the nose (Ugwoke et al., 2000).  For example, nasal sprays deposit drugs mainly 
in the anterior sections of the nasal cavity, leading to slower clearance than nasal drops 
which are directly instilled into the deeper regions of the nose (Illum, 2003).  
 
Hydrophilic molecules are highly soluble in the mucous and are highly cleared by MCC 
and their passage across the nasal membrane is very slow. Hence, factors that influence 
the MCC may modify the drug absorption profile. Environmental factors such as cold 
air (Diesel et al., 1991) and air pollution (e.g. presence of sulfur dioxide) (Wolff, 1986) 
caused reduction in the MCC. Cigarettes may increase the viscosity of the mucus and 
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decrease the MCC (Houtmeyers et al., 1999). Pathological factors also affect the MCC, 
for instance, in asthmatic and chronic obstructive pulmonary disease (COPD) patients 
(Merkus et al., 1998) (Table 1.5).  
 
Table 1. 5: Pathological conditions that may affect nasal mucociliary clearance 
(Adapted from Merkus et al., 1998). 
Pathological conditions MCC activity Proposed mechanism  
Asthma Increased 
Decreased 
Irritation and inflammatory process 
Epithelium damage 
Diabetes mellitus Impaired  dehydration and damaging of  
microvascular  
Cystic fibrosis Impaired Epithelium damage 
Bacterial and viral 
infections 
Impaired Loss of cilia and change of mucus 
properties 
Primary ciliary 
dyskinesia 
Impaired Absence or dysfunction of cilia 
 
 
1.4.3 Enzymatic degradation  
Bogdanffy (1990) showed that some drugs, proteins and peptides may degrade by the 
enzymatic activity in the nose. Carboxyl esterases, aldehyde dehydrogenases, epoxide 
hydrolases, glutathatione S-transferases and cytochrome P450 isoenzymes are present in 
the nasal epithelial cells and play a role in the degradation of drugs in the nasal mucosa 
(Bogdanffy, 1990). The enzymatic barrier may be overcome by using either enzyme 
inhibitors or enzyme saturators (Morimoto et al., 1991a).  Morimoto, (1991a) used 
camostat mesilate as a proteolytic enzyme inhibitors. This strategy enhances the 
permeation of vasopressin and desmopressin across the nasal mucosa. It has also been 
reported that protection of salmon calcitonin by poly(ethylene glycol) from enzymatic 
degradation may enhance the absorption of salmon calcitonin across the epithelium (Na 
et al., 2004; Shin et al., 2004).  
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1.5  Dosage forms for intranasal administration 
Delivery of drugs via the nose has some challenges. Physicochemical properties of the 
drug and nasal formulations must be considered to achieve appropriate delivery. 
Effectiveness of the drug in low dose, aqueous solubility, minimal nasal irritation, 
absence of toxicity on the nasal mucosa and chemical stability of the drug 
administration  via nose should all be considered (Behl et al., 1998).  
Nasal formulation design depends on the therapeutic requirements of the particular drug 
molecule, the time needed for the drug to elicit its therapeutic effect, the duration of 
therapy, patient population, proposed indication and marketing preferences. The nasal 
route provides potential for both controlled and conventional drug release. The mode of 
drug delivery whether it is local or systemic determines the type of excipients to be used 
(Jadhav et al., 2007). Three major types of dosage form are available for nasal 
administration: liquids, powders, and gels. Ointments and emulation are also available 
but less common (Behl et al., 1998).  
 
 
1.5.1 Liquid formulations 
Liquid dosage forms are usually aqueous solutions, suspensions or emulsions, however, 
formulations made with oily or alcoholic vehicles are also available. Humidifying effect 
is important for nasal mucosa as allergy and irritation are mainly related to dryness of 
the mucus membrane. The main drawbacks of liquid dosage forms are:  
 
(i) The microbial growth is possible, necessitating the use of preservatives.  
(ii) Long-term use of liquid dosage forms may interfere with nasal mucociliary 
function and cause irritation due to the presence of preservatives in the nasal 
formulations. 
(iii) Short half-life of the drug because of its liability for degradation (Kublik and 
Vidgren, 1998).  
(iv) Probability of dripping out of the liquid dose from the nostril following 
administration (Keldmann, 2005). Liquid dosage forms are easily removed 
to the posterior part of the respiratory tract by mucociliary clearance 
(Jiménez-castellanos et al., 1993).  
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1.5.2 Nasal Powders  
Preparation of chemically unstable drugs as powders enhance their stability profile 
compared to their solutions or dispersions. Powder dosage form is suitable for non-
peptide and peptide drugs with no preservatives or freeze storage being required (Huang 
et al., 2004; Jadhav et al., 2007). Residence of the powdered drug in the nose can be 
improved compared to liquid formulations and patient compliance might also be 
enhanced, especially with drugs having unpleasant odour or taste. However, when 
preparing nasal powders several factors need to be considered. These are solubility of 
the drug, particle size of the powdered formulation, aerodynamic properties of the 
particles and the possible irritation of the drug or excipients on the nasal epithelium 
(Kublik and Vidgren, 1998). Ideally, particles larger than 10µm are likely to deposit in 
the nasal passages ( Behl et al., 1998), whilst particles larger than 0.5 µm filtered out in 
the nose (Burgess et al., 2004). Depending on the bulk density of the powder, it is 
possible to administer up to 50 mg of the formulation, whilst the maximum volume of 
liquid administration for each nostril in one time is 150 µl (Davis, 1999).  
 
The polymer in powder formulations enhances the interaction between the drug and 
mucosa by converting into a viscous gel following contact with the fluids in the nasal 
cavity, resulting in decreased mucociliary clearance and prolonged residence of the drug 
in the nasal cavity. This can improve drug permeation, increase drug bioavailability and 
sustain drug release from its viscous matrix (Illum et al., 1987; Soane et al., 2001). 
Using sheep as an animal model and gamma scintigraphy for imaging, Soane et al. 
(2001) have found the rate of clearance of chitosan microparticles from nasal cavity to 
be slower than chitosan solution.  
 
Powder formulations consisting of water insoluble and non-swellable drug carriers 
improve the bioavailability of hydrophilic drug molecules. Ishikawa et al., (2001) 
showed systemic bioavailability of the elcatonin based on calcium carbonate in rabbits 
and rats increased after nasal administration compared to the liquid form. Optimization 
of particle size and morphology for nasal formulations may reduce the risk of mucosal 
irritation and enhance the deposition (Gad, 2008). The mucosal irritation, difficulty and 
cost of the formulation due to optimization of particle size and morphology are major 
limitations for development of powdered nasal formulations (Behl et al., 1998). 
Insufflators are convenient and simple devices for nasal administration of powders 
(Kublik and Vidgren, 1998). 
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1.5.3 Nasal Gels 
Pharmaceutical gels are semisolid preparations in which the drug is dispersed in a 
polymeric matrix. Gels have several advantages including:  
 
(i) Reduced mucociliary clearance owing to the high viscosity of gels.  
(ii) Masked unpleasant taste of the formulation due to reduced accessibility of 
the formulation to the nasopharynx.  
(iii) Reduced loss of the formulation from nostril while breathing or sneezing.  
(iv) Minimized irritation due to the soothing effect of excipients used in nasal 
gel.  
(v) Enhanced contact between the drug and nasal mucosa, which may enhance 
the absorption profile of the drug (Behl et al., 1998). Vitamin B12 was the 
first nasal gel introduced to the market. TBS-3 is an intranasal gel 
formulation of dopamine used for the treatment of Parkinson's disease 
(www.trimelpharmaceuticals.com).   
 
1.6 Factors affecting particle deposition in nasal cavity  
The nasal system is responsible for filtering air during inhalation of harmful materials, 
which may deposit in the respiratory airways. Five mechanisms have been proposed for 
deposition of nasally inhaled particles, which are impaction, sedimentation, diffusion, 
interception and electrostatic precipitation. However, only diffusion, impaction and 
sedimentation have major roles in nasal deposition of particles (Lippmann et al., 1980).  
 
Interception mechanism is important for deposition of fibrous molecules when the 
trajectory of particle is close to the epithelium. Straight fibres such as amphibole 
asbestos may have higher probability to travel to the alveolar region than chrysotile 
asbestos (non-needle shape) of similar size, because the fibres may orientate themselves 
parallel to the air flow streamline (Lippmann et al., 1980). 
 
Brownian diffusion mechanism is important for particles smaller than 0.5 µm, resulting 
in possible deposition in the alveolar region, small airways and airway bifurcations. In 
the small conducting airways, bronchioles, and the alveolar region when the air velocity 
is low the deposition of particles mainly occurs by gravitational sedimentation which is 
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influenced by changes of particle size (Lippmann et al., 1980; Kublik and Vidgren, 
1998). Stoke’s equation (Eq. 1.1) describes the rate of particle settling being 
proportional to the square of the particle diameter (Kublik and Vidgren, 1998).  
 
 
(   )                                                                                                (Eq. 1.1) 
  
Where: ρ is density of the particle; σ is density of the air; d is diameter of the particle;   
is gravitational acceleration, and   is viscosity of the air. 
The diffusion mechanism is prominent for deposition than sedimentation mechanism 
when the settling velocity of the particles falls below 0.5cm/s (Lippmann et al., 1980).  
Impaction mechanism is significant for deposition in the nose and oropharynx when the 
particles are larger than 1µm and occurs when the particle changes its direction during 
inhalation (Kublik and Vidgren, 1998). The probability of deposition by impaction 
mechanism in bend airway can be described by equation 1.2: 
 
(        )/R                                                                                           (Eq. 1.2) 
 
 
Where: θ is angle of the bend; U is airstream velocity; d is particle aerodynamic 
diameter and R is airway radius. 
 
It has been concluded from Eq.1.2 that the anatomy of the airways and inhaled particle 
size and the velocity of airstream all have effects on particle deposition by impaction 
(Kublik and Vidgren, 1998).  
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1.7 Mucoadhesive drug delivery systems 
The concept of mucoadhesion, also called bioadhesion, has been applied since 1980s, in 
order to increase the residence time of formulations at the site of absorption for local or 
systemic therapeutic effects (Patil and Sawant, 2008). Mucoadhesive agents are 
synthetic or natural polymers which adhere to biological or mucosal surfaces (Carvalho 
et al., 2010). Mucoadhesion results from strong interactions between polymer and the 
mucus (Lee et al. 2000).  
 
Mucoadhesive systems are formulations used to slow down the mucociliary movement, 
decrease mucosal enzymatic activity and open the tight junctions to enhance permeation 
of drug through the epithelial tissue (Smith et al., 2004; Chaturvedi et al., 2011). 
Mucoadhesive systems thus improve therapeutic outcomes by keeping the drug at the 
site of action for extended time, target the drug to the specific tissue and control the 
drug release, resulting in decreased frequency of drug administration and improve 
patient compliance (Carvalho et al., 2010; Shaikh et al., 2011).  
 
Mucoadhesive systems may also improve the dissolution of poorly water-soluble drugs 
(Gavini et al., 2011). Gavini et al. (2011) observed improvements in the solubility of 
rokitamycin loaded into chitosan microspheres compared to the free drug when the 
intranasal drug absorption was assessed in vivo using rat as animal model. 
Mucoadhesion is suitable for tissues covered with mucus such as those in the buccal, 
sublingual, vaginal, rectal, ocular, gastrointestinal and nasal regions, resulting in 
improved drug absorption ( Smart et al. 1984; Tsuneji et al. 1984; Morimoto et al. 
1991). A number of theories explain the mechanisms involved in the interactions 
between polymers and mucus. An optimal degree of polarity is required for the polymer 
to wet and swell sufficiently when contacting the mucus layer, and interpenetration 
between mucus and polymer chains should take place to achieve bioadhesion (Patil and 
Sawant, 2008). 
 
Various biocompatible and biodegradable polymers have been used to formulate 
mucoadhesive system for examples, poly-vinyl alcohol (Swamy and Abbas, 2012), 
PLGA (Guerrero et al., 2008), chitosan (Alhalaweh et al., 2009) and  
hydroxypropylmethylcellulose, hydroxypropyl- cellulose  and  sodium alginate 
(Rathananand et al., 2007). 
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1.7.1 Chitosan  
In recent years chitosan has been used in drug delivery formulations and widely in the 
pharmaceutical industry due to safety and availability (He et al., 1999, 1998). Chitosan 
polymer is a useful drug delivery matrix due to its polycationic nature, ability to  
improve dissolution of poorly water soluble drugs, biodegradability, biocompatibility 
non-toxicity, mucoadhesive properties and convenience in manipulating the physical 
characteristics and chemical structure (Sinha et al., 2004). Chitosan is a linear 
polysaccharide derived by the deacetylation of chitin obtained from crustacean shells 
(Figure 1.8). It is a weak base, poorly soluble in water and practically insoluble in all 
common organic solvents, however it dissolves in acidic aqueous solutions (dos Santos 
et al., 2005).   
 
Chitosan is used in tablet formulations as a disintegrant, binder or vehicle for 
controlling the drug release and improving the dissolution and bioavailability of poorly 
soluble drugs (Sinha et al., 2004). Chitosan has been formulated as microspheres for 
controlled drug delivery, for example, many drugs such as zolmitriptan (Alhalaweh et 
al., 2009), 5-fluorouracil (Sun et al., 2010), aceclofenac (Nagda et al., 2010), ketorolac 
(Nagda et al., 2012), cisplatin (Singh et al., 2012), albendazole (García et al., 2013), and 
ofloxacin (Park et al., 2013) have been formulated as chitosan microspheres. The 
mucoadhesiveness of chitosan arises from the electrostatic interactions between the 
cationic amino groups  on the chitosan and the anionic moieties on the mucus layer such 
as sialic and sulphonic acid groups )Lachman et al. 1986). In vitro studies of 
mucoadhesion on sheep nasal mucosa conducted by Patil and Murthy (2006) 
demonstrated that when the concentration of chitosan was increased the level of 
mucoadhesion also increased due to the increase of the number of cationic amino 
groups available for interaction with sialic acid residues of the mucin. Chitosan can also 
enhance the epithelial permeability of the drug through the epithelial cells (Fernandez-
Urrusuno et al., 1999; Smith et al., 2004) and can decrease the nasal mucociliary 
clearance, resulting in prolonged drug contact with nasal epithelium and enhanced drug 
absorption (Soane et al. 1999).  
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Figure 1. 8: Chemical structure of chitin and chitosan (Adapted from Jayakumar 
et al., 2010). 
 
1.7.2 Sodium alginate 
Alginic acid also called algin or alginate is a hydrophilic colloidal natural 
polysaccharide, consisting of a linear copolymer of  (1,4)-linked β-Dmannuronic acid  
(block M) and  α-L-guluronic acid residues (block G) (Figure 1.9) (Gombotz and Wee, 
1998), and a sodium ion attached to carboxylate groups to balance its charges. It is 
available in filamentous, granular or powdered forms usually having a white to 
yellowish-brown colour. It is an anionic polysaccharide extracted from cell walls of 
brown algae (seaweed). When it contacts with water alginate forms a viscous gum due 
to its aqueous solubility and can absorb more than 100 times its weight of water (Rowe 
et al., 2009). Different methods have been used for manufacturing alginate 
microparticles, including  spray drying (Coppi et al., 2002), ionotropic pregelation 
(Sarmento et al., 2006),  and  nanoemulsion dispersion (Reis et al., 2006).  
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Figure 1. 9: Chemical structure of alginic acid unites "M"is mannuronic acid and 
"G" is guluronic acid) (Adapted from Bu et al., 2005). 
 
Alginic acid has attractive physicochemical properties such as non-toxicity, 
biodegradability, non-immunogenicity and abundance for commercial use for micro and 
nano encapsulation (Soares et al., 2004). It can be used as a coating polymer, resulting 
in prolonged diffusion rate of the drug through the porous gel of the polymer. 
Furthermore, alginate is gelled in aqueous media by the presence of divalent cation such 
as calcium (Gombotz and Wee, 1998). The mucoadhesive properties can be attributed to 
the anionic carboxyl groups, facilitating the adherence to the mucous membranes by 
forming hydrogen bonds (Raj & Sharma 2003). Tafaghodi et al. (2004) showed that 
alginate has potential mucoadhesion properties and it can be used to formulate 
mucoadhesive delivery systems for intranasal administration.  
 
Alginate has been used to formulate microparticles for controlling drug release. For 
examples, metformin (Balasubramaniam et al., 2007), theophylline (Soni et al., 2010), 
norfloxacin (Chakraverty, 2011), diclofenac sodium (Amin et al., 2013), and furosemide 
(Sunilbhai et al., 2014) have been formulated as alginate based microspheres. 
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1.8 Microspheres as a drug delivery system 
Microspheres are polymeric spheres in the size range of 1 - 1000 µm. Due to their high 
surface area, microspheres can interact with mucin and increase residence time of the 
formulation with epithelial cells (Vasir et al., 2003). Microparticle carriers protect drug 
from the enzymatic or chemical degradation in vivo (Morimoto et al., 2001). Particulate 
bioadhesive systems may accommodate the drug and release it over a long period of 
time, resulting in reduced dosing frequency (Vasir et al., 2003). 
 
Mucoadhesive microspheres have the ability to swell and form viscous gels upon 
contact with mucous layer retaining the drug for extended time at the site of absorption. 
Mucoadhesive particles may also open the tight junctions between the cells further 
promoting drug absorption (Pereswetoff-Morath, 1998). Gungor co-workers (2010) 
have reported ondansetron loaded chitosan microparticles may give significant plasma 
drug concentration with maintaining plasma drug level for longer periods compared to 
the intranasal ondansetron solution using rat as animal model (Gungor et al., 2010). 
 
1.8.1 Preparation of microspheres 
There are many methods use for preparation of microspheres (Figure 1.10). Among 
these methods, spray drying is a common technology for manufacturing dry powders, 
granules and agglomerates from drug-excipient solutions or suspensions (Figure 1.11). 
It involves atomization followed by drying and deposition of powders in collecting 
vessel (Maa et al., 1998). The first stage involves supplying a liquid feed dispersed 
through an atomizer into fine droplets in inert gas in the drying chamber. The large 
surface area promotes rapid solvent evaporation. Dried particles are passed over to a 
cyclone compartment for separation and a narrow particle size distribution (1 - 5 µm) is 
yielded depending on the spray drying parameters. Various methods have been used to 
prepare microspheres by spray drying. Microspheres made of water-insoluble polymer 
polylactic acid (PLA) or poly(lactide coglycolide) (PLGA) were used to prepare 
paclitaxel loaded microspheres (Mu and Feng, 2001), ketotifen loaded microspheres 
(Guerrero et al., 2008) and for the encapsulation of water-soluble materials such 5-
Fluorouracil (Blanco et al., 2005). However, water-soluble polymers such as chitosan 
glutamate and sodium alginate were used to prepare zolmitriptan loaded microspheres 
(Alhalaweh et al., 2009) and levocetirizine dihydrochloride loaded microspheres 
(Rathananand et al., 2007). Spray drying involves dissolving the polymer in a suitable 
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solvent with the drug dispersed in the polymeric solution. The solvent is then 
evaporated in the drying chamber to form the dried microspheres.  
 
 
 
Figure 1. 10: General methods used for microspheres preparation (adapted from 
Sinha et al., 2004). 
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Figure 1. 11: Mini spray dryer B-290 (Büchi -290 Mini Spray-Drying, Büchi 
Laboratories, Switzerland) (www.mybuchi.com).  
 
 
1.9 Liposomes  
Liposomes are microscopic phospholipid bilayer vesicles that can entrap a wide range 
of therapeutic molecules (Laouini et al., 2012) (Figure 1.12). Liposomes are composed 
of biodegradable and biocompatible materials, such as phospholipids including 
phosphatidylcholines (PC), phosphatidylserines (PS) and phosphatidylethanolamines 
(PE) (Fukunaga et al., 1991). 
 
Liposomes consist of one or several bilayers each has a thickness of around 4 nm, and 
the final size ranges falls between 20 nm and to 20 µm. Liposomes were first developed 
by Alec Bangham  (Bangham et al., 1965). Upon hydration of phospholipid phase, polar 
head groups expand and vesicles are formed (Lasic, 1988) .  
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Figure 1. 12: Structure of liposomes and the entrapment of lipophilic and 
hydrophilic drug molecules (Adapted from Laouini et al., 2012). 
 
Liposomes improve the therapeutic efficiency by targeting the drug to its site of action, 
enhancing absorption and provide protection from enzymatic degradation and immune 
recognition (Kisel et al., 2001) by facilitating the drug uptake by cells via endocytosis. 
Liposomes sustain the release of the drug, resulting in maintained drug level within the 
therapeutic window for a prolonged time (Gregoriadis and Florence, 1993).  
Liposomes are prone to fusion, aggregation and hydrolysis, hence poor stability does 
not allow storage for long periods. Incorporating cholesterol into liposome formulations 
improves liposome stability (Kirby et al., 1980). Proliposomes are dry products 
consisting of encapsulated drug into phospholipid; upon addition of water proliposome 
may generate liposomes (Shaji and Bhatia, 2013). Proliposomes provide stable 
alternatives to liposome that are known to be unstable during storage (Payne et al., 
1986). The use of liposomes as drug carriers in nasal delivery for local or systemic 
effects has been investigated and regarded promising compared to other nanosystems 
(Chen et al., 2013).  
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The use of polysaccharide such as chitosan for coating liposomes has been reported  to 
obtain desirable characteristics, better targeting and controlled drug release (Takeuchi et 
al., 1996; Janes et al., 2001). The use of polymeric mucoadhesive coat on liposomes by 
mixing the polymer with the aqueous dispersion of liposomes can manipulate the 
characteristics of liposomes and enhance their storage stability (Takeuchi et al., 2000). 
Natural polymers (e.g. alginate and chitosan), synthetic polymers (e.g. polyvinyl 
alcohol) and other polysaccharides have been used to manipulate the surface properties 
of liposomes (Cheng et al., 2006; Takeuchi et al., 2000). 
Natural cationic polymers such as chitosan coat the liposome vesicles by interacting 
with the negatively charge diacetyl phosphate in the phospholipid, resulting in enhanced 
bioavailability of the liposome-entrapped drug and improved permeation by opening the 
tight junctions between the cells (Takeuchi et al., 1996). 
 
1.9.1 Classification of liposomes 
Based on their size and morphology, liposomes might be classified into Multilamellar 
liposome vesicles (MLVs), Small unilamellar vesicles (SUVs), Large unilamellar 
vesicles (LUVs), Oligolamellar vesicles (OLVs) and Multivesicular liposomes (MVLs) 
(Fig. 1.13). 
i) Multilamellar vesicles  
MLVs consist of several phospholipid bilayers and size is larger than 500 nm (Laouini 
et al., 2012) (Figure 1.13). Rotary evaporator is used to prepare a thin lipid film in 
around bottomed flask while the organic solvent (e.g. chloroform) evaporated and 
collected via a condenser for disposal or reuse. Rehydration of the thin film above the 
transition temperature (Tm) of the phospholipid takes place by addition of water with 
shaking to form MLVs (Shek et al., 1983). 
ii) Small unilamellar vesicles  
These consist of a single phospholipid bilayer enclosed in an aqueous volume. SUVs 
range in size between 25 and 100 nm (Fig. 1.13). They are prepared either by gentle 
sonication of lipid dispersion for 5 to 10 minutes using probe tip or bath sonicator, or by 
sonication of multi-lamellar vesicles (Pitcher Iii and Huestis, 2002). 
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iii) Large unilamellar vesicles  
This type of liposome is similar to SUVs and consists of a single phospholipid bilayer 
but vesicles have a larger size in the range of 0.1 μm to 1 μm (Figure 1.13).  It provides 
a high loading efficiency of hydrophilic drugs compared to MLVs. To formulate LUVs, 
ethereal phospholipid solution is added to a previously heated aqueous phase above the 
Tm of phospholipid (Deamer and Bangham, 1976).     
iv) Oligolamellar vesicles  
Oligolamellar vesicles (OLVs) are MLVs possessing two or three phospholipid bilayers 
(Fig. 1.13). The OLVs are in the range of 100 - 500 nm (Laouini et al., 2012). They are 
prepared by the reverse phase evaporation method, which produces a mixture of OLVs 
and LUVs (Szoka and Papahadjopoulos, 1978). Ethanol-based proliposome method also 
generates OLVs (Perrett et al., 1991). Ethanol-based proliposomes are concentrated 
ethanolic solutions of phospholipid that generate liposomes upon addition of aqueous phase 
and shaking (Perrett et al., 1991).  
v) Multivesicular liposomes  
MVLs are liposomes enclosing a group of liposomes (Kim et al., 1983) (Figure 1.13). 
MVLs could be used for sustained release action when prepared by reverse phase 
evaporation technique (Jain et al., 2005). This technique may increase entrapment 
efficiency by 3 to 6 times compared to the conventional MLVs. Jain et al (2005) have 
reported 70% of acyclovir was released over 96 hours, whereas 80% of the drug was 
released from the conventional MLVs within 16 hour. 
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Figure 1. 13: Liposome classiﬁcation based on reside size and morphology 
(Adapted from Laouini et al., 2012). 
 
1.9.2 Liposomes in nasal drug delivery 
Intranasal drug delivery using liposomes has been employed since 1992 by Alpar et al., 
(1992), who studied the immunogenicity of Tetanus toxid loaded liposomes using 
distearoyl phosphadylcholine (DSPC) and cholesterol (1:1) and compared the immune 
response to that elicited by the free antigen. Liposome loaded antigen significantly 
improved the immune response compared to the free antigen after intranasal delivery. 
 
Vyas et al (1995) prepared multilamellar liposomes loaded with nifedipine. When 
bioadhesive agents were included in the formulation, nifedipine bioavailability 
improved and the plasma drug concentration was maintained over a prolonged time. 
 
The rapid onset and sustained release of levonorgestrel using liposomes was 
demonstrated by Ding et al. (2007) who studied the pharmacokinetics and 
pharmacodynamics of levonorgestrel following intranasal administration. The relative 
bioavailability obtained using liposomes was 100%. Another study by Chen et al. 
(2009) demonstrated the improvement of salmon calcitonin absorption using 
ultradeformable liposomes via nasal delivery in rat. 
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Benefits of liposomes for nasal delivery of peptide vaccines together with anti-CD40 
antibody has also been reported (Ninomiya et al., 2002). Formulation of DNA-hsp65 
vaccine complexed with cationic liposomes allowed a 16-fold reduction in the DNA 
dose when given intranasally to elicit a cellular immune response (Rosada et al., 2008). 
 
The attracting applications of liposomes for targeting of the drug to the brain have been 
studied. Armugam et al. (2008) demonstrated that intranasal administration of 
rivastigmine loaded liposome significantly passed to the brain with longer half-life 
compared to the drug given as solution.  
 
The addition of bioadhesive agents to liposomal formulations delivered intranasally 
enhanced bioavailability and prolonged residence time of the drug at site of absorption. 
Alsarra et al. (2008) demonstrated that acyclovir loaded liposomal in mucoadhesive 
nasal gel formulation may significantly increase drug bioavailability (60.72%) 
compared to liposome free gel formulation (5.3%). Using rats, Qiang et al (2012) 
investigated the effect of incorporating chitosan into liposome formulations loaded with 
fexofenadine on the systemic absorption profile of the drug. Intranasal delivery 
chitosan-coated liposome significantly increased the bioavailablity of fexofenadine with 
a prolonged effect compared to powder and uncoated liposome formulation.  
 
1.10 Parkinson’s disease and restless legs syndrome  
Parkinson’s disease is a common neurodegenerative disorder of the central nervous 
system (Jankovic, 2008). It is named after James Parkinson the English doctor who 
published the first detailed description in ―An Essay on the Shaking Palsy‖ (1817). Its 
symptoms resulting the death of dopamine generating cells of the midbrain (Olanow et 
al., 2001). Shaking, rigidity, slowness of movement and difficulty in walking are 
equivalent in patients suffering from Parkinson’s disease. Symptoms also include 
sensory, sleep and emotional problems (Jankovic, 2008). It occurs in 0.3% of the 
population and it is common in elderly people of 60 years of age or over by 1% 
(Olanow et al., 2001; Samii et al., 2004). It is idiopathic and the cause is not known. 
Levodopa (L-dopa) and dopamine agonists are the main treatments used to control the 
signs and symptoms of Parkinson’s disease. Using these drugs for a long period may 
cause marked motor complications such as motor fluctuations and dyskinesia. It has 
been shown that after 4 - 6 years of levodopa therapy that nearly 40% of Parkinson’s 
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disease patients may suffer from these adverse effects (Ahlskog and Muenter, 2001), 
and this percentage increases over time (Alves et al., 2008). Using of non-ergoline 
dopamine receptor agonists may reduce motor fluctuations in patients with advanced 
Parkinson’s disease such as ropinirole, and pramipexole (Brooks, 2000). 
 
Restless legs syndrome (RLS) is a neurological disorder characterised by irresistible 
urge to move the body to stop uncomfortable sensations. Legs, arms, and torso are 
affected and the movement modulates the sensation providing relief temporarily. These 
symptoms are alleviated by movement and are more common at rest, especially in the 
evening and at night. The sensations are similar to itching and tickling that does not 
stop. Limb jerking during sleep is an objective physical marker and disrupts restful 
sleep. This disease impairs the neurological functions (Allen et al. 2002). In the human 
populations approximately 5-10% suffer from RLS, however only a small proportion 
seek medical treatment (Phillips et al., 2000; Rothdach et al., 2000). The efficacy of L-
dopa with a peripheral decarboxylase inhibitor has been established from the range of 
dopaminergenic agents available (Brodeur et al., 1988). There is a high incidence of 
long-term side effects, which increase the severity of the symptoms (Allen & Earley 
1996). An effective and well tolerated treatment has been found by using of ropinirole 
for the treatment of restless legs syndrome with improved sleep and cognitive 
functioning (Trenkwalder et al., 2004).  
 
1.11 Ropinirole hydrochloride  
Ropinirole hydrochloride (RH), commonly used for Parkinson’s and restless legs 
syndrome, is administered orally as dopamine receptor agonist. Ropinirole 
hydrochloride is identified chemically as 4-[2-(dipropylamino) ethyl]-1,3-dihydro-2H-
indol-2- one hydrochloride. The chemical structure of RH is shown in Figure 1.14. It 
has a molecular mass of 296.84 (260.38 free base) and its molecular formula is 
C16H24N20.HCl. 
 
 
 
 
CHAPTER 1 
37 
 
N
H
N(CH2CH2CH3)2 HCl
O
 
Figure 1. 14: Chemical structure of ropinirole hydrochloride. 
 
RH is a white to yellow solid with a melting point in the range of 243 - 250°C and an 
aqueous solubility of 133 mg/ml. The tablet formulation of this drug contains 0.29 mg, 
0.57 mg, 1.14 mg, 2.28 mg, 3.42 mg, 4.56 mg, or 5.70 mg RH equivalent to ropinirole, 
0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, or 5 mg respectively (GlaxoSmithKline, 
2009).  
 
As mentioned above, Ropinirole is used to treat Parkinson’s disease by alleviating the 
dopamine defficiency. It is a non-ergoline dopamine D2/D3 receptor agonist that 
stimulates striatal dopamine receptors (Matheson and Spencer, 2000).  Ropinirole binds 
to central and peripheral dopamine receptors with an order of receptor affinity similar to 
that of dopamine (Jost and Angersbach, 2005). It is highly selective D3 rather than D2. 
Ropinirole is 20 times more selective for D3 receptors than D2 receptors and about 50 
times more selective for D3 than D4 receptors, with negligible affinity for D1 receptors 
(Matheson and Spencer, 2000). It has little or no affinity for β-adrenoceptors or 
adrenergic, serotonergic, GABA or benzodiazepine receptors. Ropinirole acts on 
postsynaptic dopamine receptors in the CNS associated with Parkinson’s disease 
(Matheson and Spencer, 2000).  
 
Ropinirole has about 50% bioavailability since it undergoes first pass effect after 
absorption. The main metabolic pathway is the cyto-chrome P450 (CYP) isozyme 
CYP1A2, with a minor contribution from CYP3A. 10% of a ropinirole dose is excreted 
unchanged in urine (Kaye and Nicholls, 2000). The distribution volume of ropinirole is 
7 L/kg, with plasma protein binding of 10–40%. Ropinirole has an average elimination 
half-life of approximately 6 hours (DrugBank, 2013). 
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1.12 Devices used for nasal delivery  
Variety of devices can be used for the nasal administration of dosage forms. Nasal drops 
and nasal sprays are delivery devices for liquids formulations, while nasal insufflators 
are delivery devices for powders. 
 
1.12.1 Nasal drops 
Nasal drops are the most traditional nasal devices for intranasal administrations of 
liquids owing to their low manufacturing cost. The main disadvantages of nasal drop 
devices are lack of precision in the administered dose and the risk of contamination 
during treatment. An issue that is overlooked is the special expertise required during use 
of nasal drops. For maximum benefit the patient should keep the nostril uppermost and 
the administration angle at 90
o
 angle (angle between subject’s head and nasal drop 
device) while instilling the dose. The head is swirled from side to side after application 
of drops to nostrils (Washington et al., 2001).   
i) Drops delivered with a pipette 
In this type of nasal drops, the quantity of dose administered depends on pulling a 
volume of the formulation into a glass dropper followed by placing the tip of the 
dropper into the nostril and squeezing the rubber top to release the formulation as drops 
(Figure 1.15a) (Djupesland, 2013). Clinical efficacy of fluticasone formulation using 
single dose pipette has been reported to be significantly higher than that using a nasal 
pump in patients with nasal polyps (Penttilä et al., 2000). 
ii) Squeeze bottles 
Squeezing bottles and nasal drops with pipette are recommended for exerting local 
therapeutic effects such as those used for delivery of liquid nasal decongestant 
formulations (Figure 1.15b). Squeezing a plastic bottle causes the release of air inside 
the bottle from a narrow orifice. This generates a small spray volume into the frontal 
region of the nostril. The drawback of this device is air pulled back into the container 
following the release of the dose which may pull part of the nasal secretions into the 
bottle, resulting in contamination of the formulation (Djupesland, 2013). The droplet 
size and dose accuracy are strongly dependent on the force applied on the plastic bottle 
to release the medication (Djupesland, 2013) resulting in poor control over the delivered 
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dose. Thus, this device is not recommended for use in children (Kublik and Vidgren, 
1998).    
 
 
Figure 1. 115: (a) Nasal drops with pipette (www.adelphi-hp.com), and (b) nasal 
squeeze bottles (www.webpackaging.com).  
 
1.12.2 Nasal Sprays 
Nasal spray system consists of a chamber, a piston and an operating actuator. Unlike 
nasal drops, nasal spray generates precise doses (25 - 200 µl) per spray due the presence 
of pumps and actuators. In vitro studies have shown nasal sprays to produce consistent 
doses and reproducible plume geometry. Particle size of the generated drops, spray 
pattern, dose accuracy are affected by the formulation properties such as thixotropic 
behaviour, viscosity and surface tension (Kublik and Vidgren, 1998). The applied force, 
orifice size, design of the pump and formulation can all affect the droplet size and 
plume geometry of the spray (Djupesland, 2013). Doses are delivered by nasal sprays 
either by using metered-dose spray pumps or pressurized metered dose inhalers 
(pMDIs).  
i) Metered- dose spray pumps 
Spray pumps operate by replacing the generated liquid spray with air. Hence, 
preservatives are needed to prevent microbial contamination of the formulation. Priming 
and repriming are required before starting the delivery and when keeping it for a long 
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time to maintain consistency of the delivered dose. Different types of spray systems 
have been developed by manufacturers to overcome the risk of contamination and 
minimise irritation caused by inclusion of preservatives in the formulations. This was 
achieved either by designing a movable piston, collapsible bag or compressed air 
(carbon dioxide or nitrogen) to replace the vacuum created by the emitted volume. The 
pump prevents air from being pulled into the container during the generation of the 
spray (Kublik and Vidgren, 1998) (Figure 1.16). These systems generate reproducible 
spray regardless of the position of the device and spraying angle, offering convenience 
for use by children and patients confined to bed (Djupesland, 2013). 
 
 
Figure 1. 16: (a) Airless nasal device with collapsibile bag (Bag on valve system) 
(Adapted from www.aptar.com), and (b) airless nasal device with sliding piston 
(PAS 27, Valois S.A., Le Neubourg, France) (Adapted from Kublik and Vidgren, 
1998). 
                    
Another system (Figure 1.17a), is preservative-free and operates by employing an 
aseptic filtration system, hence the air is pulled into the container while dose is emitted 
and filtered, resulting in prevention of microbial contamination (Kublik and Vidgren, 
1998). Single and double-dose spray device (Figure 1.17b) is more useful than metered 
dose spray pumps for drugs that have narrow therapeutic index. Examples of this 
system are Zomig
®
 (Zolmitriptan) nasal spray and Migranal
®
 (dihydroergotamine 
mesylate, USP) nasal spray which are used for the treatment of migraine headaches 
(Djupesland, 2013). 
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Figure 1. 17: (a) Preservative free pump with air filter (Adapted from 
www.aptar.com), and (b) nasal unit-dose system with glass container 
(www.aptar.com). 
 
ii) Nasal pressurized metered-dose inhalers  
Nasal pressurized metered-dose inhalers (pMDI) systems have been used for eliciting 
local therapeutic effects in the nose. The major sites of dose deposition are the anterior 
non ciliated regions of the nasal vestibule and anterior parts of the narrow nasal valve. 
Cholrofluorocarbon propellants cause irritation and dryness to the nasal mucosa. 
Moreover, the speeds of particles are much higher than those emitted from spray pumps. 
For these reasons, cholorofluorocarbon propellants have been replaced by 
hydrofluoroalkane propellants (Djupesland, 2013). Examples of pMDIs are budesonide 
and beclometasone dipropionate, which are used for the treatment of allergic rhinitis.  
1.12.3 Delivery devices of powdered nasal formulations 
Several designs of devices are available for delivery of nasal powders consisting of two 
pieces connected to each other, the mouthpiece and the nosepiece. When the patient 
blows air into the mouthpiece, particles are delivered to the nosepiece and then to nasal 
passage. Other systems operate by allowing the patient to sniff the powder stored in 
capsule or a blister placed within larger devices. Compressible compartments might be 
employed to expel the powders into the nostril with the aid of air pressure (Djupesland, 
2013). The most commonly used devices for delivery of nasal powders are nasal 
insufflators. 
(b) 
(a) 
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i) Nasal insufflators for experimental purposes 
Nasal insufflators or powder aerosolizers are tube-like containers in which powdered 
drug formulations can be stored. Alternatively, these tubes are connected with syringes 
or air pump to blow the powder into the nostril (Figure 1.18).  
 
 
 
Figure 1. 18: (a) Penn-Century Dry Powder Insufflator™ - Model DP-4 connected 
with commercial syringe, (b) Dry Powder Insufflator™ Air Pump Assembly 
(www.penncentury.com). 
ii) Bi-Directional
TM
 nasal insufflators 
Bi-Directional
TM
 nasal insufflators have been developed by OptiNose breath-powered 
nasal delivery technology. This design consists of mouthpiece and nosepiece (Figure 
1.19a). The breathing force carries particles from prefilled gelatin capsule with powder 
doses into nostril, while soft palate separates the nose from the throat. This device offers 
potential particle distribution into deep part of the nose, resulting in minimized lung 
deposition and enhanced powder targeting of the drug to the sinus ostia (Dhakar et al., 
2011). Sumatriptan powder is an example that is currently in phase III clinical trials 
using the Bi-Directional
TM
 nasal insufflator to treat acute migraine. 
 
(b) 
(a) 
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iii) Miat
®
 monodose nasal insufflator 
Miat
®
 monodose nasal insufflator has been developed by Miat S.P.A Milan, Italy and 
consists of compressible pump, a revolving chamber with a grip tab, a nozzle, a two-
push-button (pin) and a protective cap (Figure 1.19). Upon squeezing the pump the 
compressible compartment creates a stream of air that passes through an in-let puncture 
in the capsule made by two opposite pins, resulting in particle delivery to the nostril by 
means of air stream (Cocozza, 1989). The delivery of powder dose from the monodose 
insufflator is evaluated by the weight of capsule before and after each puffing (Patil and 
Sawant, 2011). The delivery performance was evaluated by Patil and Swant, (2011), 
who reported that more than 98% of the dose was delivered after three puffs. 
 
 
Figure 1. 19: (a) Optinose Bi-Directional
TM
 nasal insufflator (www.optinose.com), 
and (b) Miat
®
 monodose nasal insufflator. 
 
iv)  Monopowder P
®
 insufflator 
The Monopowder P
®
 insufflator developed by Valois Dispray, France consists of a 
pump, a nasal adaptor and a powder reservoir. The piston actuates a stream of air to 
expel the powder into the nasal pathway (Sacchetti et al., 2002). Deposition and particle 
size of the delivered powder depends on formulations and actuator performance. 
Moreover, a multi-dose dry powder device has been developed to improve patient 
compliance (Kublik and Vidgren, 1998). For example, the multi dose system of 
budesonide powder (Rhinocort Turbuhaler
®
; www.az.com) has been marketed by 
Astrazeneca, to treat allergic rhinitis (Agertoft et al., 1993).  
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1.13  Hypothesis and objectives
Despite of the advantages offered by delivering drugs via the nasal route for various 
therapeutic applications, the duration of therapeutic activity following intranasal 
administration is short owing to rapid mucociliary clearance in the nose. Inclusion of 
bioadhesive agents into formulations improves drug absorption and possibly controls 
the rate of drug release. Amongst drug carriers, microspheres are considered effective at 
prolonging the contact time between the drug and mucosal membrane and increasing 
drug permeation, hence, this may improve the therapeutic effect of the drug. In a similar 
manner liposomes are highly promising carriers for drug targeting to the applications 
site, owing to the ability of liposomes to entrap hydrophilic and hydrophobic therapeutic 
agents and enhance the residence time of the liposome entrapped drug at the application 
site, hence this can improve the permeation and bioavailability of drug. 
Encapsulating of the anti-Parkinson drug ropinirole hydrochloride (RH), into 
mucoadhesive microparticles or liposomes may improve the management of Parkinson's 
disease and restless legs syndrome when the drug is administered via the nose. 
The main aims of this study were to prepare formulations of RH loaded into 
mucoadhesive agents (e.g. chitosan glutamate or low viscosity sodium alginate) via 
spray drying and ropinirole loaded liposomes via ethanol-based proliposome  
technology for intranasal delivery using appropriate medical devices, and  to study the 
potential of mucoadhesive microspheres and liposomes as drug carriers for  delivery of 
the microspheres using Miat
®
 nasal insufflator and to spray liposomes as liquid 
dispersion using a range of nasal spray devices. 
 
Objectives of the study: 
 
  To conduct preformulation studies in order to investigate the interactions between 
the drug and polymer (e.g. chitosan or sodium alginate).  
 To prepare optimum RH loaded mucoadhesive microsphere formulations from 
chitosan glutamate and low viscosity sodium alginate via spray drying. 
  To examine the properties of RH loaded mucoadhesive formulations. 
 To investigate the physical properties of encapsulated drug in relation to polymer to 
drug ratio. 
 To conduct toxicological study for the best performing RH loaded mucoadhesive 
microspheres using isolated sheep nasal mucosa. 
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 To study device performance in relation to microsphere formulations using Miat® 
nasal insufflator and investigate the cloud produced from the device. 
 To formulate optimum RH loaded liposome formulations using proliposome 
technology. 
 To examine liposome properties in relation to inclusion of different mucoadhesive 
agents. 
 To study nasal spray devices performance in relation to liposome formulations and 
investigate the cloud generated from the sprayed liposome formulations. 
 To analyze the data obtained and present them as PhD thesis. 
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2.1 Materials 
Chitosan Glutamate salt, Protasan Up G113 (Ch G2113) (mW: <200 kDa, DD: 75-90% 
(degree of deacetylation)), and Protasan up G213 (Ch G213) were supplied by 
Novamatrix/FMC biopolymer (Sandvika, Norway). The carboxymethyl chitosan (CM 
ch) was supplied by Santacruz Biotechnology, USA. Ropinirole hydrochloride (RH) 
USP-grade was supplied by Shanghai Yancui (China), Soya phosphatidylcholine (SPC; 
Lipoid S 100) was obtained from Lipoid (Steinhausen, Switzerland). Low viscosity 
sodium alginate (LVSA) and medium viscosity sodium alginate (MVSA), cholesterol 
(99%), sucrose (≥99.5% GC), absolute ethanol, sodium phosphate monobasic, sodium 
hydroxide and deoxycholate hydrate were purchased from Sigma Aldrich, UK. 
Acetonitrile (HPLC grade), High performance liquid chromatography (HPLC) grade 
water, and 1-butanol were all purchased from Fisher Scientific Ltd, UK. Miat
®
 
monodose insufflator was kindly supplied by Miat, Milan, Italy (Figure 1.19b) and three 
different multi-dose nasal spray devices were used in this study: device A (Zolmist 
nasal spray, Cipla Ltd; Batch No. K21137, India), device B (Model V04.2480, 
Costerpharm) was kindly provided by Costerpharm, Italy and device C (Model VP3/93, 
Valois) from a Beconase
®
 aqueous nasal spray (Figure 2.1).   
 
 
Figure 2. 1: Nasal spray devices used in this study. 
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2.2 Compatibility studies  
The compatibility study between RH and polymers were conducted using Thin Layer 
Chromatography (TLC) and Fourier transform infrared spectroscopy (FTIR) to detect 
any drug decomposition or drug-excipient interactions before and after spray drying. 
To determine decomposition or interaction of ropinirole hydrochloride (RH) and 
polymer using TLC, the solution of RH crude material and solution of RH loaded into 
microsphere formulation in a specific concentration equivalent to 400 µg/ml RH were 
prepared and spotted separately onto TLC plate and then dried using a laboratory "hair-
style" drier. TLC chamber that contains the mobile phase consisted of methanol and 
acetonitrile (80:20 v/v) and one drop of glacial acetic acid was added to the mobile 
phase to prevent tailing of the spot was prepared before and left at room temperature for 
20 minutes to saturate the chamber with the mobile phase before running the TLC sheet. 
The spotted TLC was placed into the chamber; it was left for sufficient running time 
and dried at room temperature. The UV chamber was used to detect the spots of the 
drug (Patel and Chaudhari, 2012).  
Compatibility studies between the drug and polymer were carried out using FTIR 
spectroscopy analysis. The IR spectra of the formulations and physical mixture of the 
drug and polymer were then analyzed in comparison with the spectrum of RH raw 
material to determine the compatibility of formulations. A small quantity of RH as raw 
material, physical mixture of the drug and polymer, or RH loaded into microsphere 
formulation (polymer: RH, 50:50 w/w) were analyzed using FTIR (Thermo Scientific, 
NICOLET is10, USA). The scan was collected at the range of 400 – 4000 cm-1 using 
OMNIC software to analyze the data. The experiment was conducted in triplicate.  
 
2.3 Standard calibration curve of ropinirole hydrochloride 
A stock solution was prepared by weighing 10 mg of RH accurately on the electronic 
sensitive balance (Ohaus Corporation, USA) followed by dissolution in 100 ml HPLC 
water. Aliquots were pipetted out (0.5 ml, 1 ml, 2 ml, 3 ml, 4 ml, 5 ml, 6 ml, 7 ml, 8 ml, 
9 ml and 10 ml) to prepare a number of samples from the stock solution into a series of 
10 ml volumetric flasks and made up to level mark with HPLC water in order to get 
concentrations in the range of 5 to 90 µg/ml. Quantities of 2 ml from every diluted 
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solution were placed into small vials and arranged in ascending order from low to 
higher concentrations using HPLC (Agilent Technology 1200 Series, USA) and C18 
column 250 x 4.6 mm, 5 µm. The temperature of the column was set at 40
o
C, and the 
mobile phase comprising phosphate buffer pH 6.0 and acetonitrile HPLC grade in a 
ratio 50:50 v/v was used, and the flow rate was set up at 0.5 ml/min and the detection 
wavelength was adjusted to 249 nm (Sreekanth et al., 2009). Figure 2.2 shows the 
calibration curve of ropinirole hydrochloride. 
 
 
Figure 2. 2: Calibration curve of ropinirole hydrochloride.  
 
2.4 Preparation of phosphate buffers (pH 6 and 6.5) 
Sodium dihydrogen orthophosphate (6.8 g) (British Pharmacopoeia, 2011) was weighed 
accurately and dissolved in HPLC grade water to produce 1000 ml, solutions 10M 
NaOH was used to adjust the pH to 6 using Corning pH meter (Corning Science 
Products, UK). 
Sodium dihydrogen phosphate monohydrate (13.8 g) was weighed accurately and 
dissolved in 900 ml of HPLC grade water. Solution of 10M NaOH was used for 
adjusting the pH to 6.5, and then diluted to 1000 ml with HPLC water. 
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2.5 Preparation of microspheres 
Spray drying is widely used to prepare solid particles, dry powders, granules and 
microparticles. It is a rapid one step technique of drying with high reproducibility of 
production of spherical particle with micro size range. The principle of spray drying is 
based on three steps; atomization of the feeding liquid with aid of nitrogen gas, drying 
of the droplets containing solid particles within a drying chamber and collection of dried 
powder by the effect of gravity within a collecting vessel (Figure 2.3). 
A Büchi -290 Mini Spray-Drier (Büchi Laboratories, Switzerland) was used to prepare 
the microsphere formulations. Four formulations of the polymer (chitosan or low 
viscosity sodium alginate) and the drug (RH) were prepared using various polymer to 
drug ratios (Table 2.1). The formulations were compared with drug free microspheres 
(% 0.5 w/v polymer). The method was adapted from the study conducted by Alhalaweh 
et al., (2009). The feed solutions were prepared by dissolving the specified quantity of 
the polymer and the drug in 100 ml of HPLC water using a magnetic stirrer to enhance 
the dissolution. The feed solution was atomized under 0.7 mm nozzle size, and inlet 
temperature was set at 160
o
C. The outlet temperature was varying between 75 to 80
o
C. 
The feed rate was 5 - 6 ml per minute, atomizing air flow rate and aspiration rate were 
kept at 357 L/h and 100% respectively. After evaporation of the solvent from atomized 
droplets, dried microparticles passed through the cyclone and were collected in the 
collecting vessel by the effect of gravity. For each batch, 200 ml of solution was 
processed in triplicate.  
 
Table 2. 1: Formulation composition of mucoadhesive microparticles. 
 
Weight ratio 
(polymer: RH) 
Polymer 
(mg) 
RH 
(mg) 
Total weight 
(mg)/100ml 
100:0 500 0 500 
90:10 450 50 500 
70:30 350 150 500 
50:50 250 250 500 
30:70 150 350 500 
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Figure 2. 3: A schematic presentation of spray drying (Adapted from Büchi -290 
Mini Spray-Drying, Büchi Laboratories, Switzerland). 
 
2.5.1 Viscosity measurements of feeding solution 
Anton Paarʼs viscometer (Figure 2.4) is commonly used in pharmaceutical and 
biotechnology industries as an alternative to the  traditional  type of capillary viscometer 
due to its calibrated system, small volume of sample required (150 µl), no sample/air 
contact (close measuring system), and highly precise and reproducible measurements. 
The measurement is based on Stoke’s law (Eq. 2.1).  To determine the viscosity of a 
liquid, the required time to roll a ball in a sloping cylindrical tube filled with sample 
liquid under the influence of gravity was determined (Figure 2.4b). The travelling time 
taken by the ball for fixed distance is measured using two sensors. The viscosity of the 
known sample can be expressed as dynamic viscosity (mPa.s) and kinematic viscosity 
(mm
2
/s) for each ball rolling time. 
 
  
  
 
   (    ) 
    
                                                                                     (Eq. 2.1) 
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Where dy/dx is the settling rate of particle, d is the diameter of the particle, pi is the 
density of the particle, pe  is the density of the liquid, g is the constant of gravity, and ɳ 
is the viscosity of the liquid. 
This study used a microviscometer (AMVn Automated Microviscometer, Anton Paar, 
Austria) at 20
o
C to determine the viscosity of the solution. Density of the solution was 
measured with DMA 35N density meter (Anton Paar, Austria). A special glass capillary 
tube was used to measure the viscosity. A small ball was introduced into the capillary 
tube which was then filled with the sample solution using a syringe to draw up the 
sample solution from a beaker. The capillary tube was completely free of air bubbles. 
The tip of the capillary was dried with a tissue and closed with the sealing cap before 
being placed into the Automated Microviscometer to measure the viscosity of the 
solutions. 
 
   
Figure 2. 4: (a) Automated Microviscometer, (b) cylindrical tube (Adapted from 
AMVn Automated Microviscometer, Anton-Paar) (www.anton-paar.com). 
 
 
 
 
(a) (b) 
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2.6 Characterizations of mucoadhesive microspheres 
2.6.1 Production yield 
The production yield was calculated as the weight percentage of the final product with 
respect to the total amount of the drug and polymer originally being used in the 
beginning of the experiments (Harikarnpakdee et al. 2006). The following equation was 
used:  
         (
  
  
)                                                                                (Eq. 2.2) 
Where W1 is the weight of dried microspheres and W2 is the initial dry weight of 
starting materials. 
2.6.2 Particle size measurement 
Microspheres (5 mg) generated by spray drying were suspended in 3 ml of 1-butanol 
and sonicated for 15 seconds to deaggregated the microparticles. The resultant 
microsphere dispersion was diluted further with1-butanol and size was measured using 
laser diffraction (Malvern Mastersizer 2000, UK) (Figure 2.5). The equipment was 
thoroughly cleaned with distilled water after each sample measurement, in order to 
eliminate cross-contamination. For liposome formulations aqueous media was used as a 
dispersion medium for particulate sample suspension. The average value of particle size 
was expressed as the volume mean diameter (D0.5). Polydispersity was expressed as a 
Span: 
     
(         )
    
                                                                                    (Eq. 2.3) 
where D0.9, D0.5 and D0.1 are 90% undersized, 50% undersize and 10% undersize 
respectively (Gavini et al. 2006).  
Mastersizer 2000 software analyses the data to determine the size and size distribution 
of particles based on measuring the angular variability and intensity of the laser beam 
scattered by a series of photosensitive detectors. When laser beams pass through a 
dispersed particulate sample, the scattering of light depends on particles size in the 
sample; larger particles gives smaller angles of scattering while smaller particles give 
larger angles of scattering (Figure 2.5) (Manual of Malvern Instrument). The laser 
diffraction instrument in this study employed ―Mie theory‖ to analyze the size of 
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particles. This theory relies on the refractive indexes of dispersed particles and the 
dispersion medium (manufacturer personal communication). Deionized water and 
butanol-1-ol were used as dispersion medium and their refractive index were 1.33 and 
1.3993 respectively. 
 
 
 
 
Figure 2. 5: The Malvern Mastersizer instrument used in the present study (upper 
picture) and a schematic illustration of light scattering from small and large 
particles (lower picture) (Malvern-Instruments Ltd, 2012) (www.malvern.com). 
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2.6.3 Zeta potential analysis  
A Zetasizer Nanoseries (Malvern Instruments Ltd., UK) (Figure 2.6) was used to 
measure the surface charge of liposomes. Liposomal suspension was vigorously shaken 
and Gilson pipette was used to place 70 μl of formulations into a disposable polystyrene 
zeta cell (Malvern Instruments Ltd., UK). The analysis was carried out after equilibrium 
time of 2 min at 25°C. 
To measure the zeta potential of microspheres formulations, 1 ml of phosphate buffer 
solutions (pH 6.5; 0.001 M) was added to 5 mg of the formulations and 70 μl of the 
dispersion was placed into the zeta cell. The difference in potential between a 
conducting liquid and the surface of a dispersed vesicle in the liquid is the zeta potential 
(Maherani et al., 2012).  
 
Figure 2. 6: Malvern Zetasizer Nanoseries 2000 used in the present study. 
 
2.6.4 Powder tapped and bulk density measurement  
Tap density of mucoadhesive microspheres was measured by using Tapped density 
meter (ERWEKA
®
 Gmbh, D-63150 Heusenstamm/ Germany). A known quantity of 
powder was poured into 5 ml cylinder. The volumes occupied by the powder before and 
after tapping were recorded. The tapped density of microparticles was determined until 
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no further change in the powder volume was observed (6 min).  Measurements were 
repeated in triplicate. Bulk density (BD) and tapped density (TD) for microparticles 
were calculated by using equation 2.4 and 2.5. Hausner’s ratios were used to determine 
the powder flow properties of mucoadhesive microspheres as follows (Eq. 2.6) 
(Allamneni et al., 2012): 
   (
 
 
)                                                                                                (Eq. 2.4) 
   (
 
  
)                                                                                                (Eq. 2.5) 
                                                                                               (Eq. 2.6) 
              *  (
             
             
)+                                                 (Eq. 2.7)                                          
Where D = density of the powder (g/ml), BD = Bulk density (g/ml), TD = tapped 
density (g/ml), W = weight of powder (g), V = volume of powder before tapping (ml), 
Vt = tapped volume of powder.  
                                                                
2.6.5 Encapsulation efficiency and drug loading  
Total amount of the drug within the microspheres was estimated by weighing 4 mg of 
microspheres followed by microsphere dispersion into 30 ml phosphate buffer solution 
(pH 6.5). This was left for 5 h, then vortexed for 1 minute to extract the entrapped drug. 
The solution was then filtered through micro filter paper (0.22 µm) in size and 
quantified using High Performance Liquid Chromatography (Agilent 1200, Agilent 
technology Ltd, USA) to determine the encapsulation efficiency (EE) and drug loading 
(DL) present within the microspheres (Parul et al. 2008) using equation 2.8 and 2.9.  
 
  ( )  (
                           
                        
)                                                 (Eq. 2.8) 
  ( )  (
                                    
                          
)                                     (Eq. 2.9) 
 
CHAPTER 2 
57 
 
2.6.6 Swelling index 
The swelling ability of mucoadhesive microparticle formulations intended for intranasal 
delivery is correlated to their mucoadhesive properties. The swelling capacity of the 
microspheres was calculated by measuring the extent of swelling of microspheres to 
their equilibrium in phosphate buffer (pH 6.5). The experiment was performed by 
dispersing microsphere formulations (15 mg) in the buffer solution followed by 
allowing them to swell for up to 4 hours, to ensure complete equilibrium of swelling. 
Excess amount of water was removed from the surface of swollen microparticles by 
gentle blotting using a soft tissue. A digital balance (Ohaus electronic balance, Ohaus 
Corporation, USA) to an accuracy of 0.00001g was used to weigh the swollen sample. 
The swelling index was calculated according equation 2.10 (Patil and Sawant, 2011). 
The experiment was repeated three times. 
 
  
     
  
                                                                                               (Eq. 2.10)                                   
Where   = Degree of Swelling, Ws = weight of swollen microspheres, and Wo = weight 
of dry microspheres. 
 
2.6.7 Scanning electron microscopy  
Microparticles were scanned after mounting on to a carbon pad (Agar Scientific, UK). 
Spray air was used to remove excess amount of powder, then microparticles were 
coated by thin layer of gold using a sputter coater apparatus (Bio-Rad, England) under 
vacuum. The shape and surface characteristics of the microparticles were observed 
under vacuum using scanning electronic microscopy (SEM) using a voltage of 20kV 
(Quanta 200, Czech Republic). 
2.6.8 X-Ray Diffraction 
Physical states of RH, chitosan glutamate and RH loaded microspheres were determined 
by X-ray diffractometry (Equinox 2000 Inel, France). The powder samples were spread 
on metal sample holders, and glass slide was used to press and smooth the powder 
surfaces. The diffraction intensity was recorded at 2-theta and a run time was 20 min. 
The current and voltage generator were set at 28 mA and 32 kV, respectively. 
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2.6.9 Differential scanning calorimetry  
Differential scanning calorimety (DSC) is a thermo analysis technique; it can be used in 
various fields; pharmaceutical research, biotechnology, food, polymer, and nanomaterial 
products. DSC determines the thermal change events of a given material by measuring 
enthalpy and onset of the thermal event, or by determining the melting point of the 
crystalline material and glass transition temperature of the amorphous material (Figure 
2.7). This instrument generates data that can be useful to understand the physical 
behaviour of materials (e.g. crystalline or amorphous form) (Gill et al., 2010). During 
sample analysis the reference pan (empty) and the test pan which contains the sample 
for thermal analysis are heated at constant heat flow. The detector records thermal 
changes happen to the sample either when absorbing or evolving heat (www.ami.ac.uk).  
Differential scanning calorimetry (DSC823e, Mettler Toledo, Switzerland) was used to 
determine the thermal behaviour of the pure drug and drug loaded microspheres as 
powder samples. DSC was calibrated before the experiment was performed using 
indium and zinc oxide. The analysis was done for pure drug, chitosan, and drug-loaded 
microspheres. A weight between 3.5 to 4 mg was placed into an aluminium pan (40 µl) 
and the pan was sealed using the sealing press apparatus. The samples were heated at a 
rate of 10
o
C/min, and the scanning was performed between 35 and 300
o
C.  
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Figure 2. 7: Schematic presentation showing the principal components of a DSC 
equipment (Adapted from www.ami.ac.uk). 
 
2.6.10 Thermogravimetric analysis  
The weighed sample in crucible or aluminium pan was placed into the 
thermogravimetric (TGA) analyzer connected to a highly sensitive balance to determine 
the mass change of the sample during heating at a constant heating rate under purge of 
nitrogen gas. Difference in mass (decreasing or increasing) may indicate sample 
degradation (Figure 2.8).  
Thermogravimetric analysis (TGA) was used to detect the weight lost as function of 
temperature (TGA/SDTA851e, Mettler Toledo, Switzerland). The equipment was 
calibrated before analysing the samples using indium and zinc oxide. Approximately 4.5 
to 5.3 mg of the microsphere formulations were placed in to the aluminium pan (40 µl) 
and sealed with a sealing pressure of crucible. A hole was made at the top of the cover 
using a pin to allow evaporation of moisture during heating process under a purge of N2 
gas. The sample was then placed onto the highly sensitive balance of 0.01 mg in 
accuracy and the equipment was set at a heating rate of 10
o
C/min from 20 to 300
o
C. The 
change in mass of the powder formulation was determined as percentage of weight lost 
when no more weight loss of the sample was detected by the TGA instrument. The 
percentage of weight loss was determined when the temperature reached 120
o
C. 
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Figure 2. 8: Schematic diagram of a TGA equipment (www.ami.ac.uk). 
 
2.6.11 In vitro drug release 
Microsphere formulations containing 2 mg of RH were dispersed into 70 ml phosphate 
buffer (pH 6.5) in glass bottle, and the temperature was maintained at 37
 o
C ± 0.20 and 
continuous shaking was provided in a water bath at a rate of 100 rpm. Samples were 
taken at different time intervals (0.5, 1, 2, 5, 10, 20, 30, 60 and 90 min) and in order to 
keep a sink condition the taken sample was replaced by the same volume of 
formulation-free dissolution medium. The amount of drug released per time was 
analyzed using HPLC. These studies were conducted in triplicate and the results were 
expressed as average values (Huh et al., 2010). 
 
2.6.12 Histopathological study 
Freshly isolated nasal mucosa was taken immediately after sacrificing a healthy eight 
months in age Makui sheep. The sample was used to conduct the histopathological 
study (Seju et al., 2011). This experiment was conducted at the College of Pharmacy-
Hawler Medical University, Erbil-Iraq according to their ethical regulations. The nasal 
mucosa was sectioned into four pieces. Each piece was treated for 2 hours with drug 
loaded-microspheres dispersion containing 2 mg/ml of RH from either drug-loaded 
chitosan microspheres (90:10 polymer to drug ratio) and drug-loaded alginate 
CHAPTER 2 
61 
 
microspheres (90:10 polymer to drug ratio), drug solution (2 mg/ml) in phosphate buffer 
solution (pH 6.5), phosphate buffer solution (pH 6.5) as a negative control and sodium 
deoxycholate (1% w/v) solution as a positive control. Samples were taken out and 
washed with NaCl (0.9%) and the tissue was fixed in 10% buffer formalin and 
embedded in paraffin wax for 4 h. Paraffin sections 7 - 5 mm were cut onto glass slides 
and stained with haematoxylin and eosin (Sigma Aldrich, UK). Sections were examined 
by light microscopy (Olympus microscope) to detect any damage during incubation. 
The examination was carried out by a pathologist who was not involved in the 
formulation work and by assigning numbers to the samples to minimise bias. 
Examination of the tissue included the observation of all essential components of the 
respiratory epithelial cells such as goblet cells, ciliated cells, mucosal and sub mucosal 
layers, sero-mucinous glands. The possible epithelial necrosis was examined and 
sloughing of the epithelial cells and inflammatory cells were also studied. 
 
2.7 Characterization of microspheres emitted from a nasal device  
2.7.1 Quantative determination of dose uniformity  
To determine the consistency of the dose discharged from nasal insufflator, the Miat
® 
nasal insufflator (provide as a gift from MIAT S.P.A. Milan, Italy) was used and gelatin 
capsule No.3 was filled with accurately weighed 5 mg, 10 mg or 20 mg powdered 
microsphere formulations using Ohaus electronic balance (Ohaus Corporation, USA). 
The capsule was placed into revolving chamber and introduced into the body of nasal 
insufflator. Sufficient pressure was added to the ends of capsule to pierce it with a 
needle, and then the powder was sprayed by squeezing the rubber bulb of the 
insufflator. The shot weight was determined based on weight difference of the capsule 
after each puff for a total of three puffs. The experiment was conducted in triplicate 
(Patil and Sawant, 2011). 
2.7.2 Qualatative analysis of spray pattern of microsphere formulations  
The qualitative study for the microspheres powder to be delivered via nasal route 
included spray investigations of the pattern and plume geometry. To perform spray 
pattern and plume geometry of the microspheres, MIAT
®
 A.S.P Milan, Italy nasal 
insufflator was used. The technique was used to determine the plume geometry which is 
the same technique used for nasal spray. The resultant images were characterized in 
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terms of shape of the powders emitted from insufflator, plume angles and spray time. 
To determine spray pattern, blue pressure sensitive tape was used instead of TLC plates. 
It was placed 3 cm away from the tip of nasal insufflator (Figure 2.9). The microspheres 
were fired towards it, then the resultant images were analyzed for maximum and 
minimum diameters (DMax and DMin) and ovality ratio (DMax/ DMin) (Pringels et al., 
2006).  
 
 
Figure 2. 9: An illustration of (A) technique used to determine spray pattern of 
powder, and (B) an example of spray pattern. 
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2.8 Liposome formulations 
Several liposome formulations have been investigated and the details are given below.  
 
2.8.1 Ethanol-based proliposomes  
Ethanol-based proliposomes were used to prepared ropinirole hydrochloride loaded 
liposomes by adapting the method used by Perrett and co-workers (1991). Proliposomes 
were made by adding 60 mg ethanol (equivalent to 76 μl) to 10 ml glass vial  containing 
50 mg of lipid phase (soya phosphatidylcholine (SPC) and cholesterol, 2:1 mole/mole) 
at 70
o
C for two minutes to obtain a clear lipid solution (i.e. proliposomes). RH (0.5 ml) 
in concentrations of 0.5, 1, 2, 4 or 8 mg/ml were quickly added to the lipid solution and 
vortexed for two minutes using the Whirl Mixer TM (Fisherbrand, Fisher, and UK). 
This resulted in the generation of concentrated liposomal suspensions (primary 
hydration step). The rest of HPLC water (4.5ml) was added to the concentrated 
liposomal suspension and vortexed again for two minutes (secondary hydration step) to 
yield the final liposome suspensions which were left at room temperature for 1 hour to 
anneal. 
2.8.2 Polymer-coated liposomes 
In this study 5 types of mucoadhesive agents were used: Protasan up G113 and Protasan 
up G213, Carboxymethyl chitosan, Low viscosity of sodium alginate or Medium 
viscosity of sodium alginate (0.2% w/v). The polymers were separately dissolved in 4.5 
ml HPLC water. Vortex mixing enhanced the rate of dissolution of the polymer then 
addition of mucoadhesive solutions in secondary hydration step of the ethanol-based 
and again vortexed for two minutes generated liposomes coated with mucoadhesive 
polymer. 
2.8.3  Drug entrapment studies 
To separate the entrapped drug from un-entrapped drug, liposome dispersion was placed 
into centrifuge tube for centrifugation at 50,000 rpm (251,818 x g) for 20 minutes at 6
o
C 
using Beckman ultracentrifuge (Beckman LM-80, Beckman Coulter Instruments, UK). 
After centrifugation, the supernatant was collected and liposome pellets were 
redispersed in 5 ml of HPLC water to remove the drug adsorbed onto the surface of 
liposomes. Centrifugation was repeated for 20 min at the same condition, and then 
supernatant collected. The un-entrapped drug from the supernatants was measured by 
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HPLC (Agilent 1200 series, USA). The area under curve of the un-entrapped drug was 
used to quantify the amount of free drug present in the supernatant to determine the 
drug entrapment efficiency in liposomes. Equation 2.11 was used to calculate the 
entrapment efficiency (EE) (Elhissi et al., 2006).  
  ( )  (
                           
          
)                                               (Eq. 2.11) 
 
2.8.4 Liposome morphology study using transmission electronic microscopy  
Transmission electron microscopy (TEM) offers highly resolution microscopic images 
of micro and nano structures. To carbon-coated copper grids (400 mesh) (TAAB 
Laboratories Equipment Ltd., UK), a drop of  the liposome dispersion  was spotted  and   
negatively stained with 1% w/v  phosphotungstic acid (Elhissi et al., 2006), then viewed 
and a number of  high resolution images were taken by a Philips CM120 Bio-Twin 
transmission electron microscope (Philips Electron Optics BV, Netherlands). This study 
was conducted at the University College London. 
 
2.8.5 Size analysis of droplets emitted from nasal devices using laser diffraction  
Laser diffraction is a non-aerodynamic based method that measures droplet size in air. 
Moreover, laser diffraction provides the percentage of transmission (%T) and Span 
((D0.9 – D0.1)/D0.5). The data obtained from laser diffraction was used to study each 
plume by three phases: formation phase, fully developed phase and dissipation phase. 
Droplet size change is consistent with the changes of percentage transmission (%T) or 
changes in obscuration, the settling values of droplet sizes and the settlement of 
obscuration or %T are observed within approximate time period  (CDER, 2003).  
Liposomes (5 ml) prepared using the ethanol-base technique proliposomes were 
centrifuged at 50,000 rpm using the Beckman ultracentrifuge at 6
o
C. The supernatant 
was discarded and replaced with 5 ml of fresh HPLC water to redisperse the liposome 
pellet with aid of vortexing. Rehydrated liposomal suspension (5 ml) was placed into 
the nasal spray device and spray was generated while holding the device 
perpendicularly 5 cm away from the beam of the Malvern Spraytec (Malvern 
Instruments Ltd., Model 3321 Aerodynamic Particle Sizer
®
 (APS) Spectrometer UK) 
(Figure 2.10). Prior to particle size measurement, each formulation loaded into different 
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nasal devices was firstly primed by actuation of the pump of nasal device for seven 
times. When the sample unit discharged from the nasal device, geometric droplet size 
based on laser diffraction was determined using laser diffraction. The data was analyzed 
in terms of volume median diameter (VMD) and size distribution (Span).  
 
 
 
Figure 2. 10: The Malvern Spraytec system used to characterize particles since 
delivered from nasal sprays or insufflators.  
   
2.8.6 Determination of shot weight and spray content uniformity  
According to FDA recommendation, multiple metered dose nasal spray should be 
analysed for the amount of the spray discharged via actuation at the beginning to the 
end of the experiment for the individual nasal device used (CDER, 2002). 
Prior to the experiment, a number of actuations (priming actuations) are required to 
purge the air off the system and dip tube used to generate the full dose. The number of 
actuations required to prime on initial used, number of actuations at fully developed 
phase and numbers of the actuations at the tail-off phase were determined for multiple 
metered dose nasal sprays. The accuracy of discharged volume from the nasal devices 
was determined. Low volumes of solutions within nasal devices might lead to 
generation of low discharged volumes of spray, compromising the content uniformity of 
the dose. This is referred to as ―tailing-off‖ (Schultz, 1995), that continues until no 
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spray is discharged upon actuation. The phenomenon of tailing-off for the various nasal 
formulations and devices was recorded and the number of actuations required to obtain 
full actuation delivery was determined. 
For shot weight measurement the spray pump devices were weighed prior and after each 
actuation using Ohaus electronic balance to accuracy 0.00001g (Ohaus Corporation, 
USA). This was referred to as delivered dose per single actuation of the nasal device 
(Guo and Doub, 2006). 
Centrifuged liposome formulations were redispersed (5 ml) and placed in the nasal 
devices then the number of actuations required to prime, the number of full actuations 
discharged from devices, and the number of actuations in the tailing-off phases for the 
different nasal devices were determined. 
 
2.9 Nasal spray characteristics  
To determine the characteristics of nasal spray, droplet size and size distribution, spray 
pattern and plume geometry were analyzed (Guo and Doub, 2006). According to the 
guidelines of Centre for Drug Evaluation and Research (2003), two techniques are 
available to determine and analyze the spray pattern, impaction and non-impaction 
techniques (CDER, 2003). Impaction technique was used in this study to determine and 
characterize the discharged spray after actuation from the nasal devices. 
Spray pattern was characterized after impaction onto TLC. It was performed at the 
specific distance from the tip of the nasal device to determine the shape of aerosol 
delivered from nasal device upon actuation. Spray pattern may give an indication of the 
site of deposition of the delivered dose in the nose. Before each experiment, each nasal 
spray was actuated 5 - 7 times to waste to ensure the device is primed. Solution (5 ml) 
was coloured with 3 drops of natural food colour (foodfinders Ltd, UK) to visualize the 
splatter pattern on the TLC sheet. For this purpose, nasal spray device was placed 3 cm 
in distance away from collection surface of the TLC sheet (Figure 2.11). Liposome 
formulation was fired toward TLC sheet (Guo and Doub, 2006). The image of the spray 
pattern on the TLC was taken immediately after actuation of the nasal device using a 
professional digital camera (LSH Canon 550 D 55 mm – 08, Cannon Ltd., Tokyo). 
Maximum diameter (DMax), minimum diameter (Dmin) and ovality ratio (DMax/Dmin) of 
the spray pattern shape were determined according to CDER guidelines (2003). Ovality 
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ratio gives indication of the shape of the impaction spray which is round, irregular or 
ellipsoid shape. 
Plume geometry describes the shape of the discharged sample parallel to the axis of 
plume after actuation of nasal pump device. Two techniques are available to visualize 
plume geometry; (1) laser light sheet and high speed digital camera and (2) high-speed 
photography according to Center for Drug Evaluation and Research (CDER) guidelines 
(2003).  
 
 
Figure 2. 11: Schematic illustration of (a) the technique used to determine spray 
pattern, and (b) an example of spray pattern. 
 
To study plume geometry, actuations were fired upward and recording was conducted 
by placing the digital video camera (Full HD, JVC Ltd., Malaysia) in front of the nasal 
spray device, while keeping a black background at the opposite side at the back of the 
nasal device (Figure 2.12). The digital video camera was used to record the spray cloud 
generation while the sample proceeded to evolve from the tip of the nasal device. The 
recoding videos were transferred to personal computer and the elapsed recoding time 
was framed at different rates using AVs Video Editor software. The fully developed 
phase was printed and characterized for the three stages; at the early stage upon 
formation (formation phase), during an intermediate time of spray (fully developed 
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phase) and when the plume spray started to separate from the nasal device tip 
(dissipation phase). Studies were also performed to determine plume angle and widest 
horizontal distance of spray clouds after actuation of the nasal pump devices for the 
different samples using protractor from the printout images, while longest vertical 
distanced (plume height). The distance that was derived by the spray samples from the 
tip of devices was determined according to previously made graduation on the 
background using a ruler. According to the regulatory guidelines of CDER (2002; 
2003), the image analysis was carried out at the fully developed phase while the spray 
cloud was still in contact with the tip of the nasal device. 
 
 
Figure 2. 12: Schematic illustration of the technique used to monitor the plume 
geometry. 
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2.10 Statistical analysis 
All experiments were carried out in triplicates; One-way Analysis of Variance 
(ANOVA) and student's t-test were used for statistical data analysis to compare more 
than two groups of data and two groups of data respectively. Values were expressed as 
mean ± standard deviations and p-value <0.05 indicated that difference between the 
groups were statistically significant.  
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3.1 Introduction 
Mucoadhesive systems incorporate bioadhesive agents to enhance the drug absorption 
by prolonging the period of contact between the drug and the cellular mucosa (Jain et 
al., 2004). Nasal delivery is a promising route for delivery of drugs, which are 
susceptible to enzymatic, acidic or first pass effect for treating systemic or nasal 
diseases because nasal mucosa may offer higher drug permeability compared to other 
mucosal membranes. Intranasal drug delivery has been investigated for treating CNS 
conditions such as brain tumour (Hashizume et al., 2008; Shingaki et al., 2010). This 
route is particularly attractive due to relatively high vascularity, which results in high 
absorption rates for small molecules, peptides and proteins that are difficult to be 
administered by other delivery routes (Illum et al. 2001; Vyas et al. 2005). Additional 
advantages include high surface area of the nasal cavity which provides rapid onset of 
drug action, convenience of using nasal formulations by patients, avoidance of first pass 
metabolism by the liver, and lower enzymatic activity in the nose compared to the GIT 
(Illum et al. 2001; Vyas et al. 2005). Targeting drug to the brain also circumvents the 
brain blood barrier (Graff and Pollack, 2005); therefore it is considered a smart route for 
drug targeting to the brain.  
Mucociliary clearance is a barrier that plays an important role at clearing the nose from 
foreign particles. Hence, the use of bioadhesive polymers for the preparation of drug 
loaded microspheres could lead to enhanced residence time of the drug in the nasal 
cavity, thus increasing drug absorption (Soane et al., 1999).  
Nasal formulations in powder form offers advantages over nasal drops and nasal sprays 
in terms of stability, hence offering a preservative-free alternative (Huang et al., 2004; 
Jadhav et al., 2007). The expediency of the powder formulation is however highly 
dependent on solubility, particle size, aerodynamic properties and nasal irritation of the 
active drug and/or excipients (Aurora, 2008). 
Drug carriers such as mucoadhesive microspheres consist of a drug and natural or 
synthetic biodegradable excipients (e.g. chitosan) used to improve drug absorption by 
enhancing residence time in the nose, opening tight junctions between cells, increasing 
concentration at the site of absorption or providing protection from enzymatic 
degradation (Wang et al., 2006; Duan and Mao, 2010).  
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Chitosan prepared from chitin by alkaline deacetylation is a cationic polysaccharide. 
This is considered to be a second copious polymer next to cellulose (Singla and Chawla, 
2001). Chitosan is insoluble in water but is soluble in dilute acids (pH less than 6.5) 
(Chandy and Sharma, 1990). In contrast, chitosan salts such as glutamate and 
hydrochloride are water soluble (Alhalaweh et al., 2009). The wide use of chitosan in 
pharmaceutical formulations is attributed to its safety, biodegradability and 
biocompatibility (Singla and Chawla, 2001). The polycationic property of chitosan 
facilitates its interaction with mucin and other negatively charged ions in the nasal 
mucosa resulting in prolonged retention time within the nasal cavity and enhanced drug 
permeability (Fernandez-Urrusuno et al., 1999). Abdel Mouez et al. (2014) have 
reported that verapamil hydrochloride loaded chitosan microparticles enhanced 
bioavailability significantly (58.6%) compared to the drug solution after intranasal 
administration (4.8%) and oral drug solution (13%) in rabbit animal model. Chitosan 
can also act as a permeation enhancer to promote the rate of drug transfer through nasal 
mucosa, hence improving bioavailability (Fernandez-Urrusuno et al., 1999).  
Ropinirole hydrochloride (RH) is a non-ergot dopamine D2-agonist used in the 
management of Parkinson’s disease alone or as an adjunct to reduce 'on-off' fluctuations 
in levodopa response (Pahwa et al., 2004). When used orally only approximately 50% is 
absorbed since it undergoes extensive first pass effect (DrugBank, 2013). Beside to 
pramipexole and gabapentin, FDA has approved RH for use in patients with restless 
legs syndrome (Kurlan et al., 2006). 
Hydrophilic drugs have difficulty in crossing the nasal epithelium due to their large size 
in tight junctions hence absorption via the transcellular pathway is difficult. The 
incorporation of polar drugs into chitosan microspheres may improve their absorption 
by transiently opening the tight junctions in the cellular membranes and enhancing the 
contact time of the drug with the site of absorption (Illum, 2002). 
RH loaded chitosan microsphere formulations were prepared in this study using spray 
drying. Various characterization techniques were used to select the best performing 
formulation for subsequent studies. Thus, histopathological study using isolated nasal 
sheep mucosa, physical particle size analysis using laser diffraction, plume geometry 
and spray pattern using impaction method were all investigated.  
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3.2 Methodology  
3.2.1 Compatibility studies 
The methods used to study the compatibility of the drug with polymer were outlined in 
section 2.2. 
 
3.2.2 Preparation of chitosan microspheres 
Ropinirole hydrochloride-loaded chitosan microsphere formulations were prepared as 
described in section 2.5, by adapting the method used by Alhalaweh et al. (2009). Five 
formulations of the drug-loaded microspheres were prepared including drug free 
microspheres for comparison (Table 3.1). Chitosan glutamate (Chg) and RH were 
dissolved in HPLC-grade water and the solution was made up to 100 ml in a volumetric 
flask. Automated microviscometer was used to determine the viscosity of the resultant 
solutions. Spray drying was performed using a Büchi-290 Mini Spray-dryer (Büchi 
Laboratories, Switzerland). The peristaltic pump fed the solution (5 - 6 ml/min) into the 
nozzle (0.7 µm in diameter). The inlet air temperature was 160˚C, which is the optimum 
inlet air temperature for chitosan microspheres prepared from its aqueous solution (He 
et al., 1999). Other spray drying parameters were: outlet air temperature 75 - 80
o
C, 
aspiration rate 100%, and gas flow 357L/h. For each batch of microspheres 200 ml of 
feed-solution was used. 
 
Table 3. 1: Microsphere formulations using various ratios of chitosan to drug. 
 
Formulation Ratio (w/w) 
(Chg: RH) 
Chitosan 
glutamate 
(mg) 
RH 
(mg) 
Total weight 
(mg)/100 ml 
F1 100:0 500 0 500 
F2 90:10 450 50 500 
F3 70:30 350 150 500 
F4 50:50 250 250 500 
F5 30:70 150 350 500 
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3.2.3 Characterization of microspheres  
The percentage yield, particle size, size distribution, entrapment efficiency, zeta 
potential, bulk density, swelling index, physical state of the drug in formulations, 
thermal behaviour of the formulations, powder morphology, drug release profile, and 
histopathological characteristics of the nasal epithelium using animal tissue were 
studied. For selected formulations, characterizations were conducted for emitted powder 
(e.g. physical particle size, plume geometry and spray pattern) using nasal insufflator. 
Methods used were described in related sections in chapter two.  
 
3.3 Results and discussion 
3.3.1 Compatibility studies 
The pre-formulation studies are essential to detect undesirable interaction between the 
active ingredient and excipients which can affect the stability or bioavailability of the 
active ingredient, hence affecting the safety and/or efficacy of the formulation (Taylor 
and Zografi, 1997; Verma and Garg, 2005). A suitable excipient is required to prepare a 
stable and effective formulation (de Carvalho et al., 2006). To investigate the interaction 
between the formulation ingredients, a number of experimental techniques have been 
used such as FTIR spectroscopy, DSC, X-Ray diffraction and HPLC (Drebushchak et 
al., 2006; Bozdağ-Pehlivan et al., 2011).  
The FTIR spectra of pure drug, physical mixture and spray dried formulations are 
shown in Figure 3.1. The FTIR data confirmed that the frequency of RH did not change 
significantly when drug-loaded microspheres were compared with the physical mixture 
formulation. Sharp peaks at 1241.19, 1455.36, 1702.18 and 3068.95 cm
-1
 for (C-N), 
(C=C stretching), (C=O stretching) and (N-H stretching) functional groups respectively 
were found for pure RH (Table 3.2). When infrared spectrum of pure RH was compared 
to the spectrum of RH in mixture form and spray dried RH loaded microspheres, no 
significant band-shift in wave number was observed between the spectra, indicating that 
the drug consistency and absence of significant interaction, modification or loss in drug 
characteristics (Figure 3.1). Thin layer chromatography study showed one spot for every 
run sample;  RH as raw material, physical mixture of RH and chitosan glutamate (50:50 
w/w), and co-spray dried microparticles all had similar Rf values (Rf=0.55), indicating 
no interaction between chitosan glutamate and RH had occurred. 
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Figure 3. 1: FTIR spectrum of (A) RH, (B) chitosan glutamate, (C) physical mixture of chitosan 50% w/w and RH 50% w/w, and (D) RH 
loaded microspheres. The lower graph magnifies the wave numbers area between 900 and 1850 cm
-1
. 
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Table 3. 2: Frequency of functional groups of pure RH physically mixed with 
polymer and drug-loaded microspheres. 
 
Functional 
groups 
Frequencies of 
pure RH (cm
-1
) 
Frequencies of RH in 
physical mixture 
(cm
-1
) 
Frequencies of RH 
in microspheres 
(cm
-1
) 
C-N 1241.19 1241.92 1242.24 
C=C stretching 1455.36 1455.56 1456.39 
C=O stretching 1702.18 1702.97 1703.52 
N-H stretching 3068.95 3068.45 3071.91 
 
 
3.3.2 Percentage yield 
The percentage yield of powder collected ranged from 70.5% ± 0.45 to 76.9% ± 1.01, 
thus spray drying was characterized by generating high product yield. However, the 
percentage of yield increased significantly (p<0.05) when RH and chitosan glutamate 
were co-sprayed, whilst increasing the drug to polymer ratio in subsequent formulations 
significantly decreased the production yield (70.5% ± 0.45) (Figure 2), possibly due to 
adherence of the drug powder to the drying chamber of the spray drier. It was confirmed 
when the spray drying was performed for RH (raw material) 0.5% w/v, the percentage 
yield was only 49.84%.  
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Figure 3. 2: Percentage yield of chitosan microsphere formulations (F1 – F5) for 
formulation composition refer to table 3.1. Data represent mean ± S.D (n=3). 
 
3.3.3 Particle size and distribution  
Particle size for various spray dried mucoadhesive microspheres was between 1.98 ± 
0.09 µm and 3.66 ± 0.04 µm (Figure 3.3). As the ratio of the drug to chitosan glutamate 
increased particle size was increased (p<0.05). It is possible that at low drug to chitosan 
glutamate ratio, low drug concentration was available per particle, whilst increasing the 
ratio of the drug may lead to an increase in the amount of the dispersed drug molecules 
within the microparticles. In contrast, size distribution (Span) decreased significantly as 
the drug concentration was increased compared to the blank formulation. Span values 
for microspheres were ranged from 4.11 ± 0.92 to 1.10 ± 0.04. The decreasing in Span 
may be due to the solution viscosity of the formulations, which was higher in F1 
formulation and decreased significantly as the ratio of chitosan decreased in formulation 
F5 (Figure 3.4).  
Figure 3.5 illustrates the relationship between viscosity of the feeding solution and 
particle size and size distribution. The viscosity decrease could be due to lower 
intermolecular entanglement, resulting in increasing the freedom of movement of 
individual chains of chitosan in solutions (Graessley, 1974), and possibly the formation 
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of uniform droplets during atomization within spray drier. Oliveira et al. (2005) have 
reported larger particle with wider size distribution were obtained with spraying viscous 
chitosan solution. These results agree with those reported by Learoyd et al. (2008a) who 
prepared respirable particles of beclometasone dipropionate encapsulated by chitosan 
via spray drying.  In this study, particle size of RH as a raw material and spray dried 
were 59.72 ± 3.07 µm and 23.62 ± 4.66 µm, whereas Span was 1.63 ± 0.14 and 1.84 ± 
0.48 respectively. 
 
 
Figure 3. 3: Particle size and size distribution of RH-chitosan microparticles. Data 
represent mean ± S.D (n=3). 
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Figure 3. 4: Relationship between chitosan concentration and viscosity of the 
solution. Data represent mean ± S.D (n=3). 
 
 
 
Figure 3. 5: Relationship between viscosity of the solution and particle size and size 
distribution (Span). 
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3.3.4 Zeta potential 
Zeta potential of particles may influence adhesiveness onto the surface of mucous 
membranes. Free amino groups confer positive surface charge to the chitosan 
microparticles (Berthold et al., 1996). The positive charge of chitosan microspheres 
enhances the bioadhesion upon the strong interaction between the particles and 
negatively charged moieties of the membranes (e.g. mucin) (Illum et al., 1994).  
In this study the positive charge of the microspheres decreased significantly (p<0.05) 
with increasing the ratio of drug to chitosan from 52.13 ± 1.15 mV to 32.93 ± 2.5 mV 
(Figure 3.6). This may be attributed to the decrease in free amino groups responsible for 
positive charge in chitosan microparticles as the concentration of chitosan decreased 
(Berthold et al., 1996). Oliveira et al. (2005), have shown that the zeta potential of the 
particles is positive (53.7 mV) when 0.5% concentration of chitosan was used with 
spray drying. Dhawan et al. (2004) showed that chitosan microparticle preparation 
method may have a great effect on the zeta potential, and values were in the range of 
20.7-50.2 mV when thermal cross-linking, emulsification and ionotropic gelation 
methods were used for preparation of microparticles.   
 
 
Figure 3. 6: Zeta potential of chitosan microparticles. Data represent mean ± S.D 
(n=3). 
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3.3.5 Entrapment efficiency (EE) and drug loading (DL) 
The encapsulation efficiency (%) and drug loading (%) values are shown in Figure 3.7. 
Almost all microsphere formulations were characterized by offering high drug 
encapsulation efficiencies; these were 93.28% ± 1.66 for F2 and 98.91% ± 0.98 for F5. 
Significant increase in the entrapment efficiency (p<0.05) was found upon increasing 
the drug to polymer ratio as observed for formulations F2 and F5. The high drug 
loading supports the use of spray drying, since the actual drug content was close to the 
theoretical drug amount. Mahajan et al. (2008),  Alhalaweh et al. (2009) and   Gavini et 
al. (2008)  support the conclusion that spray drying is reliable for the preparation of 
chitosan microspheres with high encapsulation efficiencies. For example, the 
entrapment efficiency values were 89-98% for ondansetron hydrochloride when loaded 
in microspheres (Mahajan et al., 2008), 93-105 % for zolmitriptan-chitosan 
microparticles (Alhalaweh et al., 2009) and 94.5 to 100% for metoclopramide 
microspheres (Gavini et al., 2008). 
 
 
Figure 3. 7: Drug loading (DL) and entrapment efficiency (EE) in spray-dried 
microspheres at various drug/polymer ratios. Data represent mean ± SD (n=3). 
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3.3.6 Tapped and bulk density  
Tapped density and particle size are required for theoretical estimation of the powder 
flow properties (Kilian and Müller, 1998) which are essential for optimum delivery 
from the device to the desired site of deposition. Hausnerʼs ratio is useful to determine 
the powder flow properties which may influence the delivery of drug from the device. 
Powders with Hausnerʼs ratio <1.19 have good flow property; this is influenced by a 
number of parameters such as size, size distribution and cohesiveness of the particles 
(Copley, 2008).  
 Results of bulk and tapped density with Hausner's ratio are shown in Figure 3.8. The 
bulk density was relatively high for the formulations F2, F3, and F4, due to smaller 
particles compacting more closely compared to lager particles leading to lower volume 
to mass ratio. Larger microparticles have poorer packing properties with higher volume 
to mass ratio, agreeing with the finding of Sun et al. (2009). A significant difference in 
the tapped density amongst formulations is evident. The tapped density was greatest for 
F2 formulation, probably due to the highest Span values owing to the fact that the 
particles were much more compact than the drug-free formulation (F1). In contrast, F3, 
F4 and F5 formulations had lower Span values and lager particle size measurements, 
and hence they had more voids causing reduction in the tapped powder density to a 
level that was lower than that of F2 formulation. Hausnerʼs ratio for F2, F3, and F4 
formulation was between 1.26-1.34, indicating acceptable flow properties.  
  
CHAPTER 3 
83 
 
 
Figure 3. 8: Bulk density (BD), tapped density (TD) and Hausnerʼs ratio of RH 
free and RH-loaded chitosan formulations. Data represent mean ± SD (n=3). 
 
3.3.7 Swelling index 
Chitosan glutamate showed good swelling properties in phosphate buffer (pH 6.5) and 
could take up several times of its weight of water. This rapid swelling was followed by 
dissolution. The swelling index equilibrium depended on the amount of chitosan present 
in the microsphere formulation. The chitosan ratio in microspheres had a direct effect on 
the swelling ability in phosphate buffer (pH 6.5). As the ratio of chitosan to drug 
decreased the swelling index decreased significantly (p<0.05), possibly due to reduced 
number of the positively charged amino groups, hence capturing less water (Roy et al., 
2009). The high swelling property of chitosan microspheres may uncoil the polymer 
chains into extended and flexible chains (Agarwal and Mishra, 1999), which increases 
interpenetration and entanglement into mucous, hence improving mucoadhesion (He et 
al., 1998). Significant difference (p<0.05) was observed in swelling ability as a result of 
decreased polymer/drug ratios (Figure 3.9). Oliveira et al. (2005) have reported that 
microspheres had higher swelling capacity when prepared from the more concentrated 
and viscous chitosan solution using spray drying. Linear relationship was observed 
between swelling index and surface charge of the microparticles (Figure 3.10). 
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Consequently, increasing drug-loading into microspheres may lead to a decrease in the 
swelling properties and zeta potential, possibly this would affect the mucoadhesion 
properties of the microspheres and drug bioavailability. 
 
 
Figure 3. 9: Swelling index of RH free microspheres and RH-loaded chitosan 
microspheres. Data represent mean ± SD (n=3).  
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Figure 3. 10: Relationship between swelling index and zeta potential of spray dried 
particles. Data represent average values (n=3). 
 
3.3.8 Mucoadhesion 
In vitro study of the formulate mucoadhesive properties are needed to predict the in-vivo 
performance of mucoadhesive microspheres used for intranasal delivery (Gad, 2008). A 
number of in vitro methods have been developed to assess the mucoadhesiveness of 
formulations. Many research groups documented the bioadhesive properties of chitosan 
formulations ( He et al., 1998; Harikarnpakdee et al., 2006; Sun et al., 2009). As the 
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the negatively charged mucous glycoprotein and sialic acid of the mucous membrane 
(Martinac et al., 2005; Patil and Murthy, 2006; Hafner et al., 2007). 
The interaction between mucin and microparticles is conveniently measured and may 
help for the prediction of the in vitro performance of mucoadhesive microparticle 
formulations (He et al., 1998). The amount of the drug loaded into the polymeric 
structure of the microspheres may influence bioadhesion (Gavini et al., 2008). The 
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charged contribution of the epithelium (e.g. mucin and anions present in the mucous 
membrane like sialic acid (Harikarnpakdee et al., 2006; Robinson et al., 1987).  
In this study, the intensity of chitosan adsorption onto the surface of mucin decreased 
significantly (p<0.05) as the ratio of chitosan was decreased from formulation F1 to 
formulation F5 (Figure 3.11). This observation was accompanied by a decrease in the 
intensity of the negative zeta potential of mucin to reach neutrality when formulation F5 
was included and revert to positive values upon increasing the concentration of chitosan 
in microparticle formulations (i.e. by using formulations F4, F3, F2 and F1). Reduced 
adsorption is due to lower chitosan concentration, resulting in less positively charged 
particles for interaction with mucin (Sun et al., 2009). Rapid swelling of small 
microparticles may provide a more powerful mucoadhesive system than larger particles 
(El-Hameed and Kellaway, 1997). Pereswetoff-Morath (1998) has report that 
microspheres can swell and take liquid up upon coming in contact with mucous 
membranes, resulting in dehydration of the epithelial cells with subsequent shrinkage. 
This may eventually cause the tight junctions to open, causing enhanced drug 
permeation. 
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Figure 3. 11: Zeta potential of the mucin and the mixture of mucin from porcine 
stomach (Type II) with the microsphere formulations. Data represent mean ± SD 
(n=3).  
 
3.3.9 Surface morphology of microparticles  
The morphology of drug-free and RH loaded microspheres were examined using 
scanning electron microscopy (SEM) (Figures 3.12, 3.13 and 3.14). RH particles had 
irregular shape before and after spray drying (Figure 3.12). Incorporation of chitosan 
glutamate in various ratios into RH solutions followed by spray drying made the 
microparticles spherical irrespective to the polymer: drug ratio, (Figures 3.13 and 3.14). 
Optimization of particle size, morphology and powder flowbility is necessary to reduce 
the risk of nasal irritation and improve deposition in the nasal cavity ( Behl et al., 1998).  
Furthermore, SEM images showed absence of crystals and irregular shapes on the 
surface of microparticles, indicating that all drug particles were encapsulated within the 
polymeric structure of chitosan. These properties of microparticles may decrease 
mucosal irritation, enhance deposition pattern and improve drug absorption following 
intra-nasal delivery. Gavini et al. (2006) have reported improved nasal bioavailability of 
carbamazepine upon preparation of drug-loaded chitosan glutamate microspheres via 
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spray drying. Overall, SEM images indicated that RH-loaded chitosan microparticles 
are likely to be amorphous and efficiently encapsulated drugs since it is established that 
spray drying technology predominantly generates amorphous powders (Corrigan, 1995; 
Learoyd et al., 2008b). 
  
 
 
 
Figure 3. 12: SEM images of RH (a) before spray drying and (b) RH after spray 
drying. Magnification: 750x (a) and 1200x (b). 
(a) 
(b) 
    10µm 
    10µm
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Figure 3. 13: SEM images of (a) the blank microspheres F1, (b) F2, and (c) F3. 
Magnification: 2500x.  
 (a) 
(b) 
(c) 
    10µm 
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Figure 3. 14: SEM images of (a) is F4 and (b) is F5. Magnification: 2500x.
(b) 
(a) 
    5µm 
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3.3.10 X-Ray diffraction 
X-ray diffractogram of RH, drug-free microparticles, drug-loaded microspheres and the 
physical mixture of RH and chitosan glutamate are shown in Figure 3.15. The 
diffractogram of RH raw material showed sharp peaks at different angles, indicating the 
crystalline nature of the drug. The absence of crystal peaks for RH in chitosan 
formulations F2 and F3 (Figure 3.15h and f) indicates that the drug was converted into 
amorphous form and was uniformly dispersed into the polymeric network of chitosan. 
On the other hand, the intensity of the peak decreased in formulations F4 and F5, 
(Figure 3.15d and c), indicating some of the drug remained in the crystalline form and 
was only partially converted into amorphous. These findings agree with previous 
investigations by Shahi et al. (2011) using atenolol-loaded spray-dried bioadhesive 
microspheres. Generally, the amorphous form of a given material has better dissolution 
than its corresponding crystalline form (Craig et al., 1999). However, amorphous form 
is less stable and has a tendency to revert to crystalline form during storage, causing 
changes in the physical properties of the formulations (Learoyd et al., 2008a).  
The stability study of microsphere formulations following storage in the fridge (5
o
C ± 
1) and room temperature (20
o
C ± 2) over two months demonstrated no change in 
amorphicity of the encapsulated RH was observed (Figure 3.16), which agree with 
Learoyd et al. (2008a) who prepared respirable powders of beclometasone dipropionate 
loaded into chitosan microparticles via spray drying. Administration of an amorphous 
powder via insufflations could be advantageous owing to the ability of chitosan to form 
a mucoadhesive gel following hydration of the microspheres within the nose and hence 
this may improve drug bioavailability.  
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Figure 3. 15: X-Ray spectra of (a) pure RH and mucoadhesive formulations of  (b) 
drug free microspheres (F1), (c) F5, (d) F4, (e) physical mixture (co-ground) of 
chitosan and RH, 70:30 ratio, (f) F3, (g) physical mixture (co-ground) of chitosan 
and RH, 90:10 ratio, and (h) F2.  
 
 
Figure 3. 16: X-Ray spectra of (a) fresh F2 formulation, (b) F2 formulation stored 
at fridge and (c) F2 formulation stored at room temperature for two months.
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3.3.11 Thermo Gravimetric analysis (TGA) 
Moisture content (%) of spray dried microsphere formulations may give an indication of 
the dispersion properties of the particles following intranasal delivery. Dispersion of 
small hygroscopic particles prior to inhalation might be negatively influenced by the 
tendency of particles to agglomerate following adsorbing some moisture from the 
surrounding environment (Ståhl et al., 2002). In the present study, the percentage 
weight loss ranged from 1.82% ± 0.18 to 5.76% ± 0.23 for formulations F5 and F1 
respectively (Figure 3.17). The moisture content was not statistically different (p>0.05) 
when F1, F2, and F3 were compared, whilst it was statistically different (p<0.05) when 
F4 and F5 were included in the comparison. This is attributed to the higher ratio of 
chitosan glutamate to RH in F1, F2 and F3 formulations, since the higher polymer 
content may reduce water evaporation during spray drying process. These findings are 
comparable to Ståhl et al. (2002) who prepared spray dried insulin powder via spray 
drying.  
 
 
 
Figure 3. 17: Weight loss of chitosan microparticle formulations. Data represent 
mean ± SD (n=3). 
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3.3.12 Differential scanning calorimety (DSC)  
Behaviour of drug within microparticles was evaluated by conducting DSC analysis. 
Chitosan microparticles showed broad endothermic peak between 150 and 180
o
C, 
which might be attributed to the salt of glutamate. The same observation was reported 
by other authors (Genta et al., 2003; Maestrelli et al., 2004) (Figure 3.18). Thermogram 
of RH raw material revealed a single sharp endothermic peak at 248.5
o
C, with 
endothermic energy of 117.36 J/g, indicating the crystallinity of the drug and it is 
corresponding to its melting point (243-250°C) (DrugBank, 2013). Endothermic peak of 
the drug in the physical mixture was closer to the peak of pure drug when the drug 
content increased (Figure 3.18), indicates the amount of crystalline RH in physical 
mixture increased as the ratio of the drug to polymer increased. However, endothermic 
peak of RH loaded microspheres disappeared for formulation F2, indicating that the 
drug molecules were dispersed in the polymeric matrix at the molecular level. By 
contrast, a dramatic decreased in the crystalline peak was observed for F3, F4 and F5 at 
202.13, 210.3 and 224.25
o
C respectively. Additionally, the enthalpy measures the 
degree of crystallinity for melting materials, showing lowered enthalpy of encapsulated 
RH form 117.36 J/g to 6.79 J/g for F3, 8.8 J/g for F4 and 48.44 J/g for F5 formulations. 
These results suggested that the encapsulated drug was partially converted to 
amorphous form. The decomposition of chitosan was observed next to the melting of 
the drug at 253.88
o
C. However, an exothermic peak was observed for F3, and may be 
attributed to recrystallization of the drug at 238.82
o
C (i.e. the amorphous form reverted 
to crystalline). These DSC findings were in accordance with the results by Avachat et 
al. (2011) who prepared sustained release RH loaded microspheres using emulsion-
solvent evaporation method from combination of ethylcellulose and poly-ethylene 
glycol (PEG) 6000. 
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Figure 3. 18: DSC thermograms of (a) drug free microsphere, physical mixture of 
chitosan-RH; (b) 90:10, (c) 70:30, (d) 50:50, (e) 30:70 and RH loaded chitosan 
microspheres; (b) F2, (c) F3, (d) F4, (e) F5 and (f) pure drug. 
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3.3.13 Drug release from microspheres 
In vitro drug release study was carried out in PBS (pH 6.5), similar to the pH of the 
nose. The drug alone had very fast dissolution rate, due to its high solubility in water. 
However, the release rate from microsphere formulations was dependent on the amount 
of chitosan present in the formulation. The time required to obtain maximum drug 
concentration (Tmax) was observed at 60 and 20 min for formulations F2 and F3 
respectively, whilst for formulations F4 and F5 the total amount of the drug recovered 
was found to be at 5 and 10 min respectively (Figure 3.19). This suggests that the drug 
diffusion rate from the microspheres into the medium was controlled by formation of a 
boundary gel layer around the microparticles. The viscosity and thickness of this layer 
were dependent on drug loading and polymer concentration in the microparticles, 
suggesting that higher levels of drug loading can provide faster drug release. Genta et al. 
(1995) have reported drug loaded into non-cross-linked spray dried chitosan 
microparticles offered rapid drug release which was ascribed to rapid swelling and 
dissolution of microspheres upon contacting water. The results were in accordance with 
those reported by Alhalawa and co-workers (Alhalaweh et al., 2009) for zolmitriptan 
loaded chitosan microspheres prepared by spray drying for nasal delivery. Rapid 
methotrexate release from spray dried chitosan microspheres has been reported by Sun 
et al. (2009). 
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Figure 3. 19: In-vitro dissolution profiles of spray dried RH loaded chitosan 
microsphere formulations carried out in phosphate buffer solution (pH 6.5). Data 
represent mean ± SD (n=3). 
 
3.3.14 Toxicity of RH-loaded chitosan microspheres 
Drug formulations designed for nasal delivery to give local or for systemic effects 
should not cause damage to the nasal mucosa or interfere with the normal mucociliary 
clearance. Hence, a histopathological study is necessary to evaluate the safety of 
formulations designed for intranasal applications (Hermens and Merkus, 1987). 
Microscopic images showed nasal mucosa of a sheep treated with PBS (pH 6.5) and 
used as negative control (Figure 3.20a), and sodium deoxycolate which was used as 
positive control (Figure 3.20b). In the same experiment, the histological characteristics 
of RH-loaded microsphere dispersions (F2) (Figure 3.21a), chitosan glutamate 
microspheres (Figure 3.21b) and RH solution (Figure 3.21c) were investigated. It was 
observed that the entire cilia became detached when the nasal mucosa was treated by the 
positive control. In contrast focal sloughing of cilia was observed when the nasal 
mucosa was treated with the negative control, drug solution, chitosan and RH-loaded 
chitosan dispersion. The details of the histopathological studies are given in Table 3.3. 
Previous studies have reported chitosan is non-toxic to mucosal membranes, strongly 
supporting its suitability and safety as a mucoadhesive carrier for delivery of drugs to 
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the nose (Islam et al., 2012). The results revealed no necrosis or major changes of the 
integrity of nasal mucosa upon the treatment with RH loaded microspheres. Goblet 
cells, Sero-mucinous glands and ciliated cells remained intact with very little focal 
sloughing of cells being detected. The study was in agreement with results obtained by 
several research groups (Nanda and Murthy, 2007; Seju et al., 2011; Shah et al., 2011; 
Mahajan et al., 2012). The microscopic results indicated that RH-loaded microparticles 
had no harmful effect on the nasal mucosa. The safety of RH was also documented by 
Khan and co-workers, using thermogel formulations of the drug for brain targeting 
(Khan et al., 2010).  
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Table 3. 3: The comparative histopathological evaluation of nasal mucosa treated with a range of formulation. 
Treated nasal mucosa Necrosis Ciliated cells Goblet cells Inflammatory cell infiltrate in the 
sub mucosa 
Sero-mucinous 
glands 
Phosphate Buffer solution 
(pH 6.5) (Negative control) 
Absent Intact with focal 
sloughing 
Not affected Mild sub mucosal inflammation and 
increased intraepithelial lymphocytes 
Not affected 
Sodium deoxycholate  
solution (positive control) 
Severe Mostly sloughed Present Sever sub mucosal inflammation and 
increased number of intraepithelial 
lymphocytes 
Inflamed 
Drug-free chitosan 
microparticle  
Absent Intact with focal 
sloughing 
Not-affected Mild sub mucosal inflammation Not affected 
RH solution Absent Detached focally but still 
present 
Not-affected Mild sub mucosal inflammation Not affected 
Chitosan: RH (90:10)  
F2 
Absent Focal sloughing of the 
cilia 
Not-affected Mild sub mucosal inflammation Not affected 
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Figure 3. 20: Microscopic (Olympus) images of sheep nasal mucosa treated by; (a) 
negative control (phosphate buffer pH 6.5) (10 x 10 magnification, n=3) and (b) 
positive control (Sodium deoxycollate) (10x 10 magnification, n=3). "S" means 
sloughed, "N" means necrosis, "I" means inflammation. 
(a) 
(b) 
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Figure 3. 21: Microscopic (Olympus) images of sheep nasal mucosa treated by (a) 
formulation F2, (b) drug-free microspheres and (c) RH solutions (10 x 10 
magnification, n=3). "S" means sloughed, "N" means necrosis, "I" means 
inflammation. 
(a) 
(b) 
(c) 
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3.3.15 Characterization of RH loaded chitosan microspheres delivered using 
Miat
®
 nasal device 
Delivery of powder to the nasal cavity is not well explored and little has been done on 
characterization of powder spray pattern, plume geometry and deposition using nasal 
insufflators. Passive and active systems are the main delivery systems that have been 
used to deliver powders into the nose. Active systems involve devices designed to emit 
powder originally loaded by using air pressure, whilst passive systems rely solely on 
inhalation power of the patient to deliver the powder to the nose. Most devices in the 
market are active devices (Kozlowski, 2012). A Valios Monopowder insufflator (Valios 
pharmaceutical division, France) has been experimented for delivery of anthrax vaccine 
powder (10 mg) to the nasal cavity of rabbit (Klas et al., 2008). Deposition of powders 
in the nasal cavity is influenced by powder formulation and type of nasal device used.  
Unit dose nasal devices can be used for delivery of vaccines (Wang et al., 2012), 
biotechnology products (Lochhead and Thorne, 2012) and other active molecules 
(Ghimire et al., 2007; Djupesland and Docekal, 2010) into the nasal cavity either for 
local, systemic or CNS effect.  In this study, Miat
®
 Monopowder device (Miat, Milan, 
Italy) was investigated to determine the spray pattern and plume geometry (i.e shot 
weight, mean particle size, spray cone angle, plume width, plume length and spray 
velocity) (CDER, 2003). These in vitro studies are recommended by FDA to 
characterize the device performance and give information relating to drug 
bioavailability (CDER, 2002). 
3.3.15.1 Determination of shot weight (Fraction of delivered formulation) 
In this study, the effect of loading dose on the fraction of formulation delivered was 
determined. For this purpose three different weights of powder (5, 10 and 20 mg) were 
used. During spraying the movement of the powder within the capsule was affected by 
the void volume of the powder formulation and air turbulence within the device 
reservoir. These were responsible for emitting the powder from the capsule (De 
Ascentiis et al., 1996).  
The quantitative delivery of RH loaded chitosan microspheres from Miat
®
 nasal 
insufflator was determined by calculating the difference between the weight of the 
device reservoir (gelatin capsule) after each puff. It has been observed from the second 
puff that more than 94% of the powder formulation was emitted from the device with 
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the aid of air force, whilst after the third puff more than 96% of the powder was 
delivered (Table 3.4).   
Results showed that the loading quantity had no effect on the fraction of formulation 
delivered following the first, second and third puffing using F2 formulation with various 
weights. Similar findings were recorded by De Ascentiis and co-workers who studied 
the delivery of β-Cyclodextrin powders using nasal insufflators (De Ascentiis et al., 
1996). Results were also in accordance with Patile and Sawant (2011). Therefore, the 
uses of Miat
®
 nasal device can be useful when the drug dose is very small such as in 
case of using potent drug formulations.  
Table 3. 4: Percentage of RH loaded chitosan microspheres delivered using Miat
®
 
nasal insufflator. Data represent mean ± SD (n=3). 
Loading 
weight (mg) 
Cumulative dose delivered (%) 
First Puff Second Puff Third Puff 
5 89.6±0.26 94.21±1.11 96.88±1.43 
10 90.36±0.67 94.83±0.41 96.77±0.36 
20 90.96±1.76 95.64±1.47 96.97±1.63 
 
 
3.3.15.2 Physical particle size analysis using laser diffraction 
The most important consideration for nasal delivery is the determination of physical 
particle size. The compactness of the cloud produced from the emitted powder may be 
affected by particle size, which can affect the impaction of the powder in nasal cavity 
following intranasal administration. VMD, particle size <10 µm (%) and Span were 
determined using the Spraytech instrument (Malvern Instruments Ltd, UK) and found to 
be 76.02 ± 4.57 µm, 14.37 ± 1.85 µm and 3.96 ± 1.3 respectively. Most nasal pumps 
used to deliver liquid formulations produce droplets in the range of 20 - 120 µm. 
Increasing particle size and Span might be observed if cohesion between particles 
causes agglomeration, which might be useful for deposition in the nasal cavity. If 
particle size produced by the nasal delivery device is more than 10 μm, the deposition in 
the upper respiratory tract may predominate, whereas particles between of 5 –7 μm  
might be retained in the nasal cavity (Donovan and Huang, 1998). However, particles 
with size larger than 0.5 µm may deposit in the nose due to filtration of the inspired air 
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by the nasal vibrissae (Burgess et al., 2004). In principle, the likelihood of particle 
deposition into the lower respiratory tract decreases as particle size increases, however 
particles having physical size below 5 µm are likely to deposit in the olfactory region 
(Keldmann, 2005).  
3.3.15.3 Determination of plume geometry and spray pattern 
Improving nasal bioavailability has been related to type of delivery device, physical 
status of the formulation (liquid, semi-liquid or solid) and the technique of 
administration. These factors may affect the site and pattern of spray deposition in the 
nose, consequently effecting drug bioavailability (Arora et al., 2002). Spray pattern 
investigation can help to determine the site of powder deposition after administration 
and give reliable prediction of nasal bioavailability.  
Spray pattern is a useful quality control test for determining the bioequivalence of 
formulations and/ or feasibility of nasal devices (CDER, 2003). The representative 
image of spray pattern using impaction method (section 2.7.2) for F2 formulation, at the 
distance of 3cm was investigated. The longest diameter (Dmax), shortest diameter (Dmin) 
and ovality ratio (Dmax/Dmin) were 15.67 ± 0.52 mm, 14 ± 0.89 mm and 1.12 ± 0.04 
respectively (Figure 3.22). The image showed spherical and intense spray pattern of F2 
formulation (chitosan glutamate to RH, 90:10 w/w ratio).  
Investigations of spray cloud demonstrated the required spray time to reach the fully 
developed phase was 0.16 sec whilst the total spray time to deliver 10 mg of RH loaded 
microparticles was 0.32 sec, indicating rapid delivery of the powder from the Miat
®
 
device (Figure 3.23).  
Powder particles were ejected from the monopowder delivery device at an angle of 14.3 
± 1.03 and the plume width was 11.3 ± 1.03 at 3cm distance from the tip of the nasal 
device. It has been reported that anterior deposition of the emitted dose from nasal 
devices predominates when the spray has large angle (60 – 70o), whereas deposition in 
posterior part of the nasal cavity happens when the plume cone is small (around 30 to 
35
o
) (Pringels et al., 2006). Thus, deposition of the delivery dose at the anterior region 
may increase when the plume angle is increased. Conversely, the decrease in plume 
angle enhances the likelihood of targeting the turbinate region of the nose (Foo et al., 
2007).  
CHAPTER 3 
105 
 
Powder formulation released from the monodose nasal insufflator was observed as an 
elongated puff with a homogeneous core, indicating the effective distribution pattern of 
the delivered microspheres. The compactness of the clouds might be affected by powder 
particle size, with small particles generating clouds that fluffy and homogeneous in 
density, whereas large particles may produce clouds with visible individual particle 
trajectories (De Ascentiis et al., 1996). 
 
 
Figure 3. 22: Spray pattern of RH-chitosan microparticles (90:10 w/w, chitosan 
glutamate to RH) at 3cm distance from the nasal device tip (n= 4). 
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Figure 3. 23: RH-chitosan microspheres (F2) delivery sequences from Miat
®
 monodose insufflator monitored by videography (n= 4). 
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3.4 Conclusions 
Results of this study supports the theory that chitosan-based microspheres are promising 
drug delivery systems for nasal administration of RH by using Miat
® 
nasal insufflator 
devices. FTIR spectra revealed no interaction between RH and chitosan glutamate. The 
ratio of polymer to drug in formulations had a crucial effect on particle size, size 
distribution, intensity of positive charge of the microparticles and swelling index. 
Improvements in the drug particle morphology and powder flowability were obtained 
by co-spraying the drug with chitosan. X-ray spectra and DSC demonstrated chitosan to 
drug ratio had remarkable effect on the physical state of the entrapped drug. Absence of 
crystal peak in formulation 90:10, polymer to drug ratio indicates that the drug was 
molecularly dispersed within the polymeric matrix. TGA revealed that the humidity 
content (%) was minimized as the ratio of chitosan/drug decreased. The release study 
demonstrated that chitosan to drug ratio has controlled the rate of drug released. 
Histopathology study revealed RH-chitosan microspheres formulations are relatively 
safe for intranasal administration.  
The Miat
®
 monopowder insufflator efficiently delivered nearly 90% upon first actuation 
regardless of the weight of the powder. Laser diffraction study of the cloud 
demonstrated that the sprayed particles were less likely to deposit in the lower 
respiratory tract, owing to particle agglomeration. The generation of homogeneous 
cloud with narrow plume angle might enhance powder deposition in the nasal cavity 
and particularly in the olfactory region of the nose where direct drug delivery to CNS 
may occur. Thus, particle agglomeration in this study was advantageous since it is 
expected to maximize the drug deposition in the nasal cavity (i.e. minimize deposition 
in the lower respiratory system) and enhance targeting properties to the olfactory region 
and the proportion of the drug available for absorption into the systemic circulation. The 
microsphere powder formulations prepared in this study, taking into account the 
therapeutic effects of RH, is suggested for nasal administration to treat Parkinson’s 
disease and restless legs syndrome. Further in vivo studies are needed to explore the 
validity of this hypothesis.  
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4.1 Introduction 
Microparticles represent a powerful drug delivery technology for incorporating drugs 
into polymeric excipients prepared as spherical particles. These delivery systems 
modulate release and improve drug absorption due to the high surface area to volume 
ratio of the microparticles (Gavini et al., 2006).  
Formulation of drugs as microparticulate powder dosage forms has been suggested to 
enhance chemical stability of drugs and excipients. Powder formulations are free from 
preservatives and can be administered in larger doses, and can be used for peptide and 
conventional drug molecules (Chaturvedi et al., 2011). The bioavailability of drug can 
be improved when it is administered in powder formulations compared to liquid dosage 
forms via the nose (Ishikawa et al., 2001). 
As mentioned in chapter 3 the nasal route is characterized by its relatively high 
permeability, lager surface area (150 cm
2
) and high blood supply. Therefore, it is highly 
appropriate for drugs that undergo extensive first pass metabolism, because the drug is 
directly absorbed to the circulation without passing through portal vein to the liver 
(Chaturvedi et al., 2011). The nasal route takes advantage of the neuronal connection 
between the nose and brain to elicit effects in the CNS (Wen, 2011; Kumar et al., 2013). 
This strategy may minimize systemic side effects of drug (Kumar et al., 2013). Nasal 
route is well established for administration of drugs to treat local diseases such as 
rhinitis and nasal congestions and CNS diseases such as migraine. 
The drug is cleared rapidly from the nasal cavity towards nasopharynx by mucociliary 
process within 15 min when applied as a solution (Mao et al., 2004). Bioadhesive 
polymers interfere with the ciliary movement, hence drug loaded into microspheres may 
have prolonged contact with the mucous membranes compared to the corresponding 
drug solution (Illum, 2003). 
Bioadhesive polymers are natural, synthetic or semi synthetic intended to carry, protect 
and prolong the residence time of the drug. Mucoadhesive agents may prolong the drug 
contact with the absorption site in the nose for up to 3-5 h, depending on type of 
mucoadhesive polymer. This may be particularly useful for enhancing absorption of 
drugs with poor bioavailability (Rai et al., 2008). Enhancement of carvedilol absorption 
and bioavailability improvement have been reported when the drug was encapsulated 
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into sodium alginate microspheres prior to administration into the nose (Patil et al., 
2012). 
Sodium alginate is a natural polyanionic polymer used for controlled drug release. It is 
relatively inexpensive, non-toxic and biodegradable (Farid et al., 2012). The 
mucoadhesive properties are directly proportional to the polymer’s molecular weight 
and are influenced by the polar groups (Kharenko et al., 2009). Mucoadhesive 
properties of sodium alginate are ascribed to formation of hydrogen bonds as a result of 
carboxyl-hydroxyl interactions with mucin (Patil et al., 2012). This interaction ensures 
success of this polymer as a vehicle for drug absorption through the nasal epithelium 
(Farid et al., 2012). A wide range of active constituents have been encapsulating into 
alginate microparticles such as peptides, proteins (Coppi et al., 2002) and small 
therapeutic molecules (e.g. metoprolol tartarate) (Rajinikanth et al., 2003). 
Ropinirole hydrochloride (RH) is non-ergoline antiparkinson drug, which may elicit 
therapeutic effect due to the selective agonistic activity on the D2 dopamine-like 
receptors (DrugBank, 2013). RH is widely used in the management of Parkinson’s 
disease, either alone or in combination with other drugs to minimize on-off fluctuation 
in response to levodopa (Tulloch, 1997).  The drug is inactivated by the liver, hence its 
oral bioavailability is only around 50% (DrugBank, 2013).  
This study hypothesises that intranasal administration of alginate microspheres of RH 
prolongs the contact between the formulation and nasal epithelium and facilitates the 
uptake of the drug to the brain, hence avoiding fluctuating plasma levels of the drug due 
to on-off phenomenon in Parkinson's disease.  
This study aimed to design and develop microspheres based on sodium alginate 
polymer as a delivery carrier system using spray drying. In this study the effect of inlet 
temperature of the spray dryer on the microparticulate powder characteristics including 
particle shape, product yield, and particle size and size distribution were investigated to 
select the optimum inlet air temperature. Spray drying parameters were optimised and 
used to develop RH-sodium alginate microspheres, and full characterization of the 
formulations was conducted. The best performing formulations were further 
investigated using nasal insufflators. 
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4.2 Methodology 
4.2.1 Compatibility Study 
The compatibility between RH and sodium alginate was investigated by preparation of 
RH loaded alginate microspheres (50:50 w/w) using spray drying.  FTIR spectroscopy 
and TLC were used to detect interaction or formation of new bonds between the drug 
and polymer as described in section 2.2. 
 
4.2.2 Optimization of sodium alginate microsphere formulation 
i) Preparation of sodium alginate microspheres (0.5%) 
To optimize the formulation and spray drying parameters for the preparation of RH 
loaded sodium alginate microspheres, an aqueous solution of the polymer (600 ml; 
0.5% w/v) was prepared by dissolving 500 mg in 100 ml HPLC water with magnetic 
stirrer to enhance the rate of dissolution. The resultant solution was divided into three 
equal volumes, each was atomized using certain spray drying conditions (Table 4.1) and 
using the Büchi-290 Mini Spray-Drying (Büchi Laboratories, Switzerland). The 
experiments were conducted three times and the microspheres were characterized for 
yield, particle size, size distribution and morphology as described in the section 2.5. 
Table 4. 1: Conditions for the preparation of sodium alginate microspheres. 
 
Condition Inlet 
Temperature 
(
o
C) 
Outlet 
Temperature 
(
o
C) 
Aspiration 
rate (%) 
Gas flow 
rate (L/h) 
Pump 
rate 
(%) 
1 160 72-81 100 357 17 
2 140 64-71 100 357 17 
3 120 56-58 100 357 17 
 
ii) Characterization of sodium alginate microspheres 
The production yield (%) of microspheres at different conditions, size and size 
distribution of alginate microparticles and morphology of spray dried sodium alginate 
microparticles were determined as described in chapter 2.  
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4.2.3 Preparation of RH loaded alginate 
Four formulations using low viscosity sodium alginate and RH were prepared using a 
range of polymer to drug ratios (Table 4.2). Drug-free microspheres were prepared 
(0.5% w/v) for comparison using the same spray drying conditions. The feed solutions 
were prepared by dissolving sodium alginate and the drug in 100 ml of HPLC water. 
Automated microviscometer was used to measure viscosity of the solutions before spray 
drying. The feed solution was atomized through 0.7 mm nozzle. The spray dry 
conditions used were as follows: inlet temperature 140
o
C, outlet temperature 64 - 71
o
C, 
aspiration rate 100%, gas flow rate 357 L/h and pump ratio 17% (5 - 6 ml/min). 
Solution (200 ml) was prepared for each batch and each experiment was repeated three 
times. 
 
Table 4. 2: Composition of sodium alginate microparticle formulations. 
Formulation 
code 
Ratio (w/w) 
(polymer: RH)  
Sodium alginate 
(mg) 
RH 
(mg) 
Total weight 
(mg) in 
100ml 
A1 100:0 500 0 500 
A2 90:10 450 50 500 
A3 70:30 350 150 500 
A4 50:50 250 250 500 
A5 30:70 150 350 500 
 
 
4.2.4 Characterization of RH loaded alginate microparticles 
Microsphere formulations prepared in this study were investigated and characterized for 
powder yield, microscopic morphology, physical state using X-ray crystallography, and 
thermal behaviour using DSC and TGA. Following dispersion of the formulations, 
particle size, size distribution, zeta potential, drug entrapment efficiency, and in vitro 
drug release were investigated. As described in section 2.6.11, histopathological studies 
were conducted to evaluate the safety of microspheres for nasal administration. Using 
the best performing formulation, fraction output, VMD, size distribution, spray pattern 
and plume geometry were studied as explained in sections 2.7 and 2.8.5.     
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4.3 Results and discussion 
4.3.1 Compatibility study 
This study detected the interactions between the drug and polymer. It provided 
information on physicochemical properties of the drug and excipients since undesirable 
interactions could affect the stability of formulation, efficacy or dissolution behaviour 
of the drug (Taylor and Zografi, 1997). In this experiment drug-excipient interaction 
was studied using thin layer chromatography (TLC) and FTIR spectroscopy.  
i) Thin layer chromatography (TLC)  
The Rf values of RH as a co-spray dried, physical mixture and pure drug were similar 
(Rf = 0.55). No extra spot was observed in the TLC plate, suggesting no chemical 
interaction between drug and polymer.  
ii) FTIR spectrum 
FT-IR spectrum of RH, sodium alginate, physical mixture of RH and sodium alginate 
and spray dried formulations (1:1 ratio w/w) were compared to investigate possible 
interactions between drug and polymer (Figure 4.1). Sharp peaks of RH were found at 
1241.19, 1455.36, 1702.18 and 3068.95 cm
-1
 for C-N, C=C stretching, C=O stretching 
and N-H stretching functional groups respectively, whilst the IR spectrum of sodium 
alginate showed peaks at 3273.05, 1595.09 1408.25 and 1026.88  cm
-1
  for O-H 
stretching, C=O stretching, COO- and C-O-C stretching respectively (Figure 4.2). When 
IR spectrum of pure RH was compared to the IR spectrum of physical mixture and 
spray dried RH loaded alginate microspheres, no remarkable band-shifts of wave 
number were observed. Hence, FTIR data confirmed no merging of peaks of RH with 
sodium alginate occurred, indicating no interaction between RH and sodium alginate.  
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Figure 4. 1: FTIR spectra of (A) RH, (B) sodium alginate, (C) physical mixture of sodium alginate and RH  (1:1) ratio, and (D) spray dried RH 
loaded sodium alginate microparticles. The lower graph magnifies the wave numbers area between 900 and 1900 cm
-1
. 
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4.3.2 Optimization of sodium alginate microparticles 
i) Production yield 
Sodium alginate solutions (0.5% w/v) were spray-dried at different inlet air 
temperatures. The production yield decreased significantly (p<0.05) from 70.27 ± 1.26 
to 58.87 ± 2.95 as the inlet temperature was decreased from 160
o
C to 120
o
C, resulting in 
a decrease in the outlet air temperature from 77.2
o
C ± 2.7 to 59.2
o
C ± 2 respectively. 
This may be attributed to less heat energy available in the drying chamber, which is 
required to dry the atomized droplets quickly before non-dried droplets leave the drying 
chamber with vacuum. A positive relationship between inlet temperature and yield of 
product was found up to a point depending on the properties of the material used. When 
the inlet air temperature increased the process of drying the droplets also increased, 
resulting in yield promotion (Rathananand et al., 2007). However, no significant 
difference (p>0.05) in yield was seen when comparing the inlet temperatures 140
o
C and 
160
o
C (Figure 4.2). Rathananand et al. (2007) reported that evaporation of solvent in 
droplets depends on the latent heat, whereas  an incremental change of inlet temperature 
can lead to a slight difference in the outlet temperature, resulting in minor effect on 
solvent evaporation at the surface of the droplet (Rathananand et al., 2007). Aspiration 
rate has a positive impact on the outlet air temperature, whilst the feeding rate (i.e. 
pump rate) has a negative effect on the outlet air temperature and so on the production 
yield. Tee et al. (2012) reported that the production mass of maltodextrin coated Piper 
betle L. (Sirih) decreased when the feed rate (pump speed) was increased. High inlet 
temperature increases outlet temperature, thus enhancing the solvent evaporation 
efficiency from the sprayed droplets, which reduces droplet deposition on the walls of 
the drying chamber and improves droplet drying, resulting in promoting the production 
yield (Maury et al., 2005). These experiments agree with those reported by Amaro et al. 
(2011) for maximizing the production yield of spray-dried trehalose and raffinose from 
methanol (80%)/n-butyl acetate (20%) v/v using laboratory-scale spray dryers.  
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Figure 4. 2: Relationship between inlet air temperature and the production yield 
(%). Data represent mean ± SD (n=3). 
 
i) Particle size and size distribution 
Particle size and size distribution (Span) of sodium alginate microparticles prepared at 
different inlet temperatures are shown in Figure 4.3 and Figure 4.4. The size ranged 
from 2.35 ± 0.10 to 2.58 ± 0.06 µm and the Span was in the range of 2.11 ± 0.53 to 2.71 
± 0.02 for microparticles produced at 120
o
C and 140
o
C respectively. Statistically no 
effect of the inlet air temperature was observed (p>0.05) on particle size when the inlet 
temperature decreased from 160 to 120
o
C. The decreasing trend for particle size 
prepared under 120
o
C inlet temperature might be ascribed to low efficiency of heat 
vaporization in the drying chamber. These results disagreed with Tee et al. (2012) who 
have prepared Sirih coated by maltodextrin via spray drying. The conflicting findings 
might be due to the difference of the properties of excipients used. However, the size 
distribution (i.e. Span) of particles prepared using 120
o
C, 140
o
C and 160
o
C inlet 
temperatures did not significantly change (p>0.05) (Figure 4.4). 
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Figure 4. 3: Relationship between inlet air temperature (
o
C) and particle size 
(VMD) of sodium alginate microparticles. Data represent mean ± SD (n=3). 
 
 
 
Figure 4. 4: Relationship between inlet air temperature (
o
C) and Span of sodium 
alginate microparticles. Data represent mean ± SD (n=3). 
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ii) Morphology 
Particle morphology influences particle size determination, bulk density, powder 
flowbility and surface area. Furthermore, powder used for targeting specific regions of 
the respiratory tract depends on particle size and shape (Chegini and Taheri, 2013). 
Shape and residual solvent in particles produced by spray drying can be controlled via 
the optimization of inlet/outlet air temperatures. Rate of solvent evaporation from the 
droplet and formulation may affect morphology of the particles produced by spray 
drying. For example, particles may have defective shapes if drying occurs rapidly 
(Chegini and Taheri, 2013). The shapes of microparticles spray dried using the three 
drying conditions (120, 140 and 160
o
C) are shown in Figure 4.5. SEM images 
demonstrated that larger fractions of particles generated at 160
o
C inlet temperature were 
dimpled and holed. In contrast, the shape of particles became spherical, and surface was 
observed to have fissures/cracks as the inlet air temperature was decreased to 120
o
C. 
This might be attributed to incomplete water evaporation from the atomized droplet 
(Figure 4.5c). SEM images revealed that changing the inlet temperature had a great 
effect on the surface morphology of spray dried sodium alginate microspheres.  
 
Based on these experiments, inlet air temperature of 140
o
C was selected to prepare 
various formulations of RH loaded sodium alginate microparticles, as round shaped 
particles are believed to improve powder flow and possibly can cause less irritation to 
the nasal mucosa. 
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Figure 4. 5: SEM images of sodium alginate microparticles where inlet air 
temperatures were: (a) 160
o
C (magnification: 5000x), (b) 140
o
C (magnification: 
5000x), and (c) 120
o
C (magnification: 2500x). 
(a) 
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4.3.3 Characterization of RH loaded sodium alginate  
4.3.3.1 Product yield 
The product yield was relatively high (approaching 70%) and the increase of drug to 
polymer ratio did not affect (p>0.05) the powder yield (Figure 4.6).  
 
 
Figure 4. 6: Production yield (%) of sodium alginate microsphere formulations. 
Data represent mean ± SD (n=3). 
 
4.3.3.2 Size and size distribution of microparticles 
Generally, particle size of the powders obtained by spray drying depends on the 
proportion of atomized droplets. Droplet size is directly proportional to concentration, 
viscosity and feed rate of the feeding solution, and inversely proportional to gas flow 
rate (Chegini and Taheri, 2013).  
Particles size determines the final dosage form performance for oral, parenteral and 
pulmonary delivery (Thanoo et al., 1995). Particle size affects surface area of the 
particles; this influences the rate and duration of drug release at the site of absorption 
(Narayani and Panduranga Rao, 1996). The smaller the size of microsphere the larger its 
surface area, thus the release of insoluble drug from microspheres can be controlled 
owing to high surface area to volume ratio of the small particles (Sinha et al., 2004). 
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Particle size of RH-sodium alginate microspheres (Table 4.3) was 2.58 ± 0.35 µm and 
4.37 ± 0.29 µm for formulations A2 and A5 respectively. As the ratio of drug to sodium 
alginate increased the particle size also increased significantly (p<0.05). With regard to 
size distribution, Span values ranged from 1.52 ± 0.03 to 4.13 ± 1.19. 
 
Table 4. 3: Particle size, size distribution and viscosity of alginate microparticle 
formulations. Data represent mean ± SD (n=3). 
Formulation VMD (µm) Span Viscosity (mPa.s) 
A1 2.60±0.03 2.71±0.01 6.52±0.001 
A2 2.58±3.35 1.72±0.06 5.60±0.003 
A3 3.05±0.53 1.52±0.03 4.04±0.002 
A4 3.87±0.17 2.11±0.04 2.80±0.003 
A5 4.37±0.29 4.13±1.19 2.05±0.001 
 
Size distribution was affected by formulation (p<0.05), possibly due to the change in 
solution viscosity, resulting in effects on atomized droplets during spray drying. The 
significant decrease in feed solution viscosity (p<0.05) might be attributed to the 
decrease in the intermolecular entanglement, resulting in promoting the freedom of 
individual polymer chains movements in solution (Graessley, 1974); thus the change in 
feed composition and viscosity has produced larger droplets with broader size 
distribution during atomization (Figure 4.7 and Figure 4.8). Interestingly, particle size 
and Span of RH as a raw material were 59.72 ± 3.07 µm and 1.63 ± 0.14 respectively. 
However, following spray drying they became respectively 23.62 ± 4.66 µm and 1.84 ± 
0.48. However, for the large standard deviations to be reduced, the experiment needs to 
be repeated for more times in the future. 
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Figure 4. 7: Relationship between viscosity of formulations and particle size of 
spray-dried RH loaded sodium alginate microspheres. 
 
 
 
Figure 4. 8: Relationship between viscosity of formulations and size distribution of 
spray-dried RH loaded sodium alginate microspheres.  
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4.3.3.3 Drug loading and entrapment efficiency  
The percentage loading and encapsulation efficiency for RH in sodium alginate 
microparticle formulations are shown in Figure 4.9. Almost all microsphere 
formulations had high encapsulation efficiencies and drug loading; these were 
respectively 101.55% ± 3.18 and 10.46% ± 0.34 for A2, and 106.99% ± 1.77 and 
73.66% ± 0.030 for A4 formulations. Drug loading is the amount of the drug loaded into 
microparticles to the total weight of microparticles. The data showed drug loading was 
increased with increasing the ratio of RH in the formulations. These results are in 
agreement with Alhalaweh et al. (2009) who reported 93-105% entrapment for 
zolmitriptan-loaded into chitosan microspheres for nasal delivery. Spray drying 
provides formulations that have high drug loading due to the rapid evaporation of 
solvent from the droplets in the drying chamber, leading to enhance drug entrapment via 
excipient solidification (Rathananand et al., 2007).  
 
 
 
Figure 4. 9: Drug loading and entrapment efficiency of spray-dried microspheres 
at various drug to sodium alginate ratios. Data are mean ± SD (n=3). 
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4.3.3.4 Zeta potential of microparticles 
Zeta potential profoundly influences the bioadhesiveness of microparticles. Alginate is 
negatively charged due to ionization of the carboxyl moiety, resulting in the formation 
of hydrogen bonds or Vander Waals interactions with mucin or sialic acid of the 
epithelium (Patil et al., 2012). Zeta potential of the formulations ranged from -70.07 ± 
0.73 mV to -39.82 ± 2.38 mV. The results demonstrated that negative zeta potential 
values of alginate microparticle formulations decreased significantly (p<0.05) as the 
concentration of the polymer decreased (Figure 4.10).  
The in vitro study of the mucoadhesive properties of polymeric microspheres is useful 
for predicting the in-vivo performance of nasal formulations (Gad, 2008). The 
bioadhesive characteristics of sodium alginate formulations is well established (Farid et 
al., 2012; Mali et al., 2010), and may take place by formation of hydrogen bonds and 
polymer chain penetration into the mucosa (Kolsure and Rajkapoor, 2012). It has also 
been reported by Chickering and Mathiowitz (1995) and Yadav et al. (2010) that 
bioadhesion of poly anionic polymers (e.g. alginates) is more powerful than that of 
polycationic and non-ionic polymers due to the presence of strong hydrogen groups (-
OH, -COOH) in the structure of anionic polymers. Bioadhesion may depend on charge 
density of the particles. 
Hanna et al. (2013) demonstrated that the bioadhesion of gabapentin-loaded alginate 
decreased as the polymer to drug ratio decreased, which is in agreement with Allamneni 
et al. (2012) who evaluated the mucoadhesion performance of glipizide-loaded alginate 
microparticles. 
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Figure 4. 10: Zeta potential of sodium alginate microparticle formulations. Data 
represent mean ± S.D (n=3). 
 
4.3.3.5 Surface morphology of microparticles  
SEM images of RH before and after spray drying are shown in Figure 4.11. The shape 
and surface morphology of RH was improved and became spherical, by co-spray drying 
with sodium alginate compared to the spray drying of RH raw material alone without 
polymer (Figure 4.12, and Figure 4.13). 
As the ratio of the polymer to drug decreased the proportion of perforated particles also 
decreased. This remarkable change was seen clearly in formulation A3 (Figure 4.11c), 
indicating that formulation in terms of polymer to drug ratio had major effect on particle 
morphology. Further decrease in the polymer to drug ratio made the particles 
spherically shaped and increased their surface roughness. The optimization in terms of 
particle size and morphology of powder dosage forms intended for nasal use are 
necessary to reduce the risk of nasal irritation, improve nasal deposition and promote 
powder flowabilty (Behl et al., 1998). Furthermore, the absence of irregular shape in the 
SEM images indicates that RH was efficiently encapsulated by sodium alginate. 
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Figure 4. 11:  EM images of RH (a) before spray drying (magnification: 750x) and 
(b) after spray drying (magnification: 1200x). 
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Figure 4. 12: SEM images of (a) drug-free microspheres, (b) A2 and (c) A3. 
Magnification: 3000x.
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Figure 4. 13: SEM images of (a) A4 and (b) A5. Magnification: 3000x. 
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4.3.3.6 X-Ray diffraction 
The physical behaviour and crystallinity of the spray-dried drug formulations were 
studied using X-ray diffractometery. X-ray diffraction spectra for RH, drug-free 
microparticles, drug-loaded microsphere formulations and physical mixture of RH and 
sodium alginate are shown in Figure 4.14. The diffractogram of RH raw material 
showed sharp peaks at different angles, indicating that the drug was highly crystalline 
(Figure 4.14g). The intensity of the crystal peaks decreased for the spray-dried RH-
alginate formulations and the decrease was proportional to the polymer to drug ratio, 
with complete disappearance of the peaks when the alginate to RH ratio was 90:10 (i.e. 
for A2 formulation) (Figure 4.14b). This indicates that the drug has converted to 
amorphous form and was molecularly dispersed into the polymeric network (Mahajan et 
al., 2012). X-ray spectra were in accordance with results reported by Alanazi (2007) 
using a different hydrophilic polymer for improving the dissolution rate of albendazole 
via spray drying. For any material the amorphous form has a higher dissolution than the 
corresponding crystalline form (Craig et al., 1999). Conversion of crystalline form to 
amorphous state upon spray drying is attributed to rapid solvent evaporation from the 
droplet. Hence the drug molecules are not given the time to rearrange in the long range 
ordered crystalline form (Corrigan, 1995). Amorphous form is less stable and have 
tendency to recrystallize upon storage, causing changes in the physical properties of the 
formulation (Learoyd et al., 2008c). The stability of RH-alginate microspheres (A2) 
upon storage for two months was investigated at fridge (5°C ± 1) and at room 
temperatures (20
o
C ± 2). Experiments revealed that microsphere formulations had no 
marked changes in the X-ray spectra regardless of the temperature and over the time 
course of investigation (Figure 4.15).  
Administration of amorphous powders via insufflations may provide advantages, since 
formation of a mucoadhesive gel as a result of hydration of microspheres within nose 
may improve drug bioavailability; this might be facilitated by the affinity of the 
amorphous powder to absorb moisture and have higher dissolution rate. In vivo studies 
are needed to confirm whether this hypothesis is achievable. 
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Figure 4. 14: X-Ray diffractogram of (a) drug free microparticles, (b) A2, (c) A2 
physical mixture, (d) A3, (e) A4, (f) A5, and (g) RH raw material. For composition 
of formulations refer to Table 4.2. 
 
 
Figure 4. 15: X-Ray diffractogram of (a) fresh A2 formulation, (b) A2 formulations 
stored at fridge (5 ± 1) and (c) A2 formulations stored at room temperature (20 ± 
2) for two months. 
CHAPTER 4 
131 
 
4.3.4 Thermo gravimetric analysis (TGA) 
The percentage of moisture present in spray dried microsphere formulations gives an 
indication of the dispersion of particles and their stability. The dispersion of small 
hygroscopic particles prior to inhalation is not easy, which is attributed to particle 
agglomeration as a result of adsorbing moisture from air (Ståhl et al., 2002). The 
moisture content correlates with the long term stability of drug and excipients (Ståhl et 
al., 2002). In spray drying, moisture content of the product might be affected by the 
inlet and outlet air temperatures, feed content and feeding rate (Chegini and Taheri, 
2013). In this study, TGA revealed that the amount of residual water was in the range of 
4.54 ± 0.69 (%) to 18.03 ± 0.65 (%), depending on polymer to drug ratio (Figure 4.16). 
It was observed that with decreasing polymer to drug ratio, the moisture content 
decreased significantly (p<0.05). Sodium alginate could retain water within the particle 
matrix and reduce water evaporation during spray drying.  
 
 
Figure 4. 16: Moisture content (%) of sodium alginate microparticle formulations. 
Data represent mean ± SD (n=3). 
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4.3.4.1 Differential Scanning Calorimetry (DSC) 
The state of the drug and its interaction with excipients can possibly be determined by 
DSC. The thermograph of RH raw material, drug free microparticles, physical mixture 
of sodium alginate and RH with different ratios (90:10, 70:30, 50:50, and 30:70) and 
RH loaded sodium alginate microparticle formulations (A2, A3, A4 and A5) are 
presented in Figure 4.17. An endothermic peak around 100
o
C was observed for sodium 
alginate due to dehydration, then an exothermic peak appeared at 239-260
o
C due to 
decomposition of the polymer (Soares et al., 2004). The exothermic peak was absent at 
low polymer to drug ratio. The endothermic sharp peak was observed for RH raw 
material at 248.57
oC (∆H = 117.35 J/g) corresponding to its melting point, indicating a 
highly crystalline nature. The sharp endothermic peak for RH has been reported 
previously (Avachat et al., 2011). The DSC thermogram for RH formulations (Figure 
4.17B) showed a decrease in the sharpness of crystalline peak especially as the 
concentration of the polymer increased and the onset temperature shifted forward 
(224.88 to 212.58
o
C), indicating partial loss of crystallinity of RH upon loading in the 
microspheres. The peak was absent in formulation A2, indicating that the drug existed 
in amorphous form and was uniformly distributed within the polymeric matrix 
(Corrigan, 1995). The results agreed with those shown by Alanazi et al (2007), when 
they aimed to enhance dissolution of albendazole by loading into microparticles using 
spray drying. The endothermic peak of the drug may disappear when the drug is 
uniformly distributed in the microparticle matrix at the molecular level (Das and 
Senapati, 2008). 
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Figure 4. 17: DSC thermograms of (a) drug-free microsphere, physical mixture of 
alginate-RH; (b) 90:10, (c) 70:30, (d) 50:50, (e) 30:70, RH loaded alginate 
microspheres; (b) A2, (c) A3, (d) A4, (e) A5 and (f) pure drug.  
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4.3.4.2 Dissolution test 
In vitro drug release study was carried out in phosphate buffer with pH 6.5 within the 
physiological pH range of the nose. The cumulative drug release (%) from formulation 
A2, A3, A4 and A5 at different time intervals is presented in Figure 4.18. The time 
required for maximum drug release (>95%) were 60, 30, 10 and 1 minutes for A2, A3, 
A4 and A5 formulations respectively. Rapid drug released is ascribed to the solubility 
of sodium alginate and RH in aqueous media and smaller particle size of the 
formulations. Decreasing the particle size increased the surface area, hence the rate of 
dissolution is increased (Kondo et al., 1993). Polymer to drug ratio plays an important 
role in the drug release rate. As the ratio of polymer to drug was decreased from A2 to 
A5 formulations the rate of microparticle dissolution increased. This might be ascribed 
to the drug diffusion through shorter path length of microsphere layer. The drug release 
mechanism from the polymeric matrix occurs by diffusion through the matrix and 
erosion as the polymeric particles are dissolved by the dissolution medium. 
Rathananand et al., (2007) determined the release rate of levocetirizine from chitosan 
microparticles, and reported slower drug release at high polymer concentrations. Rapid 
release of RH from alginate microparticle formulations confirmed no interaction 
happened between the drug and polymer, whereas Gavini et al. (2005) reported a 
possible interaction between sodium alginate and metoclopramide hydrochloride caused 
prolonged drug released (>3hr). 
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Figure 4. 18: Dissolution profile of various spray dried RH-loaded sodium alginate 
microsphere formulations carried out in phosphate buffer solution (pH 6.5). Data 
represent mean (n=3). 
 
4.3.4.3 Histopathological study of RH-loaded sodium alginate 
The ex-vivo toxicity for the best performing formulation RH-sodium alginate 
microparticles (A2) was investigated on isolated nasal sheep mucosa, to evaluate the 
safety of formulation for nasal delivery. This experiment was adapted from the protocol 
of investigation used by Hermens and Merkus (1987). Microscopic images of RH 
loaded alginate microparticles (A2) and drug free microparticles did not show 
remarkable effect on the overall appearance of the sheep nasal mucosa (Figure 4.19a, b) 
compared to positive control (Figure 4.19c) as previously discussed in section 3.3.14. 
The cilia lining mucosa and its components were normal, and necrosis was not found as 
compared to the sample treated with the positive control (sodium deoxycholate % w/v). 
Goblet cell, sero-mucinous glands and ciliated cell were intact with only little focal 
sloughing of cells being detected (Table 4.4). These results were in agreement with 
Kolsure and Rajkapoor (2012) using nasal gels of zolmitriptan  and with Patil et al. 
(2012) using carvedilol-sodium alginate microspheres for intranasal delivery. 
Microscopic results in this study indicated that optimized RH-loaded sodium alginate 
microsphere formulations have no harmful effects on the nasal mucosa, and RH loaded 
microspheres are safe and can potentially applicable for nasal delivery. 
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Table 4. 4: The comparative histopathological evaluation of nasal mucosa treated with a range of formulations and RH-loaded sodium 
alginate microparticles. 
Treated nasal mucosa Necrosis Ciliated cells Goblet cells Inflammatory cell infiltrate in the 
sub mucosa 
Sero-mucinous 
glands 
Phosphate Buffer 
solution (PH 6.5) 
(Negative control) 
Absent Intact with focal sloughing Not affected Mild sub-mucosal inflammation and 
increased intraepithelial lymphocytes 
Not affected 
Sodium deoxycholate 
solution  
(positive control) 
Severe Mostly sloughed Present Severe sub mucosal inflammation 
and increased intraepithelial 
lymphocytes 
Inflamed 
Alginate microparticle 
dispersion 
Absent Intact with focal sloughing Not affected Mild sub mucosa inflammation Not affected 
RH solution Absent Detached focally but still 
present 
Not affected Mild sub-mucosa inflammation Not affected 
Alginate: RH (90:10) 
(A2) 
Absent Focal sloughing  Not affected Mild sub-mucosa inflammation Not affected 
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Figure 4. 19: Microscopic (Olympus) images of sheep nasal mucosa treated with (a) 
A2 formulations, (b) drug free microparticles, and (c) positive control (10 x 10 
magnification, n=3). "S" means sloughed, "N" means necrosis, "I" means 
inflammation. 
(a) 
(b) 
(c) 
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4.3.5 Characterization of delivered RH loaded sodium alginate microspheres using 
Miat
®
 nasal device 
Powder delivery to the nasal cavity has not been explored in terms of studying and 
characterization of spray pattern, plume geometry and deposition of powder dosage 
forms using nasal insufflators. The deposition of powders in nasal cavity depends on the 
powder formulation properties and type of nasal device used (Djupesland, 2013).  
Miat
®
 Monopowder device was used for spray pattern and plume geometry 
investigations. Powder spray characteristics such as shot weight, mean particle size, 
spray cone angle, plume width and spray velocity were all investigated (CDER, 2003). 
These in vitro tests are required by FDA to characterize the device performance and 
may give useful information relating to the bioavailability of the drug given in nasal 
formulations (CDER, 2002). 
 
4.3.5.1  Determination of shot weight  
Miat
®
 monodose powder insufflator was used to determine the fraction delivered of 
RH-sodium alginate microspheres (Alginate: RH, 9:1 w/w) by calculating the difference 
in weight of powder in the device before delivery and after each puff. This study 
investigated the effect of loading dose on the fraction of powder delivered. Three 
weights of powder (5, 10 and 20 mg) were used.  
Quantitative delivery of RH-sodium alginate microspheres from the Miat nasal 
insufflator is shown in Table 4.5. When the device was actuated the first time (i.e. first 
puff) around 90% of the formulation was released, regardless of formulation weight. 
The second and third puffs have forced marked fractions of the remaining powder (i.e. 
the remaining 10%) to leave the device, resulting in slight but significant (P<0.05) 
increases in the total weight released. The Miat
®
 device was highly efficient single dose 
insufflator since most of the loaded dose was emitted by the first puff. The emitted dose 
of powder was dependent on the number of puffs rather than the amount of powder 
loaded into the device. 
 Various loads were compared (5 mg, 10 mg and 20 mg) and a significant fraction of the 
dose was released by the second puff when 20 mg loading dose was compared to 5 and 
10 mg. The loading dose has effected the delivery of RH-sodium alginate microspheres 
(A2). Results of this experiment disagreed with De Ascentiis et al. (1996) and Patil and 
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Sawant (2011), who studied the delivery of chitosan microparticles using the Miat nasal 
device. The conflicting findings might be due to formulation properties (e.g. moisture 
content). 
 
Table 4. 5: Fraction delivered of RH-loaded chitosan microspheres using Miat
®
 
nasal insufflator. Data represent mean ± SD (n=3). 
 
loading weight 
 (mg) 
Fraction of powder delivered (%) 
First Puff Second Puff Third Puff 
5 88.61±0.44 
 
90.78±0.67 
 
91.63±0.99 
10  89.26.±1.36 
 
90.53±0.42 
 
92.07±0.92 
20  90.28±0.44 
 
93.11±0.56 
 
94.2±0.62 
 
 
4.3.5.2  Particle size analysis using laser diffraction 
Particles in the micrometres range may agglomerate owing to their high surface area. In 
the context of nasal drug delivery, particle agglomeration might be useful to increase the 
overall size of particles to be suitable for nasal deposition and minimize possible 
travelling of the particles to the lower respiratory tract. The weakly agglomerating 
particles may deagglomerate to a smaller size of particles during delivery, enhancing the 
surface area of the particles and obtaining a size range that is suitable for absorption by 
the nasal epithelium (De Ascentiis et al., 1996). The VMD, percentage of particle size 
<10 µm  and Span value of A2 formulation were determined by the Spraytech aerosol 
size analyser and were 87.25 µm ± 7.54, 22.65 µm ± 1.65 and 4.02 ± 0.37 respectively. 
De Ascentiis et al. (1996) have found that the size of beta-cyclodextrin particles was 
around 100 μm upon delivery for nasal deposition using the Miat® monodose device. 
This suggest that RH-sodium alginate (A2) formulation is less likely deposit in the 
respiratory region when delivered by the Miat
® 
nasal device insufflator. 
Previous reports on the particle size and impaction in the nose are conflicting. The nasal 
mucosa can efficiently filter out particles larger than 3-10 μm because it is covered by a 
protective mucous layer from the posterior part to the nasal valve which can effectively 
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trap particles and microorganisms from the inspired air (Djupesland, 2013). Donovan 
and Huang (1998) have reported that particles in the size range of 5–7 μm might be 
retained in the nasal cavity. Particle deposition in the nose increases when particle size 
is larger than 10 μm, and anterior deposition is most prominent for larger particles, and 
velocity of inhaled particles and the turbulence in the air flow determine the deposition 
site of smaller particles in the nose (Rai et al., 2008). Particles larger than 0.5 µm 
deposit intranasally via inertial impaction (Burgess et al., 2004).  In contrast, the 
deposition of particles less than 0.5 μm is dominated by delusional mechanism (Foo, 
2007). The probability of particle deposition into the lower respiratory tract may 
decrease as the particle size increases, However, particles below 5µm have greater 
possibility to deposit in the olfactory region (Keldmann, 2005).  
 
4.3.5.3 Determination of plume geometry and spray pattern 
Improving nasal bioavailability is related to the delivery device, physical form of the 
formulation (liquid, viscous or solid) and technique of administration (Arora et al., 
2002). Figure 4.21 shows representative images of spray pattern for A2 formulation, at 
a distance of 3cm from the nasal device tip. The longest diameter (Dmax), shortest 
diameter (Dmin) and ovality ratio (Dmax/Dmin) were 13.33 ± 1.03 mm, 10.67 ± 0.52 mm 
and 1.25 ± 0.04 respectively. Spherical spray pattern and the agglomeration of particles 
were seen on the impact sheet, as shown from the ejected powder formulations (Figure 
4.20). 
Spray time required to reach fully developed phase was 0.16 sec, whilst the total spray 
time to deliver 10 mg of RH loaded alginate microparticles was 0.32 sec, indicating 
rapid delivery of the powder (Figure 4.21). The spray cone angle and width 3cm 
distance from the tip of the device were 14.67
o
 ± 0.52 and 10.67 ± 0.52 mm 
respectively. The powder particles were characterized by elongated puff with visible 
individual particles as they emitted from the device. De Ascentiis et al. (1996) have 
reported the compactness of the clouds to be affected by powder particle size; small 
particle size generated fluffy clouds which are homogeneous in density, whereas larger 
particles may produce clouds with visible individual particle trajectories. Pringels et al. 
(2006) reported the anterior deposition of the emitted dose from the device to be more 
predominant when the spray had larger angle (60 – 70o), whereas deposition in posterior 
part of the nasal increased as the plume cone angle was smaller (30 to 35
o
). The 
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decrease in the plume angle increases the probability of targeting the turbinate region in 
the nose (Foo et al., 2007). Overall, the results of this study suggested deposition of RH 
loaded sodium alginate might be more prominent in the turbinate region which may 
improve absorption. 
 
 
Figure 4. 20: Spray pattern of formulation A2 at 3cm distance from the insufflator 
device tip (n= 4). 
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Figure 4. 21: RH-sodium alginate microspheres delivery from Miat
®
 monodose insufflator as monitored using videography (n= 4).
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4.4 Conclusions 
This study demonstrated that spray drying is a powerful technique for producing RH 
loaded sodium alginate microspheres. Inlet temperature had remarkable effect on the 
particle morphology and yield percent of sodium alginate microspheres. The optimum 
inlet temperature to produce RH-alginate microparticles was 140
o
C. FTIR revealed that 
no interaction occurred between polymer and RH. The characterization studies 
demonstrated that the composition of the feed solution had a remarkable effect on the 
particle shape, size and size distribution. The findings of this study represented that 
alginate to drug ratio of 90:10 (w/w) was the best performing formulations. X-ray 
diffractogram demonstrated that crystallinity of the encapsulated drug decreased and 
was completely converted to amorphous phase when the polymer and drug were co-
sprayed in the ratio of 90:10 (w/w). Additionally, X-ray study revealed RH loaded 
alginate microspheres was stable over two months. DSC thermograms demonstrated 
drug molecules were molecularly dispersed in microparticles when polymer to drug 
ratio was 90:10 (w/w). Histopathological study showed RH loaded sodium alginate is 
non-toxic to nasal epithelium. Investigation of the device performance using Miat
®
 
nasal insufflator demonstrated that fraction delivered (%) was affected by loading 
weight. Cloud study using laser diffraction demonstrated that the sprayed particles are 
less likely to deposit in the lower respiratory tract. Videography showed that the cloud 
is most likely to deposit in the nasal cavity and particularly in the olfactory region. In-
vivo studies are required in the future to determine the amount of the drug that may 
reach the brain, CSF and blood circulation after administration of RH-sodium alginate 
microspheres in the forms of nasal powders. 
The study demonstrated that the percentage of yield for F2 formulation (76.9%±1.01) to 
be higher than A2 formulation (69.5±0.68) which might be attributed to the difference 
in the inlet air temperature between the two formulations. RH loaded chitosan glutamate 
microparticles were spherical, whereas dimpled particles were present in the spray dried 
sodium alginate formulation; this difference is ascribed to the different properties of the 
polymers used. Comparison of the drug entrapment efficiency obtained from spray 
dried sodium alginate with drug has shown that entrapment provided by A2 formulation 
(104.59% ± 3.23) was higher than that of chitosan based microspheres (i.e. F2) 93.28% 
± 1.66), which might be attributed to the affinity of the cationic drug (RH) to sodium 
alginate polymer which has a negative charge whilst chitosan glutamate has a positive 
charge.  
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The emitted amount using 10 mg of F2 formulation (94.83% ± 0.41) was more than that 
using A2 formulation (90.53% ± 0.42) after the second puff of the nasal insufflator; this 
difference might be related to the difference in percentage of humidity content of the 
formulations Hence, F2 formulations produced elongated homogenous cloud, whereas, 
visible individual particles were found in the plume produced by A2 formulation.  
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5.1 Introduction 
Since their discovery in 1960s, liposomes have been of great interest to use in drug 
delivery. The interest in using liposomes is attributed to the convenience of their 
preparation and their desirable properties such as biocompatibility, non-toxicity, and 
non-immunogenicity, because they are made from natural phophoilipids or similar 
synthetic phospholipid molecules (Ahn et al., 1995). The amphiphilic properties of 
phospholipids make the encapsulation of hydrophilic and lipophilic drugs possible 
(Brandl, 2001). Particle size and surface properties of liposome can be manipulated 
upon addition of other materials during formulation of liposomes (Tran, 2011). 
Nasal administration offers several advantages over oral delivery including rapid onset 
of action, evasion of first pass effect and blood brain barrier. However, the duration of 
drug contact with epithelial surfaces for drug is given via the nose is short due to the 
rapid removal of the drug from the site of absorption via the mucociliary clearance 
(Jadhav et al., 2007). For this reason incorporation of mucoadhesive agents into 
formulation is required to improve the drug absorption. Frequent dosing is required to 
maintain drug therapeutic concentration in the plasma might increase therapeutic cost. 
Thus, prolonging the retention time of the formulation at the site of absorption and 
extending the drug release time could improve the efficacy of drug and enhance patient 
compliance. Liposome drug delivery systems are capable of reducing the mucociliary 
clearance in the nose and provide sustained release properties (Gregoriadis and 
Florence, 1993; Ahn et al., 1995). Furthermore, liposomes coated with mucoadhesive 
agents may improve drug permeation through the nasal epithelium (Naderkhani et al., 
2014). 
Various strategies have been proposed to improve the delivery of peptide and non-
peptide drugs to the nose by using microspheres, nanoparticles, noisomes and 
liposomes.  Liposomes  are suitable  carrier  systems for  nasal delivery  since  they  are  
made  from biocompatible and biodegradable materials such as phospholipids which are 
similar to the natural components of the mucous membranes (Schnyder and Huwyler, 
2005). Liposomes from hydrogenated soya  phosphatidylcholine  has  been shown to be 
safe in animals, since no critical changes in the integrity of the respiratory tract cells 
were observed  upon  acute  or  chronic  exposure  to  liposomes (Manca et al., 2012). 
Liposomes are unstable upon storage when generated by conventional technique (e.g. 
thin film hydration method), hence the difficultly in producing on large scale. To 
CHAPTER 5 
147 
 
overcome this limitation proliposome technologies such as ethanol (solvent)-based  
proliposomes  (Perrett et al., 1991) and  particulate-based proliposomes (Payne et al., 
1986) have been suggested. Furthermore, they can use for the large scale manufacture 
of stable liposome precursors.  Depending  on  the  hydration  procedure of ethanol-
based proliposomes the generated liposomes are either multilamellar  (Turánek et al., 
1997) or  oligolamellar  (Perrett et al., 1991). Polysaccharides have been used to change 
and modify liposome surface properties by improving the retention time of liposomes 
within the nasal cavity (Takeuchi et al., 2000; Cheng et al., 2006). 
Ethanol based proliposome method was used to prepare liposomes incorporating the 
model hydrophilic drug RH. Parameters involved in the preparation were investigated to 
optimize the loading of RH in liposomes using various drug concentrations ranging 
from 0.5 to 8 mg /ml. In addition, the effect of inclusion of different types of 
mucoadhesive agents (0.2% chitosan G113, chitosan G213, carboxymethyl chitosan, 
low and medium viscosity sodium alginate) on liposomes was evaluated to establish an 
optimum liposome formulation for nasal administration. The resultant liposomes were 
characterised in terms of particle size, Span, zeta potential and percentage of drug 
entrapment. The delivery of liposome formulation was performed and studied using 
three different nasal spray devices. 
5.2 Methodology 
5.2.1 Manufacture of RH liposomes 
Ethanol-based proliposome method was used to prepared RH loaded liposomes by 
adapting the procedure introduced by Arafat (Arafat, 2013) who developed a method to 
prepare liposomes loaded with protein or salbutamol sulphate for nasal delivery. 
Liposomes were generated by adding 60 mg ethanol (76 μl) into a 10 ml glass vial 
containing 50 mg of lipid phase (SPC and cholesterol; 4:1 w/w) at 70
o
C to enhance the 
dissolution of cholesterol for two minutes to obtain a clear lipid solution (i.e. the 
proliposomes). Solutions of RH were prepared in HPLC water in a range of 
concentrations (0.5, 1, 2, 4, or 8 mg/ml). To this lipid solution, RH solution (0.5 ml) 
was added and vortexed for 2 minutes using a Whirl Mixer TM (Fisherbrand, Fisher, 
UK) to obtain a concentrated suspension of liposomes (the primary hydration step). To 
generate the final liposomal suspension, the rest of HPLC water (4.5ml) was added to 
the concentrated liposomal suspension and vortexed again for 2 minutes (the secondary 
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hydration step). Liposomes were kept at room temperature (20
o
C ± 2) for 1 hour to 
anneal before conducting subsequent studies. 
5.2.2 Characterization of liposomes 
Liposomes were characterized in terms of (i) particle size and Span (section 2.6.2), (ii) 
zeta potential (section 2.6.3), and (iii) drug entrapment efficiency (section 2.8.3). 
5.2.3 Formulation of mucoadhesive liposome 
Five types of mucoadhesive agents were used: Chitosan G113 (Ch G113), Chitosan 
G213 (Ch G213), Carboxymethyl chitosan (CM Ch), (Santacruz Biotechnology, USA), 
low viscosity sodium alginate (LVSA) and medium viscosity sodium alginate (MVSA) 
in a concentration 0.2% w/v. Mucoadhesive agents were dissolved in 4.5 ml HPLC 
water with aid of vortex mixing. The resultant mucoadhesive solutions were used in the 
secondary hydration step of the ethanol-based proliposomes to generate mucoadhesive 
liposomes. Formulations were left at room temperature (20
o
C ± 2) to anneal for 1 hour. 
The technique used in this study was adapted from that of Arafat (2013). 
5.2.4 Liposome morphology study using Transmission Electronic Microscopy  
A drop of liposome dispersion was spotted onto carbon-coated copper grids (400 mesh) 
(TAAB Laboratories Equipment Ltd., UK), and negatively stained with 1% w/v  
phosphotungstic acid (Elhissi et al., 2006), then viewed and imaged using a Philips CM 
120 Bio-Twin transmission electron microscope (Philips Electron Optics BV, 
Netherlands) the voltage was 120 kV, as described in section 2.8.4.. 
5.2.5 Characterisation of liposomes after delivery using nasal spray devices 
Size and size distribution analysis was performed for carboxymethyl chitosan coated 
RH loaded liposomes using three different devices (A, B and C) as previously explained 
in section 2.6.2. Zeta potential of liposomes was determined by using the Malvern 
Zetasizer (section 2.6.3). The entrapment efficiency (%) of RH was analyzed for 
samples before and after delivery from the nasal spray devices according to the HPLC 
method (section 2.9.3). Droplet size, size distribution and percentage of droplets less 
than 10 µm were analysed by using the Malvern Spraytec instrument (Malvern 
Instruments Ltd, UK) following the generation of sprays from each device ( section 
2.8.5). The spray plume investigation was conducted for both spray pattern and plume 
geometry (section 2.9). 
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5.3 Results and Discussion 
5.3.1 Characterization of RH loaded in liposomes  
5.3.1.1 Size and size distribution of liposomes 
The effect of RH concentration (0.5, 1, 2, 4 and 8 mg/ml) on the size and size 
distribution of liposomes produced from SPC and cholesterol (4:1 w/w) using ethanol-
based proliposomes are shown in Figure 5.1 and Figure 5.2. Size and size distribution of 
RH loaded liposomes and drug-free vesicles were compared. Data showed that by 
adding drug in a concentration of 0.5 mg/ml to the formulation, VMD of the liposome 
increased significantly (p<0.05; 4.80 µm ± 0.54) compared to the drug-free liposomes 
(3.20 µm ± 0.47).  Further increases in the RH concentration resulted in insignificant 
trend of increase in the VMD. For example the measured VMD was 4.85 µm ± 0.54 
when the drug concentration was 0.5 mg/ml and was 5.74 µm ± 0.74 when the 
concentration was increased to 4 mg/ml. However, with regard to size distribution, 
expressed as Span, a significant difference (p<0.05) was observed when the drug 
formulation (2 mg/ml) (Span = 2.66 ± 0.25) was compared to the drug-free formulation 
(Span = 1.68 ± 0.17). For all RH loaded liposome formulations no significant difference 
in the Span values was found (Figure 5.1). However, for the large standard deviations to 
be reduced, the experiment needs to be repeated for more times in the future.  
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Figure 5. 1: Size (VMD) of liposomes generated from ethanol-based proliposomes 
using a range of RH concentrations (0 – 8 mg/ml).  
 
 
 
Figure 5. 2: Size distribution (Span) of liposomes generated from ethanol-based 
proliposomes using a range of RH concentrations (0 – 8 mg/ml). 
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5.3.1.2  Zeta potential measurement of liposomes 
The zeta potential of the liposome formulations was measured after separation of the 
liposome pellets from un-entrapped drug using Beckman ultracentrifuge at 50,000 rpm 
(251,818 x g) for 20 minutes at 6
o
C and re-dispersed using 5ml HPLC water. Figure 5.3 
shows the zeta potential measurements of the liposome formulations. The zeta potential 
of drug-free liposomes was -0.46 ± 0.08 mV, whilst after centrifugation and replacing 
the supernatant with a fresh dispersion medium it became -10.23 ± 0.70 mV. This 
indicates that a high centrifugation speed affected the packing and surface properties of 
liposome vesicles. As the concentration of the drug was increased, the negative surface 
charge of liposomes became less intense, and started to have a slightly positive charge 
at the drug concentration of 8 mg/ml (zeta potential = 1.09 ± 2.31 mV). This is an 
indication that the free drug in the supernatant has affected the surface charge of the 
vesicles. To the best knowledge of the author of this report, no studies in the literature 
have described the effect of water-soluble drugs on the zeta potential of liposomes, 
especially taking into account that the drug is not expected to be associated with the 
lipid bilayers. Interestingly, even when no drug was included within the liposome 
formulation, centrifugation to sediment liposomes followed by re-dispersion of the 
pelleted liposomes caused a significant change in the measured zeta potential of 
liposomes. Further investigations are required to understand the reason behind the 
different zeta potential of liposomes at different conditions.  
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Figure 5. 3: Zeta potential of liposomes generated from ethanol-based 
proliposomes using a range of RH concentrations (0-8 mg/ml).  
 
5.3.1.3 Entrapment efficiency of RH 
The  entrapment  efficiency  of  RH loaded  in  liposomes  was  analyzed  using  HPLC  
following the separation of the liposome-entrapped fraction of the drug. Figure 5.4 
shows the entrapment efficiency of RH versus drug concentration in the liposome 
formulations. These findings demonstrate that the percentage of drug entrapped in 
liposomes was dependent on the drug concentrations and entrapment efficiency was 
decreased with higher drug concentration (i.e after 2mg/ml). The maximum drug 
entrapment was 23.3% ± 0.26 for 2 mg/ml drug concentration and minimum was 
12.63% ± 2.46 for 8 mg/ml drug concentration. The entrapment efficiency values were 
lower than those found by Elhissi et al. (2006) and Arafat (2013), who reported 
entrapment efficiency to be approximately 62% and 60% respectively, when they 
generated salbutamole sulphate loaded liposomes via the ethanol-based proliposome 
method. The differences of entrapment findings might be attributed to the differences in 
the physical properties of the drugs. However, for the large standard deviations to be 
reduced, the experiment needs to be repeated for more times in the future. 
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Figure 5. 4: Entrapment efficiency (%) of RH loaded into liposomes generated 
from ethanol-based proliposome formulations in relation to drug concentration. 
Data represent mean ± SD (n=3). 
 
5.3.2 Effect of inclusion of mucoadhesive agents in liposome formulations  
Five types of water soluble mucoadhesive agents (0.2%) was  included  into  the  
selected liposome  formulation  to  promote  the mucoadhesive properties of liposomes. 
Chitosan and sodium alginate are natural polysaccharides which can enhance the 
mucoadhesive properties of liposomes thus improve drug permeability through 
biological membranes (Chen et al., 2013).  
 
The reason behind using natural polymers is attributed to the facts that they are non-
toxic and can provide strong mucoadhesion owing to their ionizable groups which can 
form electrostatic or hydrogen bonds with mucin molecules. The use of bioadhesive 
agents in pharmaceutical formulations may increase the duration of drug contact with 
nasal mucosa (Carvalho et al., 2010) and hence enhance drug permeation by opening 
the tight junctions between cells (Chaturvedi et al., 2011; Smith et al., 2004), resulting 
in improved absorption of small polar drug molecules, proteins and peptides through 
nasal mucosa and enhanced drug bioavailability and efficacy (Illum et al., 1994).  
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Furthermore, inclusion of mucoadhesive agents could potentially reduce the tendency of 
liposomes to fuse together and hence formation of larger vesicles and subsequent phase 
separation are retarded (Wu et al., 2004; Laye et al., 2008; Mady and Darwish, 2010). 
Chitosan concentrations in the range of 0.1 to 0.5% have been studied by Wu et al., 
(2004). They demonstrated that chitosan concentration and molecular weight both had 
significant effects on the hypoglycaemic activity of liposome-entrapped insulin 
following oral delivery of the formulation. Insulin-based liposomes when coated with 
chitosan (0.2%), gave high drug entrapment efficiency (75.90% ± 4.90). 
Controversial reports on the mucoadhesive efficiency of chitosan and sodium alginate 
exist. Chen et al., (2013) reported chitosan coated liposome vesicles may have 
significantly higher mucoadhesive properties than alginate coated liposomes due to 
interactions between positively charged ions of chitosan with the negatively charges 
ions of sialic acid. 
In this study, the effect of different types of mucoadhesive polymers (0.2%) on 
liposome size, size distribution and zeta potential was investigated and the loading 
efficiency of RH studied.  
 
5.3.2.1 Size and size distribution of liposomes 
The effect of inclusion of 0.2% (w/v) mucoadhesive agent on the size and size 
distribution of liposomes with RH of 2mg/ml are demonstrated in Figure 5.5. 
Mucoadhesive agents increased the particle size by a small amount compared to non- 
coated liposome. However, the size of liposomes was unaffected by the type of 
mucoadhesive agent. Size distributions of the polymer-coated liposomes are shown in 
Figure 5.6. Findings indicate that regardless of the bioadhesive polymer type, inclusion 
of the bioadhesive had no effect on the Span values (p>0.05) compared to the uncoated 
vesicles.  
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Figure 5. 5: Size of liposomes containing drug (2 mg/ml) in relation to the inclusion 
of different mucoadhesive agents in concentration of 0.2%. Data represent mean ± 
SD (n=3). 
 
 
Figure 5. 6:  Size distribution (Span) of liposomes containing drug (2 mg/ml) in 
relation to the inclusion of different mucoadhesive agents in concentration of 0.2%. 
Data represent mean ± SD (n=3). 
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5.3.2.2 Zeta potential  
Figure 5.7 shows the zeta potential of liposomes in relation to inclusion of 
mucoadhesive agents. The findings demonstrated remarkable changes (p<0.05) in zeta 
potential of the liposomes from -7.42 ± 0.21 mV toward neutrality since chitosan G113 
and G213 included into formulations caused the zeta potential to become -0.53 ± 1.82 
mV and -0.18 ± 1.5  mV respectively (Figure 5.7) due to the positive charges caused by 
chitosan adsorption on the  surface of the liposomes (Liu and Park, 2010; Mady and 
Darwish, 2010). The liposome and polymer interactions are due to the electrostatic 
forces  between the oppositely charged ions of chitosan and lipid (Laye et al., 2008) 
and/or the formation of H-bonding between the polymer and phospholipid headgroups 
(Perugini et al., 2000). This favours the adsorption of chitosan onto the surface of 
liposomes and increasing the zeta potential. Zeta potentials of vesicles became more 
intensely negative (p<0.05) upon addition of low viscosity sodium alginate (zeta 
potential = -13.41 ± 0.19 mV), medium viscosity sodium alginate (-13.56 ± 0.6 mV) 
and carboxymethyl chitosan (-11.58 ± 0.44 mV), indicating successful coating by these 
anionic polymers onto the liposomes. The zeta potential values in this experiment are an 
indication that the formulation are stable, as high values regardless of charge type 
enhance the repulsion forces between the similarly charged particles, thus reducing  
particle aggregation ( Mady and Darwish, 2010). 
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Figure 5. 7:  Zeta potential of liposomes containing drug (2 mg/ml) in relation to 
the inclusion of different mucoadhesive agents in concentration of 0.2%. Data 
represent mean ± SD (n=3). 
  
5.3.2.3 Drug entrapment efficiency 
There is some controversy amongst researchers in literature regarding entrapment 
efficiency in relation to inclusion of bioadhesive agents. Many research groups have 
reported that inclusion of chitosan significantly increases drug entrapment (Perugini et 
al., 2000; Albasarah et al., 2010). In contrast, other researchers reports have documented 
that coating the liposomes with chitosan decreased the drug entrapment efficiency (Wu 
et al., 2004; Zhuang et al., 2010). Liu and Park, (2010) have found that chitosan 
concentration had no effect on the entrapment efficiency of vitamin C. Whilst Goyal et 
al., (2011) have found that increasing alginate to liposome ratio caused an increase in 
drug entrapment efficiency. To resolve these controversies further investigations were 
conducted. Figure 5.8 showed that the effect of inclusion of mucoadhesive agents 
(0.2%) on RH entrapment efficiency. The entrapment efficiency of RH was 23.3% ± 
0.27, whilst after inclusion of mucoadhesive agents the entrapment efficiency decreased 
significantly (p<0.05) using chitosan G113 (EE= 7.36% ± 4.48) and medium viscosity 
sodium alginate (EE= 11.16% ± 4.69) and chitosan G213 (EE= 10.35% ± 4.07). In 
contrast the inclusion of carboxymethyl chitosan did not affect the drug entrapment 
efficiency (EE= 25.97% ± 3.86) (Figure 5.8). However, low viscosity sodium alginate 
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decreased the entrapment efficiency but not significantly (p>0.05). Disagreements 
between findings might be attributed to the variations in the properties of different types 
of mucoadhesive agents employed. Guo et al., (2003) have reported a decrease in the 
drug entrapment whilst mucoadhesive agents included in the formulations might be 
attributed to the polymer and phospholipid interactions interfering with drug 
entrapment. Chitosan has a positive charge and affinity to phospholipid thus it may 
compete with the cationic drug RH for phospholipids which are negatively charge. 
Subsequently chitosan may reduce the entrapment efficiency of the drug, hence lower 
entrapment efficiency observed for chitosan compared sodium alginate and 
carboxymethyl chitosan. 
  
 
Figure 5. 8: Drug entrapment (%) by liposomes in relation to the inclusion of 
different mucoadhesive agents in a concentration of 0.2%. Data represent mean ± 
SD (n=3). 
 
5.3.3 Transmission electron microscopy study 
Liposome morphology was studied using TEM (Figure 5.9). Regardless of drug or 
bioadhesive polymer inclusion, liposomes were OLVs. The strong adsorption of the 
polymer to the liposomal bilayers might have resulted in making no apparent difference 
between coated and uncoated liposomes. The same finding has been previously reported 
(Zhuang et al., 2010). 
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Figure 5. 9: TEM images of (a) drug free liposomes, (b) drug loaded liposome, and 
(c) carboxymethyl chitosan-coated drug free liposomes. Magnification: 93000x.  
(a) 
(b) 
(c) 
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5.3.4 Influence of nasal spray device on the spray cloud characteristics 
5.3.4.1 Determination of priming, tail off and shot weight 
Several tests are recommended by FDA for development of new nasal products such as 
mean delivered dose (shot weight), dose content uniformity, droplet size and size 
distribution and characterization of the spray plume (spray pattern and plume geometry) 
(CDER, 2002). To determine nasal spray performance, study of prime, full actuation 
and tail-off phases were conducted. Priming is the number of actuations which are 
required to reach the full actuation. It is useful to determine the number of actuations in 
the nasal spray device which generates reproducible dose. Figure 5.10 shows the 
characteristics of the spray using nasal spray devices such as priming, full actuation and 
number of actuations required in the tailing off phase using liposome formulations or 
deionised water.  
 
Considering prime and tail off are necessary to assess multiple nasal spray doses 
performance, the required actuations to prime were 3-6 actuations.  However, no 
difference was observed for each device to reach the prime when water and liposome 
formulation were compared, and in a similar manner no discernable difference (p>0.05) 
was observed between the nasal spray devices A, B and C. In contrast, a significant 
difference was observed in the number of full actuations between device A and B 
(p<0.05) and device B and C (Figure 5.10). The number of full actuations of water and 
liposome formulation delivered by the nasal spray device A was 27.00 ± 0.52 and 26.00 
± 0.52 actuations respectively. For device B the numbers of actuations were respectively 
21.00 ± 1.37 and 19.00 ± 1.03, and for device C they were 25.00 ± 1.03 and 22.00 ± 
1.33 respectively.  
 
The data showed significant differences for the number of actuations in the tail off 
phase between device A and B (p<0.05) and device B and C (p<0.05) (Figure 5.10). The 
total number of actuations for devices A, B and C were 37.00 ± 0.52 and 37.00 ± 0.52, 
41.00 ± 1.79 and 39.00 ± 0.52 and 39.00 ± 0.52 and 39.00 ± 1.37 using water and 
liposomes respectively. A difference (p<0.05) was observed when the total number of 
actuations of water for devices A and C was compared to those of device B. Nasal spray 
device A had larger number of full actuations among other devices, as it had lower 
number of total number of actuations. These differences between devices may be due 
design characteristics of the device, pump performance, orifice design and metering 
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chamber of the devices (Dayal et al., 2004). In contrast nasal spray B had lower number 
of full actuations, as it had larger number of actuations.  
 
 
 
 
Figure 5. 10: Number of actuations required for priming the devices, full 
actuations delivered and the number of actuations in the tail off phase. Data 
represent mean ± SD (n=3). 
 
Investigation of dose consistency was conducted by studying the weight measurement 
of the spray devices before and after actuation. Data indicate all three nasal spray 
devices delivered approximately 100 µl per actuation at the fully actuation phase and no 
remarkable difference (p>0.05) in the mean delivered volume between the devices 
(Figure 5.11).  Suman et al. (1999) have reported nasal spray pump design played a 
major role to deliver an accurate dose upon actuation. Overall, the findings of this study 
demonstrated the differences in performance of different devices owing to the 
difference in designed pump rather than formulation properties.  
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Figure 5. 11: Mean delivered volume (µl) by nasal spray devices at fully actuation 
state. Data were mean ± SD (n=3). 
 
Table 5.1 shows the effect of spraying on particle size, size distribution and surface 
charge of carboxymethyl chitosan coated RH liposomes using three different nasal 
spray devices was studied. No changes (p>0.05) were observed when liposomes before 
and after spraying were compared. Hence, these devices did not significantly affect the 
characteristics of the selected liposome formulation. Drug leakage from liposomes was 
absent (p>0.05) when drug entrapment after spraying was compared to before spraying 
(Figure 5.12). All nasal spray devices investigated in this study could potentially be 
used to deliver RH loaded liposomes to the nose, because the integrity of liposome 
formulations upon spraying was preserved. Unlike nasal sprays, previous investigations 
have shown nebulizers damage liposome structures, causing significant leakage of the 
originally entrapped drug (Taylor, 1990;  Arafat, 2013). 
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Table 5. 1: Particle size (VMD), size distribution (Span) and zeta potential of     
carboxymethtyl chitosan coated RH liposomes compared to non-sprayed liposomes 
using nasal spray devices A, B and C. 
 
Conditions VMD (µm) Span Zeta potential 
(mV) 
Non-sprayed liposome 4.22±0.25 2.93±0.21 -11.28±3.26 
Nasal spray A 4.01±0.23 2.79±0.14 -11.97±0.97 
Nasal spray B 4.04±0.23 3.09±0.26 -12.02±1.5 
Nasal spray C 3.94±0.33 3.11±0.22 -11.45±2.54 
 
 
 
 
Figure 5. 12:  Effect of spraying on the retained EE (%) of RH loaded liposomes 
coated by carboxymethtyl chitosan compared to non-sprayed liposome (NSL) 
using nasal spray devices A, B and C. Data were mean ± SD (n=3). 
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5.3.4.2 Droplet size distribution  
Droplet size distribution (DSD) and fraction of droplets <10 µm are prime determinant 
of  the location where the droplet is likely to deposit in the nasal cavity from nasal 
sprays, which might affect the bioavailability of the drug (Kippax et al., 2010). The 
droplet size, size distribution and the percentage of droplets less than 10 µm were 
measured by using the Malvern Spraytec, at the fully developed phase using device A, 
B and C. FDA recommended the fully developed phase (stable phase) for spray cloud 
characterization, because at this phase consistent particle size is produced since the flow 
rate through the device nozzle is optimal, therefore the analysis is useful in comparing 
devices and formulations (CDER, 2003).  
 
Control over the size of the sprayed droplets size is crucial to ensure that deposition in 
the nose rather than the pulmonary region because droplet size affects the deposition 
profile and retention time of sprayed particles (Kippax, 2009). Particles larger than 3-10 
µm are filtered out by the nose, minimizing the probability of lung deposition (Dahl and 
Mygind, 1998). Larger droplets may however drip out of the nose after administration 
whilst too small droplets may deposit in the lower respiratory regions (Kulkami and 
Shaw, 2012).  
 
Table 5.2 demonstrated that droplet size dramatically decreased (p<0.05) for chitosan 
coated liposomes compared to water using device A or device B, while no major 
changes were found for device C. This effect might be attributed to the thixotropic 
behaviour of liposomes. However, droplet size generated from nasal device A were 
smaller than from nasal devices B and C. Dayal et al., (2004) have demonstrated that the 
spray characteristics depend on the pump design and physicochemical properties of the 
drug formulation such as viscosity, density, thixotropic behaviour, elasticity and surface 
tension of the liquid. This finding agrees with Dayal et al., (2004), who reported that 
addition of surfactant (0.5 - 5% Tween 80) to the 2% carboxymethyl cellulose and shear 
thinning of carbopol formulation may reduce the droplet size, due to the alteration the 
rheological behaviour of formulation. Reducing the droplet size might be beneficial 
since smaller droplet size may provide better surface coverage of nasal cavity than large 
particles (Kundoor and Dalby, 2011, 2010).  
  
In contrast to the droplet size, Span and percentage of droplets below 10 µm for the 
sprayed liposome formulation using different devices were similar to that of water 
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(p>0.05). However, proportion of droplets <10 µm (%) generated by device C were 
smaller than those generated by other two devices, however droplets are unlikely to 
deposit in the respiratory region as the percentage of fraction droplets <10 µm was less 
than 5%. Overall, the droplet size in this study was within the optimal size range (10 to 
50 µm) for nasal delivery (Behl et al., 1998). Hence, liposomes coated with chitosan 
merits in-vivo investigations to evaluate their use as delivery carriers using these 
devices. 
 
Table 5. 2: Droplet size, size distribution and percentage of droplets below 10µm 
for RH loaded into liposome formulation coated by carboxymethyl chitosan. 
Nasal 
spray 
devices 
 Water   Liposome 
formulation 
 
VMD(µm) Span Droplets<  
10µm 
VMD(µm) Span Droplets< 
10µm 
A 41.13±1.02 1.35±0.09 7.04±1.19 30.69±1.3 1.45±0.12 9.11±1.81 
B 55.87±4.35 1.78±0.1 6.79±0.85 44.7±1.94 2.86±1.02 8.16±0.43 
C 49.5±3.32 1.68±0.25 4.03±0.46 47.85±3.29 2.4±0.85 3.94±2.3 
 
 
5.3.4.3 Spray pattern and plume geometry studies 
In addition to droplet size, both spray pattern and plume geometry of the spray may 
contribute to the determination of the possible site of spray deposition in the nose (Foo, 
2007). Generally, deposition in the anterior region might be more dominant when the 
plume angle is high, whereas droplets tend to deposit in the turbinate region when the 
plume angle is lower (Foo et al., 2007).  
 
As demonstrated in Table 5.3, formulation properties profoundly effected the plume 
generated. When water was sprayed, the plume angle differed using different devices 
(p<0.05). The large difference was observed for plume width of the nasal device A 
(p<0.05) as compared to the other two devices. When liposome dispersion and water 
sprayed using nasal devices A and C, it was observed that plume angle and the width of 
cloud generated from liposome dispersion were statistically (p<0.05) larger than 
CHAPTER 5 
166 
 
compared water. Deposition of droplets in the anterior region of the nose increases 
when nasal device generated cloud with wide plume angle (Cheng et al., 2001). 
 
The required time per actuation was also investigated for the nasal spray devices (Figure 
5.13 - 5.15). The full spray time per actuation for water using devices A, B and C was 
0.28 ± 0.00, 0.20 ± 0.00 and 0.28 ± 0.00 sec respectively. Device B offered fast delivery 
of the dose (0.20 sec) compared to devices A and C. However, duration of formation 
phase (0.12 sec), evolution phase (0.12 sec) and dissipation phase (0.04 sec) of nasal 
spray pumps A and C were similar (Figure 5.13 and Figure 5.14). In contrary, nasal 
device B was characterized by short evolution phase (0.04 sec) and long dissipation 
phase (0.08 sec). The differences might be ascribed to the differences in the design of 
the nasal devices (Suman et al., 1999).  
 
Additionally, the height of the spray cloud was measured before the cloud dissipated 
from the nasal device tip and was significantly lower (p<0.05) for the liposome 
formulation compared to water for all three devices due to variation in the formulation 
properties. This means that both device design and formulation properties affected the 
cloud characterization. 
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Table 5. 3: Plume angle, width and height for sprays generated from nasal devices A, B and C. 
Nasal spray 
devices 
Deionised water  Liposomes 
Plume angle Plume width at 
3 cm (mm) 
Height (cm)  Plume angle Plume width at 3 
cm (mm) 
Height (cm) 
A 59.00±3.22 35.00±2.37 23.33±1.03  64.00 ±0.89 39.33±1.37 20.00±1.79 
B 49.00±0.89 31.33±0.52 27.33±1.03  49.33±1.03 30.33±1.03 24.33±0.52 
C 48.67±1.37 30.67±1.86 36.67±1.03  56.67±2.73 39.00±0.89 30.00±1.79 
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Figure 5. 13: Generation of plume from nasal spray device A showing the different 
phases of spray cloud development as monitored by videography. 
 
 
 
Figure 5. 14: Generation of plume from nasal spray device B showing the different 
phases of spray cloud development as monitored by videography. 
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Figure 5. 15: Generation of plume from nasal spray device C showing the different 
phases of spray cloud development as monitored by videography. 
 
A traditional technique was used to characterize the spray pattern of liposomes using 
impaction method. This was performed by spraying the liposome formulation to impact 
on a thin layer chromatography (TLC) surface positioned at 3cm distance from the 
orifice of the nasal spray device. The ovality ratios of the spray produced from different 
devices are shown in Table 5.4. Different shape of spray pattern might be attributed to 
the differences in the shape of the nozzle orifice of different devices (Figure 5.16). This 
finding is in agreement with the finding of a number of research articles (Dayal et al., 
2004; Guo and Doub, 2006; Kundoor and Dalby, 2011). The ovality ratio of the spray 
was in the following order: device C > device A > device B (Figure 5.16). This study 
also found that the shape of the nozzle orifice has great effects on the shape of the spray 
pattern. Dayal et al. (2004) have reported that pump design is the determinant of the 
spray shape. 
 
Large Dmax and Dmin of spray patterns were obtained (p<0.05) from sprayed liposome 
dispersion when using all nasal devices. This might be attributed to the increase of 
plume cone and width of the sprayed aerosol compared to deionised water. The larger 
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the plume angle the larger the spray pattern, whereas smaller plume angles produced 
smaller spray pattern. The hollow-cone of the spray pattern generated from nasal 
devices may indicate the enhanced probability of spray deposition in the anterior and 
middle regions of the nasal cavity than the full-cone (non-hollow) spray and may reduce 
particle deposition in the respiratory tract (Inthavong et al., 2011).  
 
In addition to the droplet size distribution (DSD), plume angle and spray pattern, 
administration angle between nasal spray unit and the head of patient also may play a 
role at the determination of the site of droplet deposition in the nose (Foo et al., 2007). 
When the angle of the plume is greater than 60
o
 the deposition is more dominant in the 
nasal valve, whereas droplets could pass the nasal valve region when the plume angle is 
less than 45
o
 (Kundoor and Dalby, 2011).  
 
 
Figure 5. 16: Spray pattern images for water and liposome dispersion using nasal 
device A (a and d respectively), nasal device B (b and e respectively) and nasal 
device C (c and f respectively) using Conon EOS 550D digital camera. 
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Table 5. 4: Spray patterns (Dmax, Dmin and ovality ratio) generated from nasal spray devices A, B and C. 
 
Nasal spray 
device 
 
Water 
 
Liposomes 
Dmax(mm) Dmin (mm) Ovality ratio Dmax(mm) Dmin (mm) Ovality ratio 
A 40.67±1.86 35.67±1.86 1.14±0.01 46.67±2.58 41.67±1.37 1.12±0.04 
B 33.00±1.79 27.67±1.03 1.19±0.08 38.33±3.14 33.33±2.58 1.15±0.05 
C 41.33±1.37 40.00±0.89 1.03±0.01 48.67±1.03 47.33±1.37 1.03±0.01 
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5.4 Conclusions 
This study explored the suitability of nasal spray device for delivery of liposome 
formulations.  TEM images showed that ethanol based proliposomes have generated 
OLVs which could entrap maximum amount of the drug when 2mg/ml drug 
concentration was used. Inclusions of mucoadhesive agents into liposome formulations 
had major effects on the liposome properties. All bioadhesive agents used except 
carboxymethyl chitosan have decreased the drug entrapment efficiency. Changes in the 
surface zeta potential indicated liposome vesicles were coated with the bioadhesive 
polymers. Investigation of device performance demonstrated nasal pump design with 
formulation properties both affected the cloud height, plume angles and spray patterns. 
Integrity of RH loaded liposomes was not changed following spraying via a range of 
nasal devices, indicating all the devices investigated could be used for nasal delivery of 
RH loaded liposomes. Aerosol droplet size generated from all three devices was within 
the range for deposition in the nose. Overall, the analysis of the spray cloud generated 
by nasal spray device B was characterized by smaller plume angle, which may provide 
greater impaction in the vasculature area of the nasal cavity. Further studies are required 
to determine the site of droplet deposition in the nose and drug bioavailability following 
delivery of the liposome formulations in vivo using the same nasal spray devices used in 
this study. 
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6.1 Nasal insufflator system using bioadhesive polymers 
Ropinirole hydrochloride loaded microparticles and liposomes were developed via 
spray drying technique and ethanol-based proliposome method respectively. Various In 
vitro characterizations were conducted to select the optimum formulations for 
subsequent studies. Investigations were also conducted for the spray cloud generated 
from either powder or dispersed liposomes using Miat
®
 nasal insufflator or a range of 
nasal spray devices respectively.  
This study showed that no chemical interaction between the drug and polymers (e.g 
chitosan or sodium alginate) when they were co-spray dried as revealed by FTIR and 
TLC. Hence, the drug and excipients were compatible. The study showed spray drying 
is a satisfactory method to produce best performing microparticle formulations which 
entrapped large amount of RH in the range of 93–99%. Particle size analysis revealed 
that particle size increased as chitosan to drug ratio was decreased (VMD= 1.98 - 3.66 
µm) however, the size distribution (i.e. Span value) decreased from 4.11 to 1.10. SEM 
studies revealed that spray dried microparticles were spherical regardless of polymer to 
drug ratio used, which improved powder flowability compared to drug-free 
microparticle formulation. X-ray diffraction and DSC studies revealed that the 
crystallinity of the RH after encapsulation into the microparticles was reduced. When 
the polymer to drug ratio was 90:10 (w/w), the drug was completely converted into its 
amorphous form. Formulations with high polymer to drug ratio (90:10) exhibited a 
maximum swelling capacity and prolonged drug release.  
The best performing RH loaded microparticle formulation was produced when 90:10 
(w/w), polymer to drug ratio was co-spray dried. Ex vivo histopathological study using 
sheep nasal mucosa proved that the RH loaded chitosan mucoadhesive microspheres for 
intranasal administration are safe. 
Optimized spray drying conditions were developed to prepare sodium alginate 
microparticles loaded with RH. The inlet temperature was found to be a crucial 
parameter affecting the particle morphology. Inlet air temperature of 140
o
C produced 
spherical microparticles with high yield percent (approaching 70%). Similar findings 
were observed for RH loaded sodium alginate and RH loaded chitosan microparticles. 
Co-spray dried sodium alginate and drug were compatible and polymer to drug ratio had 
marked effect on the particle size (VMD= 2.60 - 4.37 µm), morphology and surface 
smoothness of the particles as shown by SEM. DSC thermograms revealed that the drug 
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was well dispersed in the microparticles when the polymer to drug weight ratio was 
90:10. X-ray diffractogram demonstrated crystallinity of the encapsulated drug by 
sodium alginate reduced and completely converted into its amorphous form in the 
concentration of 90:10, polymer to drug ratio. In vitro drug release profile demonstrated 
concentration of sodium alginate in the formulation had crucial effect on the rate of drug 
release. In a similar manner, the best RH loaded sodium alginate microparticle 
formulation was achieved when the polymer to drug ratio was 90:10. The optimum 
formulation was safe to use for subsequent studies. 
Following the manufacture of optimum formulations of RH loaded chitosan and sodium 
alginate microparticles, the potential delivery of the microparticle formulations via 
Miat
®
 nasal insufflator and its performance were studied. Additionally, the properties of 
the cloud generated from sprayed RH loaded chitosan and sodium alginate 
microparticles were investigated using the Miat
®
 powder insufflator device.   
Studies revealed that Miat
®
 nasal insufflator could deliver 90% of the dose (RH loaded 
chitosan) with the first puff regardless of loading weight and generated elongated 
homogenous cloud. In contrast, loading dose effected the dose delivered for the RH 
loaded sodium alginate formulation owing to agglomeration of the microparticles and 
caused the observation of trajectories of particle in the generated cloud using 
videography. These indicated that the spray cloud was not homogeneous. Laser 
diffraction study of the cloud demonstrated that aerosolized particle size was 76.02 µm 
for RH loaded chitosan and 87.25 µm for RH loaded alginate microparticles which is 
suitable for intranasal administration. Overall, the results of these studies suggested that 
deposition of intranasal delivery of RH loaded chitosan and sodium alginate are likely 
to be more prominent in the turbinate region and particles are less likely to deposit in 
the lower respiratory tract. 
 
6.2 Nasal spray devices using proliposome technology 
Ethanol-based proliposome technology produced OLVs liposomes as revealed by TEM. 
The maximum loading efficiency of RH was 23.3% when the drug concentration used 
was 2mg/ml. Studies using five different bioadhesive agents attempting to enhance local 
residence time of the drug at site of application were performed. Addition of any of 
these bioadhesive agents (0.2% w/v) caused a decrease in the drug entrapment except 
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for carboxymethyl chitosan which showed a slight increase in the drug entrapment from 
23.3 to 25.97%. Liposome surface zeta potential was influenced by the inclusion of 
mucoadhesive agents. These changes indicated that the polymer has coated the liposome 
vesicles. 
Studies to determine the potential delivery of RH-loaded liposomes and the effect of 
nasal spray devices on the liposome integrity were conducted. Nasal devices were 
shown to have no effect on liposome integrity (e.g. particle size, span, and drug loading 
efficiency), thus all devices investigated can be used to deliver RH-loaded liposomes 
coated with carboxymethyl chitosan. All nasal devices generated 100 µl of the dispersed 
liposome formulations, indicating formulation composition had not effect on nasal 
device performance. Study of aerosol properties generated form liposome dispersion 
using a range of nasal sprays was investigated by laser diffraction which demonstrated 
that aerosol particles are unlikely to travel to the lower respiratory region. 
 
6.3 Final conclusion of the thesis 
Overall, this study demonstrated that generation of RH loaded mucoadhesive 
microparticles via spray drying and RH loaded liposomes via ethanol based 
proliposomes may offer promising delivery systems via the nose for potential 
management of Parkinson disease and Restless legs syndrome.   
   
6.4 Future work 
Whilst this study has revealed a number of interesting findings, inevitably as with any 
research project of this type involving drug delivery many questions still need to be 
answered and offer avenues for future research:  
 Stability study of RH loaded microparticle formulations under different conditions is 
required in order to determine the physical state of the encapsulated drug since 
amorphous products are less stable and have tendency to revert to crystalline form.  
 Investigations of plume geometry and spray patterns generated using non-impaction 
method by laser diffraction are required, since laser methods are much more precise 
than the traditional methods employed for characterization of the ejected spray cloud. 
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 Drug delivery to a nasal cast model would be helpful to determine the site of dose 
deposition in the nasal cavity. Hence, an investigation of the impaction site of emitted 
dose in the nose while using either nasal insufflator or nasal sprays might constitute 
an important field in the future investigations. 
 In vivo studies are required in order to determine the amount of bioavailable drug 
particularly the proportion of the drug that may go directly to CNS and CSF after 
nasal delivery using an appropriate animal model. 
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